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1
CHAPTER I

INTRODUCTION

Urban air pollution caused by combustion of fossil fuels, refuse burning,
domestic heating systems, vehicle emissions, and coke ovens constitute a
major environmental health problem and implicated in diseases such as
cancer (U.S. EPA, 1988; Bjorseth and Ramdahl, 1985). For instance, cancer
is an important public health concern in the United States and around the
world. After heart disease, it is the second leading cause of death, accounting
for 23.0% of deaths in the U.S (Simmonds, 2003). It is estimated that the
number of invasive cancer cases in U.S. will double by the year 2050
(Simmonds, 2003). Among men, the most common cancers are cancers of
the prostate (33%), lung and bronchus (14%), and colon and rectum (11%).
The three most diagnosed cancers among women, on the other hand, are
breast (32%), lung and bronchus (12%), colon and rectum (11%).

The

incidence of lung cancer among women and in the general population has
been on rise and is expected to be the leading cause of cancer deaths in the
coming years (Simmonds, 2003).
Benzo[a]pyrene (BaP), a five ring member of the polycyclic aromatic
hydrocarbon (PAH) family present in urban air pollution and also a product of
tobacco smoke, grilled/barbecued meat, smoked fish, or green vegetables, is
a potent carcinogen implicated in various cancers, lung, cardiovascular and
other diseases in both human and animal studies (Wei et al, 2002; Kazerouni

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

et al, 2001; Yan et al, 2000; Pei et al, 1999; IARC, 1983). The United States
Environmental Protection Agency (U.S.EPA) classified BaP as a “possible
human carcinogen” (Group B2) and the International Agency for Research on
Cancer (IARC) considers BaP a known animal carcinogen and a probable
human carcinogen (Group 2k).
BaP and its metabolites are capable of causing this numerous health effects
and disease such as cancer, immunogenesis, atherosclerosis, and endocrine
disruption because of their ability to bind DNA and form BaP-DNA adducts,
causing gene mutations (Chiang, 2001). Also, BaP and its metabolites can
cause cell cycle regulations, transcriptional regulation, immunosuppression,
oxidative stress, and increased intracellular calcium in cells (Jeffy et al, 2000;
Yan et al, 2000; Canova et al, 1998). For instance, germline mutations of
BRCA1 gene are found in half of breast-ovarian cancer pedigrees and
approximately 10% of women with early onset or sporadic breast cancers
(Harkin, 2000). In a study by Jeffy et al. (2000), treatment of MCF-7 breast
cancer cells with BaP and its metabolite Benzo[a]pyrene diol epoxide (BPDE)
caused disruption of BRCA-1 expression and cell cycle kinetics in breast
epithelial cells. Subsequent studies (Jeffy et al, 2002) show that BaP lowers
BRCA-1 expression through repression of the transcriptional activity of its
promoter fragment, which triggers a cascade of non-mutational events that
leads to the onset of sporadic breast cancers. Similarly, BaP is also
associated with tissue vitamin A depletion (Edes et al, 1992), an impairment
leading

to

skin

and

other

epithelial

cancers.

This

is

supported
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by

epidemiological data that associates low vitamin A status with lung cancer in
humans. It has been shown to induce hepatic tumors in several animal
models, tissue types and cell systems including rats, mice, fish and humans
(Binkova et al, 2000). In addition, BaP and its metabolites are also linked to
endocrine disruption (Vinggaard et al, 2000; Tian et al, 1999) in humans and
animals by way of their anti-estrogen and androgen receptor activity. BaP and
other PAHs may act as antiestrogens by, 1) binding to the aryl hydrocarbon
(Ah) receptor leading to the induction of Ah responsive genes that result in
broad spectrum of antiestrogenic response, 2) by blocking activation of the
estrogen receptor (ER) in transfected cells, and 3) by simple binding to ER of
BaP or its hydroxylated metabolites. Inhibition of the action of the androgen
receptor through binding of BaP and other PAHs during the embryonic stage
often leads to alterations in the development of the male external genitalia.
Studies in rodents and humans indicate BaP and its metabolite are
immunotoxic to T and B cell lymphocytes (Davila et al, 1995; Mounho and
Burchiel, 1998; Ladies et al, 1992). BaP and its metabolite (BPDE) caused
significant elevation of intracellular calcium levels in normal human peripheral
blood mononuclear T and B cell (Mounho and Burchiel, 1998; Ladies et al,
1992).

Elevation of intracellular calcium was found to trigger increase

tyrosine phosphorylation, and tyrosine phosphorylation of two src-related
protein

tyrosine

kinases,

immunosuppression.

lyn

and

syk,

which

subsequently

lead

to

Apoptosis in Daudi human cells (Salas and Burchiel,

1998; Davila et al, 1995) was observed in response to BaP and BPDE
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4
treatment. Apoptotic responses in immune cells are critical steps in many
disease

states

including

malignancy,

neurodegenerative

conditions,

autoimmune diseases, and viral infections. Altered calcium signaling in
apoptotic responses is emerging as a primary mechanism of toxic injury for
lymphoid and

non-lymphoid cells (Salas and Burchiel,

1998).

Recent

evidence suggests that, in addition to mutagenic effects, BaP may induce
epigenetic events that contribute to the deregulation of liver growth and
differentiation induced by the compound (Parrish et al, 1998). Epigenetic
carcinogens such as peroxisome proliferators have been shown to increase
the expression of protooncogenes in mouse epithelial cells following acute
exposure, and the extent of gene induction was related to tumorigenicity (Bral
and Ramos, 1997). Bral and Ramos (1997) have shown that BaP activates
the c-Ha-ras proto-oncogene via a transcriptional mechanism that may
involve the aryl hydrocarbon (Ah) receptor complex.
The mechanisms through which BaP and other PAH compounds exert these
biological effects are still relatively poorly defined. Binding to the Ah receptor
and the subsequent activation of the metabolic enzymes (cytochrome p450)
is considered to be the major pathway for BaP toxicity. The mechanism for
these Ah receptor mediated

pathophysiological

responses

is not well

understood. The Unliganded Ah receptor is located in the cytosol associated
with heat shock protein 90 (hsp90). Upon ligand binding, hsp90 is released
from the complex, and the receptor translocates into the nucleus and
dimerizes with the aryl hydrocarbon receptor nucleus translocator (Arnt)
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protein (Barouki and Morel, 2001; Schmidt and Bradfield, 1996). The
heterodimer binds to the xenobiotic response elements (XREs) and alters
expression of genes controlled by enhancer XREs. XREs, with the conserved
core sequences “GCGTG”, are found in the promoter regions of several
genes involved in the metabolism of BaP, including cytochrome p450
(Cyp1a1, Cyp1a2, and Cyp1b1), and NAD(P)H-quinone oxidoreductase.
Oxidation

of

BaP

by

these

metabolic

enzymes

produces

reactive

intermediates that can bind to cellular macromolecules such as DNA and form
DNA adduct (Miller and Miller, 1976) and cause initiation of cancers and
adverse health effects in mammals.
Our goal in this project is to identify biomarkers or signature genes associated
with BaP toxicity. Biomarkers are commonly used in risk assessment and are
useful for determining exposure to specific contaminants. Biomarkers are not
necessarily indicative of an overall toxicological effect of a chemical, but
indicate that exposure to a contaminant or class of contaminants has
occurred. However, under certain circumstances, biomarkers may correlate
with adverse health effects. In vitro and in vivo exposure to BaP is associated
with change in expression of genes involved in apoptosis, anti-apoptosis,
detoxification, DNA repair, oncogenes and so on. However, in vivo genomewide transcriptional responses to BaP exposure in mammalian species such
as rat are not fully characterized. More specifically, no such studies have
examined the dose-response relationships and temporal (sub-acute and sub
chronic) regulation of gene expression by BaP in vivo. In addition, low dose

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

exposure to other compounds alters the mRNA transcript profiles of different
cell or tissue types. Whether or not such low dose responses can occur in
response to BaP exposure in vivo is not well characterized in the literature.
The specific hypothesis behind the proposed research is that exposure to a
low, medium and high dose of BaP at different time points alters the mRNA
transcript profiles of Fisher 344 rat liver and causes distinct patterns of gene
expression. That hypothesis is based on the following observations. First,
BaP is a known carcinogen and forms DNA adducts in rat liver. Upon
metabolic activation, BaP and its metabolites are capable of binding to DNA
forming BaP-DNA adducts, which may lead to cancer (Chiang, 2001, cavalieri
and Rogan, 1985). This may lead to increase in expression of apoptotic, antiapoptotic, detoxification and DNA repair genes. Second, increase in reactive
oxygen species is associated with BaP metabolism in the cell. This increase
in reactive oxygen species may lead to increase expression of antioxidant
genes such as glutathione-s-transferases, glutathione peroxidases and other
genes (Barouki and Morel, 2001; Flowers and Miles, 1991). Third, studies
with other chemical carcinogens have shown non-linear dose response with
low dose exposure showing significant increases in gene expression over the
high dose exposures. The gene expression tends to differ sharply with the
nature of the dose. For instance, genes involved in DNA repair and
detoxification are highly expressed under high dose conditions. Fourth,
temporal regulation is expected to play an important role in expression profile
of various transcripts.

For example, adaptive responses can occur in
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7
response to a xenobiotic challenge under low dose conditions. The nature of
the dose and the duration or extent of exposure may lead to distinct patterns
of gene expression (Hossain et al, 2000; Yoneda et al, 2001).
Based on these observations, the experimental focus of this research project
is to use DNA microarrays to evaluate the in vivo genome-wide transcriptional
response to BaP challenge or insult in Fisher 344 rat liver. Toxicologists
traditionally measure physical parameters (example, body weight, organ
weight, blood pressure, and activity level), histological features of tissue
samples (histopathology), or blood chemistry indicators to identify adverse
effects of exposure. Such data are useful diagnostic indicators, but they are
less useful for understanding the molecular mechanisms of toxicity or to gain
insight into the pathogenesis and progression of disease. In addition,
traditional toxicological methods are usually insufficiently sensitive to detect
low-level toxicity or early pre-clinical stages of disease. Moreover, previous
studies that defined molecular indicators of exposure and health effects were
limited to assaying changes in a limited number of proteins or mRNAs.
With the advent of DNA microarrays, thousands of transcripts or genes can
be

assayed

simultaneously.

Another

great

advantage

of

microarray

technology is the ability to determine relationships among genes and
biological pathways that underlie subtle changes in physiology. Measurement
of gene expression can potentially provide clues about the regulatory
mechanisms, biochemical pathways and broader cellular function. In addition,
the determination of genes expressed in disease tissue compared with their
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8
normal counterpart helps in understanding the disease pathology and also in
identifying potential points for therapeutic intervention. The rationale for
measuring mRNA expression rather than the protein product is based on the
efficiency of obtaining global and quantitative information about gene
expression.

Moreover,

the

RNA-based

approaches

to

assess

gene

expression compared to proteomic technologies are considered to be more
robust and reproducible.
Gene expression data obtained with microarrays need to be validated with
Real-Time Quantitative Polymerase Chain Reaction (RT-QPCR) or other
alternative methods. Real-time PCR quantitation of nucleic acids is based on
detection of amplified products at the end of each cycle, which permits
quantitative calculation of target RNA in an unknown sample by comparison
with the kinetics of PCR product accumulation in samples of known quantity.
Real-time PCR product accumulation is monitored during amplification by the
hybridization of an additional dual-labeled gene-specific oligonucleotide probe
that allows detection during PCR. Quantification of the transcription levels of
these genes plays a central role in the understanding of gene function and of
abnormal alterations in regulation that may result in a disease state.
Recently, epidemiologists have begun employing these early markers of
biologic effect because of the challenges in using cancer as an outcome
measure in occupational epidemiologic studies. The use of clinical disease as
an endpoint in cases such as cancer is limited by the problem of latency;
sometimes 10, 20, or even 30 years between exposure and disease. This has
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9
spurred the growth of molecular toxicology and epidemiology to characterize
new generation of biologic markers, with application to occupational diseases,
and allow identification of excess risk in the natural course of a disease. This
provides an opportunity for preventive action. Another benefit of early markers
of disease include the ability to enhance exposure assessment, especially
low-dose exposures and low risk populations, identify risks from single agents
within complex exposures, estimate the total exposure from multiple sources,
and provide data for predictive toxicological assessment.
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CHAPTER II

LITERATURE REVIEW

Properties and Sources o f Benzo(a)pyrene

Benzo(a)pyrene (BaP) is a five-ring polycyclic aromatic hydrocarbon (PAH),
also known as 3, 4-benzyrene, which was first isolated from coal tar. It was
later found to be a component of cigarette and marijuana smoke. BaP as a
member of the PAH family, only comprises less than five percent of the total
atmospheric amount of polycyclic aromatic hydrocarbons (PAHs). BaP has a
molecular formula of C2 0 H 12 . It is a yellowish crystal with a molecular weight of
252.3. The boiling point of BaP is greater than 360° C at 760 mm Hg and the
melting point is approximately 179° C. The vapor pressure of BaP at 25° C is
8.4 x 10-7 pa, enthalpy of sublimation at 25° C is 118.3 ± 2.2 KJ/mol, entropy
of sublimation at 25° C is 183.6 J/mol EK, enthalpy of fusion is 16.6 ± 0.3
KJ/mol, log P (octanol/water) is 6.04, and the Henry constant is 2.7 x 10'7
Atm-m3/mol (Bjorseth, 1983). It is soluble in benzene, xylene, and toluene. It
is sparingly soluble in ethanol, methanol, and insoluble in water.
PAHs and BaP are formed as products of the incomplete pyrolysis of organic
materials and are present in considerable quantities in fossil fuel from which
they are released by a variety of combustion processes. The principal
sources of BaP and other PAHs in the environment therefore include, in the
wider sense, power plants, domestic heating systems, petrol and diesel
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engines, refuse burning, vehicle emissions, coke ovens, and various industrial
activities, while tobacco smoke provides a more localized source of supply.
Each of these sources of PAH produce a mixture containing between 100 and
300 different individual hydrocarbons, and the estimated total annual
emission of BaP in the United States (US) is some 1200 tons (Kazerouni et
al, 2000; Harvey, 1991). Furthermore, emissions from these sources are
major contributors to urban environmental contamination, particularly in areas
adjacent to highways, industries, and airports. Although, there are natural
sources of PAHs (volcanic activity and forest fires, the anthropogenic sources
are still considered to be the most significant sources of BaP and other PAHs
in the environment.
PAH are also generated in foods through pyrolysis during charbroiling of meat
products and through contamination of foodstuffs by contact with either
petroleum products or coal tar products. Because of the geochemical
processes and atmospheric deposition of air pollution particulate on the
crops, it is possible to generate these naturally occurring PAHs in food. For
instance, Kazerouni et al (2001) observed higher BaP content in green leafy
vegetables such as kale and col lard greens, compared to other vegetables in
their study, which could be explained by their greater contact surface to the
ambient air during growth and their late harvest during the winter months. A
similar Italian study (Lodovici et al, 1995) found high levels of carcinogenic
PAHs in all vegetables except tomatoes exposed to polluted air. Therefore,
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the PAH levels in uncooked foods largely depend on the origin of the food
and subject to regional variations.
PAHs are widely distributed throughout the waters of the earth surface,
entering the food chain by being taken up by fish and plankton (Harvey,
1991). The occurrence of BaP in seafood may be attributed to aquatic
pollution as opposed to cooking methods, unless they were smoked. Fish,
shell fish, and other seafood may be contaminated by petroleum pollution
indirectly through water contact in the marine environment. Since some PAHs
including BaP are only slowly degraded, they represent a potential health
hazard to humans through drinking water and other sources. For example,
the average level of BaP in drinking water is estimated to be approximately
0.01/yg/L, which is of a similar level to that from breathing reasonably clean air
(Harvey, 1991)

Routes o f BaP Entry

The most common way BaP enters the body is through the lungs when a
person breathes in air or smoke. It may also enter the body through the
digestive system when substances containing it are swallowed. Dermal
exposure through the skin can also occur through contacts with soil
(hazardous waste site) that contains high levels of BaP or through contacts
with heavy oils that contain the compound (Agency for Toxic Substances and
Disease Registry, 1990). BaP is present in a wide variety of food items (IARC,
1983).

PAH

are

found

in

grilled/barbecued

meat,

vegetables,
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grains/cereals, fruits, smoked fish and seafood in concentrations as low as
0.001 ng/per g (200 ppb) (IARC, 1983). In human epidemiological studies,
Kazerouni et al (2001) analyzed 200 food items for BaP and estimation of
BaP intake. The highest levels of BaP (up to about 4ng BaP/g of cooked
meat) were found in grilled/barbecued very well done steaks and hamburgers
and in grilled/barbecued well done chicken with skin. BaP levels were lower in
meats grilled/barbecued to medium done and in all broiled or pan-fried meat
samples regardless of doneness level (Kazerouni et al, 2001). The Total
Human Exposure to Environmental Substances (THEES) study has shown
that people in the general population without substantial exposure to pollution
and occupational exposure had a higher exposure to carcinogenic BaP by
food ingestion than by inhalation (Butler et al., 1993). This exposure pathway
is consistent with a large pool of epidemiological data linking the incidence of
human cancer (20-50%) with dietary factors.
Many

PAHs

are

potent

carcinogens

in

animal

models

of chemical

carcinogenesis, and the ability of PAHs to compromise the immune system is
well documented in both in vitro and in vivo systems. Humans are exposed
concurrently or sequentially to complex mixtures containing carcinogenic
PAHs up to several thousand micrograms per day depending on the source,
lifestyles, such as occupation, environmental food chain, cigarette smoking
habits, and socioeconomic status (Arif and Gupta, 1996). However, there are
no comprehensive PAH database, therefore, epidemiological studies have not
been able to estimate dietary PAH intake and investigate the risk of cancer
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and other diseases associated with it. However, various investigators
(Kazerouni et al, 2001; Ward et al, 1997) have evaluated the relationship
between the intake of several foods that may have high level of PAH
(example smoked or grilled/barbecued meats) and risk for cancer at several
sites including stomach and esophagus, colorectal, pancreatic and bladder
cancer. Because PAH are contained in wide variety of foods, it is necessary
to directly estimate the dietary intake of BaP from all dietary sources to
evaluate the relationship between dietary intake of BaP and risk of cancer.
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Figure 1: Pathways in the Metabolism of BaP to Hydroxylated Metabolites.
Health Effects o f BaP

Exposure to PAH-contaminated air pollutants has been associated with the
occurrence of cancer and pulmonary diseases. BaP found in cigarette smoke
and air pollutants, is one of the most widely studied and potent PAH
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carcinogen in animal experiments. A study by Weyand et al. (1995) showed
an association between the ingestion of a diet containing BaP and
forestomach tumors in A/J strain of mice. Another study by Culp et al. (1998)
examined the histopathological sections of other sites such as small intestine,
tongue and esophagus in female B6C3F1 mice. This study showed that BaP
treatment in a 2-year feeding study resulted in an increased incidence of
papillomas and or carcinoma of forestomach, esophagus and tongue.
The United States Environmental Protection Agency (U.S. EPA) classified
BaP as a “possible human carcinogen” (Group B2) and the International
Agency for Research on Cancer (IARC) considers BaP a known animal
carcinogen and a probable human carcinogen (Group 2A). The Office of
Environmental Health Hazard Assessment (OEHHA) agrees with the IARC
Group 2A classification of BaP as a probable human carcinogen based on
sufficient evidence for carcinogenicity in animals and limited evidence in
humans. BaP has the ability through its metabolite to arylate DNA, causing
gene mutations in prokaryotic and eukaryotic cells, induce sister chromatin
exchanges in mammalian cells, and produce unscheduled DNA synthesis in
mammalian cells (U.S. EPA, 1998).
Several types of malignant tumors have been induced in rodents by BaP.
Tumor formation has been induced in a number of tissues, such as lung, skin,
forestomach, liver, the hematopoieitic system, and the mammary gland
(IARC, 1983).

The National Institute for Occupational Safety and Health

(NIOSH) has determined that workplace exposure to coal products can

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

16
increase the risk of lung and skin cancer in workers. Based on this, NIOSH
suggests that the workplace exposure limit for coal tar products is 0.1
milligram of PAHs per cubic meter of air (0.1 mg/m3) for a 10-hour workday
and 40-hour work week. Although NIOSH has not suggested a specific
workplace limit for BaP, the Occupational Safety and Health Administration
(OSHA) has set a legal limit of 0.2 milligrams of all PAHs per cubic meter of
air (0.2 mg/m3).
Similarly, cardiovascular disease remains one of the major causes of death in
industrialized nations and many have suggested that tobacco smoking is a
major contributor to cardiovascular disease. Smoking promotes platelet
hyperreactivity, accelerates atherosclerotic plaque formation, and increases
ischemic tissue damage. Experimental evidence (Yan et al, 2000) suggests
that

BaP

accelerates

smooth

muscle

proliferation

and

promotes

atherosclerosis in animals ranging from chicken to rats. In addition, Yan and
others (2000) have also detected BaP-related DNA adducts in atherosclerotic
arteries.
Carcinogenic PAH such as BaP, 7-12-dimethylbenz (a) anthracene (DMBA),
and 3-methyl-cholanthrene (3-MC) are immunotoxic to rodent and human
lymphocytes (Davila et al, 1995; Mounho and Burchiel, 1997). Both BaP and
DMBA metabolites have been shown to suppress the in vitro plaque-forming
cell (PFC) response to sheep red blood cells (Ladies et al., 1991). Humans
exposed

chronically

to

atmospheric

complex

mixtures

of

pollutants,

composed primarily of PAHs, also develop suppression of their immune
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system. For example, Szczeklik et al. (1994) examined the effect of PAH
exposure on humoral immunity in a group of male iron foundry workers in
Poland who were chronically exposed to PAHs, as assessed by personal and
area monitoring. An evaluation of serum from these men revealed that coke
oven workers exposed to high concentrations of atmospheric PAHs, including
benz[a]anthracene
immunoglobins

(BA)

and

BaP,

had

reduced

serum

levels

of

IgG and IgA compared with mill workers exposed to

concentrations of PAHs 3-5 magnitudes lower than the coke oven workers.
Furthermore, the risk of cancer is greater in humans who are immuno
compromised. For instance, children with inborn deficiencies of the immune
system have a high incidence of malignant tumors.
Also, a growing body of literature identifies PAHs as potential environmental
endocrine disruptors (Vinggaard et al, 2000). Several pieces of evidence
indicate that environmental chemicals, which are able to bind to the androgen
receptor (AR), may have an important impact on abnormalities associated
with developing male reproductive system. An inhibition of the action of the
AR during the embryonic stage very often leads to alterations in the
development of the male external genitalia such as cryptorchidism and
hypospadia. Similarly, PAHs may act as antiestrogens by binding to the Ah
receptor (Vinggaard et al, 2000) leading to induction of Ah responsive genes
that result in a broad spectrum of antiestrogenic responses.
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Chemical Carcinogenicity o f BaP

Chemical carcinogens were first recognized in humans approximately two
and half centuries ago by Hill in 1761, who noted an increase incidence of
nasal polyps and cancer after the prolonged and excessive use of tobacco
snuff. Also, the incidence of scrotal skin cancers in European chimney
workers was correlated by Percival Pott to the sub-chronic or chronic
exposure of these workers to coal soot and tar. There are three broad classes
of chemical carcinogens; Direct acting (require no metabolic activation),
Indirect acting (require metabolic activation), and Non-genotoxic or Epigenetic
carcinogens (Waalkes and Ward, 1994). Majority of the chemical carcinogens
including BaP are indirect acting, requiring metabolic activation to produce
electrophilic intermediates in order for the tumor formation process to occur.
BaP after metabolic activation is known as one of the most potent PAHs to
cause carcinogenic effects. It was first determined to be a carcinogen in the
early 1950s by Elizabeth Miller who found that a metabolite of BaP reacts with
proteins in mouse skin (Miller, 1951). BaP is potent because it has two main
features: (1) a relatively low ionization potential of 7.23eV (IP), which allows
metabolic removal of one electron forming a cation (Cavalieri and Rogan,
1985), and (2) appreciable charge localization in the radical cation, allowing
the intermediate to efficiently react with nucleophiles (Josephy, 1997). This is
evident in the most widely studied adduct formation of BaP with DNA and
other macromolecules. A review of the literature on DNA adducts formation
of BaP shows that it is activated by two main routes, 1) one-electron oxidation
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to yield reactive intermediate radical cations (cavalieri and Rogan, 1985), and
2) monoxygenation to produce bay- region diol epoxides (Cheh et al, 1993).
In the

former, the major identified BaP diol epoxides adduct arises from

formation of a covalent bond between C-10 of BaP-diol epoxide and two
amino of guanine moieties on DNA. In the latter, on the other hand, BaP is
first activated by one-electron to its radical cation, and binds the C-6 of BaP to
either the C-8 or N-7 of guanine on DNA and forms adducts (Rogan et al,
1990). In both cases, the activated intermediates react with nucleotides to
form covalently bonded compounds, causing “molecular lesions.”

O ne-electron
oxidation
+

DNA

NH jj

BaP-C8Gua

BaP-N7Gua

Figure 2. Formation of BaP-DNA Adducts by One-electron Oxidation
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Monooxygenation

if T T + DNA
01-

GH

OH

NHj

BPDE-N2Gua

BPDE-N7Gua

Figure 3. Formation of BaP-DNA Adducts by Monoxygenation

Molecular Mechanisms o f BaP Toxicity

The mechanisms through which PAFI compounds exert their biological toxic
effects are still poorly defined. Binding of this class of compounds to the aryl
hydrocarbon (Ah) receptor, which then activates the expression of metabolic
enzymes such as cytochrome p450 1a1 (Cyp1a1) and 1a2 (Cyp1a2), is
acknowledged to be a critical step in the carcinogenicity or immunotoxicity of
these

compounds.

The

process

of transcriptional

activation

of these

cytochromes is felt to proceed in large part through a signaling process
involving ligand- dependent activation of the Ah receptor. The cytosolic Ah
receptor belongs to the family of the basic helix-loop-helix (bHLH) proteins
and is occupied in the cytoplasm of the cell with heat shock protein of 90 kDa
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(hsp90), which is uncoupled from the receptor in the presence of ligand (Chen
and Tukey, 1996; Denison and Heath-Pagliuso, 1998; Schmidt and Bradfield,
1996). Following Ligand binding, the Ah receptor is released from a cytosolic
multiprotein complex (at least two hsp90 and an additional 37 kDa Ah
receptor interacting protein) to which it is associated.

The liganded Ah

receptor complexes subsequently translocate into the nucleus, where it
associates with the bHLH Ah receptor nuclear translocator (Arnt) protein, and
possibly other factors to form the high affinity DNA binding Ah-Arnt
heterodimer. The Ah-Arnt heterodimer complex then binds to specific
enhancer sequences, the dioxin response element (DRE), upstream of the
Cyp1a1 gene (as well as other responsive genes), which leads to DNA
bending,

chromatin

and

nucleosome

disruption,

increased

promoter

accessibility and increased Cyp1a1 gene transcription (Denison and HeathPagliuso, 1998). The Ah-Arnt complex synergizes with other transcription
factors such as NFI and SP1, thereby activating the transcription of the gene.
Several other genes are also the target of the Ah receptor. These include
other Cyp450 genes such as Cyp1a2, Cyp1b1, and several phase II genes
such as NQO-1 and Glutathione-s-transferase (Gst) as well as a number of
other genes.
Ligands

of

the

Ah

receptor,

such

as

BaP

and

the

dioxin

tetrachlorodibenzodioxin (TCDD) trigger a number of toxic effects in rodents
including cancer, immunosuppression, and endocrine disruption. In addition
to its role in modulating the induction of gene expression, numerous studies
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also support a role for the Ah receptor in mediating PAH toxicity. For instance,
structure-activity relationships studies using a variety of inbred strains of mice
which differ in their Ah receptor functionality reveals that the ability of PAHs
and other xenobiotic compounds to bind to the Ah receptor not only correlates
well with their ability to induce gene expression but also their ability to
produce toxicity.
The ability of the Ah receptor to produce toxicity in cells is exemplified by the
metabolism of BaP. BaP metabolism in the cell occurs through phase I and
Phase II enzymatic oxidation and hydrolysis.

Although the physiological

function of the Cyp1a1 (Phase I enzyme) seems to be detoxification,
convincing evidence suggests that high activity of the enzyme could lead to
toxicity. This is largely because the detoxification of the highly mutagenic BaP
diol-epoxides as well as other reactive intermediates depends on the activity
of phase II enzymes such as glutathione-s-transferase (Gst). Therefore, the
ratio between Cyp1a1 and phase II enzymes is critical to avoid the
accumulation of putatively toxic intermediates of BP metabolism.
Another mechanism through which Cyp1a1 could lead to toxicity is the
production of reactive oxygen species (ROS). Several monooxygenases have
been shown to release hydrogen peroxide (H20 2) during their catalytic cycle
(Barouki and Morel, 2001). Experiments in cultured cells have shown that the
induction of Cyp1a1 by BaP, as well as the transfection of a Cyp1a1
expression vector, leads to oxidative stress within the cells (Barouki and
Morel, 2001). High Cyp1a1 enzyme activity within the cell may be deleterious
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because of the generation of an intracellular oxidative stress and the
subsequent oxidation of biological macromolecules. Other studies (Flowers
and Miles, 1991) have found alterations of pulmonary BaP metabolism by
reactive oxygen metabolites. The activity of both BaP hydroxylase and the
monooxygenases

(cytochrome-p450

and

NADPH

cytochrome

p-450

reductase) was inhibited by addition of reactive oxygen metabolites to rat lung
microsomes. However, the reactive oxygen metabolites (superoxide anion
and H2 O2 ) had no effect on the formation of minor metabolites of BaP; the
BaP-quinones and BaP-dihydrodiols (Flowers and Miles, 1991). This are the
BaP metabolites thought to produce toxic effects and which may lead to the
formation of carcinogens or mutagens. The results of these experiments
suggest that exposure of lung microsomes to oxygen metabolites can lead to
a slowing of overall BaP metabolism and the increased accumulation of
potentially toxic BaP metabolites. The toxic consequences of high Cyp1a1
activity correlate with epidemiological observations in humans; some studies
have documented a correlation between high Cyp1a1 activity and lung
cancer.
Although Cyp1a1 is induced primarily by Ah receptor activation, it is unlikely
that this represents the only determinant of the level of expression of this
gene. Several other factors such as hormones, cytokines, and chemicals
have been shown to modulate this effect. The efficiency of the Ah receptor
could

be

modulated

by

phosphorylation

events.

Other studies

have

established that a number of cytokines (tumor necrosis factor-a, TNF-a,
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lnterleukin-1 (3, /L-7/3) also repress the induction of the Ah receptor gene. In
addition, an autoregulatory loop control of Cyp1a1 enzyme on expression of
the Cyp1a1 gene has been observed in experiments (Barouki and Morel,
2001). Barouki and Morel (2001) used cotransfection experiments to show
that the over expression of Cyp1a1 enzyme leads to the down regulation of
the Cyp1a1 gene promoter by targeting the same transcription factor,
NFI/CTF. Also, other regulatory loops could also be involved in the fine tuning
of Cyp1a1 gene induction. For example, the Ah receptor repressor (AhRR),
which is structurally similar to Ah receptor but lacks transcriptional activity,
antagonizes the Ah receptor by competing for Arnt.
In addition, binding of PAHs, such as BaP, to the Ah receptor, which then
activates the expression of metabolic enzymes, such as Cyp1a1 and Cyp1a2
is acknowledged to be a critical step in the immunotoxicity of these
compounds (Davila et al, 1995; Salas and Burchiel, 1998; Mounho et al,
1997).

However, certain

PAHs such as 7, 12-dimethylbenzanthracene

(DMBA) suppress both the humoral and cell-mediated immune function in Ahnon-responsive and responsive mice, suggesting that DMBA may bypass
cytochrome p450 mediated metabolism. The immunosuppressive effects of
PAH appear to be mediated through disruption of one or more cellular signal
transduction pathways either through altered cytokine production and/or
disruption of cell surface membrane signaling. Both DMBA and BaP have
been shown to suppress T-cell IL-2 secretion and expression in both in vitro
and in vivo studies (Burchiel et al, 1987; Salas and Burchiel, 1998). Also, the
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secretion of IL-1 after lipopolysaccharide (LPS) stimulation was increased in
macrophage exposed to DMBA, while BaP had no effect on IL-1 secretion.
Most PAHs are also known to have effects on cell viability and cell
proliferation in culture (Davila et al, 1995; Salas and Burchiel, 1998).
The mechanism(s) by which PAHs exert their immunotoxic effects have not
been well characterized in human lymphocytes (Mounho et al, 1997; Davila et
al, 1995). A change in intracellular calcium and induction of apoptosis in cells
is associated with the signal transduction mechanism involved in lymphocyte
toxicity (Davila et al, 1995; Salas and Burchiel, 1998). For instance, one of the
immediate consequences of mitogen contact with responsive cells is the
activation of various ion transport systems in the plasma membrane and
changes in intracellular ionic composition (Salas and Burchiel, 1998). Calcium
serves as a second messenger and therefore mitogen-induced alterations in
the levels of cytoplasmic free calcium triggers and regulates cell proliferation.
The mobilization of intracellular calcium leads to the activation of the signal
transduction

pathway.

PAHs

that

are

neither

carcinogenic

nor

immunosuppressive cause only a transient rise in intracellular calcium in
human T-cell lines, while potent carcinogens and immunosuppressant also
produce a sustained elevation in intracellular calcium (Davila et al, 1995). The
rapid rise in intracellular calcium in response to extracellular stimuli is
mediated by the second messenger inositol 1, 4, 5-triphosphate, which
triggers

the

release

of

calcium

from

the

endoplasmic

reticulum.

Furthermore, Salas and Burchiel (1998) have demonstrated that PAHs, such
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as DMBA and BaP, induce cell death by apoptosis in murine B and T
lymphocytes

via

Ca2+-dependent mechanisms. Apoptotic

responses

in

immune cells are critical steps in many disease states including malignancy,
neurodegenerative conditions, autoimmune diseases, and viral infections.
Ca2+-dependent endonucleases mediate DNA fragmentation, and Ca2+dependent pathways

have been

implicated

in mechanistic studies of

apoptosis in immune cells. The pathways for the apoptotic response are
thought to involve Ca2+-dependent protein kinases and phosphatases that
exert transcriptional control over apoptosis regulatory molecules. There is
also accumulating evidence that Ca2+ regulation is a primary target of gene
products, such as Bcl-2 gene family members that serve as molecular
integration sites for signals that regulate mitogenesis, differentiation, and
apoptosis (Salas and Burchiel, 1998).
Additionally, the phosphorylation of proteins provides for direct signal
amplification and is an important way by which the activities of proteins can
be modulated. Many products of oncogenes are tyrosine kinases and
phosphorylation of these tyrosine residues causes conformation changes in
the protein, allowing other proteins that contain specific tyrosine phosphate
binding-sites to bind to the phosphorylated protein and activate other
enzymes. For example, the ras oncogenes product, which is induced by BaP,
is a membrane associated GTP-binding/GTPase and is a key component of
signal transduction pathways, linking receptor tyrosine kinases with cytosolic
signaling proteins that ultimately impinge on the cell nucleus. Activated ras
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oncogenes have been identified in various forms of human cancers, most
notably colon and pancreatic cancers (Marshall, 1995). Some oncogenes
may be directly activated by interactions between the target genes and
chemical carcinogens, while other oncogenes may be indirectly activated
during the progression of chemical carcinogenesis by non-target genetic
events (Brown et al, 1990). Studies (Brown et al, 1990) of mouse skin tumors
initiated by different chemical carcinogens showed that for each chemical
initiating agent, a distinct spectrum of ras mutations was observed and that
the distribution of ras gene mutations differed between benign papillomas and
carcinomas, which suggests that the nature of the molecular initiating event
influences the probability of papillomas progression to malignancy.

Research Goals and Instrumentation

Our research goal is to identify and characterize molecular markers or
biomarkers associated with exposure to BaP, in order to understand the
relationship
susceptibility.

between

environmental

exposure

and

human

disease

In addition, we hope to characterize potential mechanisms of

action of environmental contaminants through the identification of gene
expression networks, which in turn will be useful to elucidate the biological
processes that govern or underlie specific health effects such as cancer or
immunogenesis. An integrated functional genomics approach is employed in
this study to characterize the nature of the gene response associated with the
in vivo exposure of Fisher 344 rats to BaP. The genomics techniques that
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would be utilized are high density oligonucleotide microarrays (Affymetrix
GeneChips,

Affymetrix

Inc,

CA) and

Real-Time

Quantitative

Reverse

Transcriptase Polymerase Chain Reactions (RT-QPCR) to analyze the doseresponse as well as temporal regulations associated with BaP-induced gene
expression patterns in Fisher 344 rat livers.
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Figure 4. Possible Mechanism(s) of BaP Activation through the Ah Receptor
Pathway.
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Gene Expression Profiling and DNA Microarrays

Each year as hundreds of new drugs or chemical entities are introduced into
the market or environment, a substantial challenge has been to determine the
potential adverse health effects associated with exposure to such substances
(Neumann and Galvez, 2002; Bartosiewicz et al, 2001). Risk assessment
depends on the use of biomarkers or biological indicators of exposure to such
compounds. Biomarkers are often used as a measure of exposure to a
xenobiotic, and are physiological markers altered in response to chemical
exposure. Biomarkers are not necessarily indicative of an overall toxicological
effect of a chemical, but indicate that exposure to a contaminant or class of
contaminants

has

occurred.

However,

under

certain

circumstances,

biomarkers may correlate with adverse health effects. Traditional risk
assessments to define molecular indicators of exposure and health effects
were limited to assaying changes in a limited number of proteins or mRNAs.
Currently, toxicological screening of these chemicals relies heavily on the use
of a combination of short-term assays that often require separate bioassays
to determine immunotoxicity, neurotoxicity, and genotoxic end points. These
assays, however, are costly, require many animals, and may take several
years and millions of dollars to complete.

For example, the USEPA uses

three-species bioassays to determine the relative toxicity in water of specific
chemicals or specific effluents to wildlife. These tests are limited to lethality,
growth, and

reproductive end

points, therefore,

optimization of these

processes is required in order to develop methodologies that are more
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efficient, informative and cost effective (Bartosiewicz et al, 2001, Thomas et
al, 2001).
With the advent of DNA microarrays, thousands of transcripts or genes can
be assayed simultaneously. DNA microarrays are a powerful, high throughput
tool for monitoring the expression of thousands of genes simultaneously.
Considerable attention has been given to the application and use of DNA
microarrays in drug discovery and development, in identifying changes in
gene expression associated with various disease processes, and in screening
populations for allelic variants or single nucleotide polymorphisms (Reninger
et al, 2000; Afshari et al; 1999).
Public access to genome sequence data, accompanied by rapid advances in
sequencing

technology

and

molecular

biology

tools

development,

is

enhancing the elucidation of the molecular mechanism of cell metabolism.
Microarrays are instrumental in providing a holistic picture of the underlying
genetic complexities that orchestrate biochemical pathways and networks.
Moreover, microarrays are also been used to assess the expression of entire
organism genomes, thereby paving the way towards global mapping and
modeling of the regulatory mechanisms of genetic networks.
Another advantage of DNA microarrays is that they combine the ability to
analyze the expression of a large number of genes with parallel data
acquisition. This parallel-processing power allows experimental designs that
are much less costly, time-consuming, and produce significantly more data
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than

conventional

molecular

methods,

yet

produce

similar

results

(Bartosiewicz et at, 2001; Neumann and Galvez, 2002).
Recently, there has been considerable interest in using DNA microarrays for
assessing the toxic effects induced by drugs and environmental contaminants
on host physiology (Bartosiewicz et al, 2001; Waring et al, 2001; Afshari et al,
1999; Amin et al, 2004). Microarrays can be used to quickly classify toxicants
based on characteristic expression profiles and to use these profiles as a
means of identifying putative mechanisms of action (Amin et al, 2004), as well
as for identifying genes that are co-expressed or under similar regulatory
control (Waring et al, 2001). For example, the expression profiles associated
with a heavy metal, a PAH, and an oxidant stressor may differ considerably
and could be useful in assessing the potential toxicity of the new chemical
entities, as well as, in environmental risk assessment monitoring.

DNA Microarrays Technology

DNA microarrays are rapidly becoming a fundamental tool in genomic
research. DNA microarrays are an organized arrangement of multiple DNA
probes fixed on an immobilized surface. DNA microarrays function using the
classical hybridization techniques (Southern and Northern blots) of molecular
biology. The key to the method is the property of nucleic acids to bind
specifically and strongly to each other using Watson and Crick base pairing
(cytosine to guanine, and thymine to adenine). The specificity of the binding
is such that mismatches at a single position in a DNA strand of, for example,
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20 bases, under suitable conditions sufficiently reduce the binding affinity as
to completely prevent hybridization.
There are several microarray technologies, however, two approaches are
currently prevalent; cDNA arrays and oligonucleotide arrays. Although they
both utilize hybridization, they differ in how DNA sequences are laid on the
array and in the length of these sequences. A detailed review of the technical
aspects of these technologies is provided by Schena (2000). Briefly, in
spotted DNA arrays, mRNA from two different biological samples is reversetranscribed into cDNA, labeled with dyes of different colors, and hybridized to
DNA sequences, each of which is spotted on a small region, or spot, on a
glass slide. Spotted arrays are manufactured using x-y-z robots that use
hollow pins to deposit cDNA, clones, or short and long oligonucleotides onto
specially coated glass microscope slides (Schena et al, 1995). Spot sizes
range between 50 and 500 pm in diameter depending on the type of pin used.
After hybridization, a laser scanner measures dye fluorescence of each color
at a fine grid of pixels. Higher fluorescence indicates higher amounts of
hybridized cDNA, which in turn indicates higher gene expression in the
sample. The strength of this technology is its flexibility and also allows the
simultaneous interrogation of two biological samples such as untreated cells
versus treated cells, or healthy tissue compared with cancer. The major
disadvantage of spotted arrays is due to the variability in spot quality from
slide to slide, and in addition, they provide information only on the relative
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gene expression between specific cells or tissue samples as opposed to
direct quantification of RNA expression.
High density oligonucleotide GeneChips (Affymetrix, Santa Clara, CA), on the
other hand, are produced by synthesizing tens of thousands of short
oligonucleotides in situ onto glass wafers, one nucleotide at a time, using a
combination of photolithography and light-directed solid-phase DNA synthesis
(Lipshultz et al, 1999).
In Affymetrix arrays, expression of each gene is measured by comparing
hybridization of the sample mRNA to a set of probes, composed of 11-20
pairs of oligonucleotides, each of length 25 base pairs. The first type of probe
in each pair is known as perfect match (PM) and is taken from the gene
sequence. The second type is known as the mismatch (MM) and is created
by changing the middle (13th) base of the PM sequence to reduce the rate of
specific binding of mRNA for that gene. The MM serve to control experimental
variation and nonspecific binding of mRNA from other parts of the gene. A
detail description of Affymetrix GeneChips technology is discussed by
Lockhart et al. (1996). Affymetrix GeneChips are ideally suited for large scale
gene expression analysis, where high quality is desired and the same array
design can be used repeatedly.
Another advantage is the ability to measure the absolute expression of genes
in cells or tissues. The sensitivity of the GeneChip enables detection of
mRNAs present at levels as low as 1 transcript in 100000 (Lipshultz et al,
1999).
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DNA Microarrays and Toxicogenomics

It is postulated that measurement of gene expression can potentially provide
clues about the regulatory mechanisms, biochemical pathways, and broader
cellular function associated with exposure to a xenobiotic compound (Afshari
et al, 1999). Gene transcription lies at the beginning of the transcription of a
cell to a xenobiotic. Therefore a transcriptional response can give a
preliminary indication of the biochemical or biological mechanism being
affected by a xenobiotic, and gene expression data can provide starting
points in a toxicological examination. The rationale for measuring mRNA
expression rather than the protein product is based on the efficiency of
obtaining

global

and

quantitative

information

about

gene

expression.

Moreover, the RNA-based approaches to assess gene expression compared
to proteomic technologies are considered to be more robust and reproducible.
Toxicogenomics attempts to define how the regulation and expression of
genes mediate the toxicological effects associated with exposure to a
chemical. The basic premise is that a certain degree of similarity or
generalized pattern of gene expression is expected during exposure to
different classes of toxicants (Afshari et al, 1999). Also, subtle differences in
gene expression patterns induced by chemicals belonging to a specific class
of toxicants may be sufficiently distinct so as to identify chemical-specific
signatures of exposure. Current toxicogenomics studies have focused on
classifying toxicity according to unique gene transcriptional profiles induced
by different classes of compounds.
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According to Afshari et al (1999), gene expression profiling using DNA
microarrays may be used to 1) Characterize potential mechanisms of action
of environmental contaminants through the identification of gene expression
networks, 2) Identify modes of action for previously uncharacterized toxicants
based on correlations with the molecular signatures of toxicants with well
characterized etiologies, 3) Assess toxicant-induced gene expression as a
biomarker of chemical exposure, 4) Ascertain overlapping patterns of gene
expression in animal species exposed to specific toxicants, 5) Use microarray
information to extrapolate effects of toxicants from one animal species to
another, 6) Characterize the biological effects of complex chemical mixtures,
7) Examine the effects of chronic versus acute exposure to chemicals, and 8)
characterize

genetic

polymorphisms

in

populations

and

assess

the

importance of genetic polymorphisms in modifying individual susceptibilities to
a contaminant or toxicant.
In spite of the wide range of possible applications of DNA microarrays,
several assumptions are inherent to a toxicogenomic-based approach in
toxicology,

many of which

remain to be validated.

Some of these

assumptions relate to the following: First, the influence of toxicant exposure
on convergence and divergence patterns of gene transcription. It is generally
assumed that gene transcription profiles induced by different contaminants
may either converge to produce similar toxicological effects or similar gene
expression profiles may eventually diverge at later time points to produce
different toxicological effects.

For example, although the toxicity of PAHs
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such as BaP is related to Ah receptor binding and subsequent induction of
cytochrome p450 genes (Bartosiewicz et al, 2001; Mounho et al, 1997; Davila
et al, 1995), sometimes binding to intracellular signaling proteins downstream
of the Ah receptor may affect a multitude of distinct biochemical pathways. In
some cases, genes with apparently opposite effects may be induced, even
under the same treatment conditions, as shown by Burczynski et al (2000),
who observed induction of both apoptotic and anti-apoptotic genes in a
human cell line in response to treatment with cisplatin. On the other hand,
gene expression profiles induced by different contaminants as observed by
Waring et al (2001) may converge at distinct temporal or spatial points to yield
similar toxicological effects. For instance, Waring et al (2000) observed that
treatments of rats with methapyrilene (250 mg/kg/day for 3 days) induced
gene expression patterns in liver tissues that were more closely related to
arsenic exposure than to other related hepatotoxins.
Second, the

influence of temporal

and

spatial

parameters on

gene

transcription is an important assumption in any toxicogenomic study. In
classical toxicological studies, acute and chronic dose responses are utilized
as distinct endpoint measurements. Toxicity, on the other hand, represents a
continuum of possible effects governed by both temporal and spatial factors
that are contingent upon exposure conditions. Therefore, the perceived
toxicological properties of any chemical are dependent on the route, dose,
and duration of the exposure, and as such gene expression patterns are also
subject to these variables (Neumann and Galvez, 2002) The data obtained

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

using DNA microarrays gene expression profiling represent a snapshot of the
gene transcriptional responses occurring at a particular time (temporally
restricted)

and

within

a

particular tissue

(spatially

restricted).

Gene

transcriptional programs in biological systems are intricately controlled by
temporal (early, mid, and late-induced genes) and spatial mechanisms such
as alternative RNA splicing. Hence, correct interpretation of DNA microarray
data for the assessment of the toxicological properties of chemicals will
require that temporal and spatial gene expression profiles be accounted for.
Finally, it is also postulated in the literature that clustering of gene expression
responses among different chemicals may be predictive of the mechanisms of
toxicity (Waring et al, 2000; Afshari et al, 1999; Thomas et al, 2002).
However, as shown in experiments by various researchers (Thomas et al,
2001; Waring et al, 2000), the toxicity data may not necessarily equate to a
common mechanism of action even for similar classes of chemicals. This also
depends on the type of clustering algorithm used to group chemicals into
various toxicological classes.

Applications o f DNA Microarrays in Toxicogenomics Studies

Recently, a number of studies (Waring et al, 2001; Afshari et al, 1999;
Thomas et al, 2002; Burton et al, 2002; Bartosiewicz et al, 2001; Amin et al,
2004) have been published which illustrate the use of DNA microarrays for
toxicogenomics analysis. Using microarray gene expression profiling, Hossain
et al. (2000) were able to identify a potential mode of action for lead-induced
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neurotoxicity characterized by a loss of integrity of the blood-brain barrier.
Exposure of human fetal astrocytes to lead in culture resulted in a 3-fold
increase in mRNA expression of vascular endothelial growth factor (Hossain
et al, 2000). Furthermore, gene expression profiling revealed that lead
exposure induced the expression of a variety of stress response genes,
amino acid biosynthesis genes, and transfer RNA synthase genes in
astrocytes, an observation that correlated with other known mechanisms of
action of lead on these cellular processes.
Using custom arrays with a relatively limited gene set, Bartosiewicz et al.
(2001) has examined the gene expression patterns in liver and kidney in
response

to

five

methylcholantrene;

classes

of

chemicals

DNA alkylators:

(PAH:

benzo(a)pyrene,

dimethylnitrosamine,

3-

ethylnitrosurea;

peroxisome proliferators: diethylhexypthalate, clofibrate; heavy metals: CdCh,
HgCI2; and oxidative stressors: CCI4, bromobenzene). Each pair of chemicals
yielded a similar pattern of gene expression distinct from the other four
classes of chemicals in time course and dose-response studies in mice
(Bartosiewicz et al, 2001). Moreover, for each of the five classes of
compounds tested, several induced or repressed genes were in common in
each chemical exposure, whereas other genes were unique for that specific
class of compound (Bartosiewicz et al, 2001). Similarly, Waring et al. (2001)
compared

rat

characterized

hepatocytes

gene

hepatotoxicants.

A

expression
strong

profiles

correlation

among
between

15 wellknown

mechanisms of hepatoxicity and clustering of specific gene sets were
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observed, indicating that chemicals with similar toxicological effects elicit
closely related patterns of gene expression. For example, using hierarchical
cluster analysis, aroclor 1254 and 3-methylcholanthrene elicited similar
patterns o f gene expression in microarrays (Waring et al, 2001). In other
studies, DNA expression microarrays have been employed to characterize
temporal regulation of gene expression (Yoneda et al, 2001; Huang et al,
2001).

Yoneda et al. (2001) has observed that gene expression in human

epithelial cells undergo distinct temporal phases when exposed to oxidants
such as hydrogen peroxide and smoke. Increased expression of antiapoptotic genes was observed in epithelial cells one hour after exposure to
smoke or hydrogen peroxide (Yoneda et al, 2001).
Similarly, Huang et al (2001) has shown in Sprague-Dawley rats exposed to
cisplatin for 7 days, specific gene expression changes associated with
temporal regulation of the damage/repair process. The genes altered by
cisplatin were subdivided into eight functional categories that included
calcium metabolism, oxidative stress, cell cycle regulators, transporters, and
metabolism. Temporal regulation was observed as a gradient of responses
involving different gene expression patterns associated with the different
functional gene categories (Huang et al, 2001). These studies indicate that
the genetic cellular response to toxicant exposure can be categorized into
distinct phases in which cells first respond to the initial exposure by
attempting to counteract the chemical-induced effects on cellular metabolism,
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followed by mechanistic counter-active responses that ensure continued
cellular function and survival during and after toxicant exposure.
Furthermore, Lu et al. (2001) used gene expression arrays to study toxic
effects of arsenic on human populations in China exposed to high levels of
arsenic through arsenic-laden coal used for heating and cooking. Liver
biopsies from chronically exposed

individuals showed

increased gene

expression for numerous cell cycle regulators and transcription factors
involved in oncogenesis and differentiation.
In a study by Thomas et al. (2002), age-related changes in gene expression
patterns in rat livers were assessed using DNA microarrays, and compared to
changes in human livers. Concomitant increases in the expression of
important antioxidants and detoxifying genes were noted in the livers of both
rats and humans (Thomas et al, 2002). The induction pattern suggests a
complex link between changing hepatic detoxification/redox capability and
senescence. Although this study is not directly related to toxicology, the
results of this study demonstrate the applicability of using gene expression
arrays to characterize mechanisms of action specific to a cellular process.

Real-Time Quantitative Polymerase Chain Reaction (RT-QPCR)

Due to inherent variations from technical and biological sources in microarray
experiments, the gene expression results need to be validated using RTQPCR or other alternate techniques such as northern or western blot. RTQPCR method allows for the quantitation of gene expression from small
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starting mRNA concentrations. It also used to assess discrepancies between
or due to hybridization differences in microarray experiments (Goodsaid et al,
2004). RT- quantitative PCR (Overbergh et al, 2003; Grove, 1999) provides a
sensitive, reproducible and accurate method for determining mRNA or total
RNA levels in tissues or cells. The method is based on the detection of a
fluorescent signal produced and monitored during the amplification process,
without the need for post-PCR processing (Overbergh et al, 2003).
Quantification of the transcription levels of these genes plays a central role in
the understanding of gene function and of abnormal alterations in regulation
that may result in a disease state. As a result, the RT-QPCR technique is now
widely applied in quantitation of relative gene expression, single nuclear
polymorphism detection, cancer and other disease diagnostics, pathogen
detection, etc. It is based on the detection of a fluorescent signal produced
and monitored during the amplification process, without the need for postPCR processing.
Various researchers have used RT-QPCR to validate gene expression data
obtained using microarray or other large scale toxicogenomic methods (Baker
et al, 2004; Heid et al, 1996; Bustin et al, 2002; Burczynski et al, 2001; Grove
et al, 1999). Recently, RT-QPCR has been employed to determine reliability
and interlaboratory reproducibility of microarray data (Baker et al, 2004). As
part of a series of studies conducted by the International Life Sciences
Institute Health and Environmental Science Institute Technical Committee on
the application of genomics to mechanism-based risk assessment, the
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biological response in rats to various hepatotoxicants was investigated. In one
of these studies, Baker et al (2004) examined clofibrate-induced gene
expression changes in rat liver using membrane cDNA arrays and RT-QPCR.
Quantitative RT-PCR was used to confirm modulations for a number of
peroxisome proliferator marker genes (Baker et al, 2004). In spite of minimal
variability in the quantitative nature of microarray data due experimental
procedures and data analysis, the RT-QPCR validation studies indicate the
potential for gene expression profiling to identify toxic hazards by the
identification of mechanistically relevant markers of toxicity.

Signal Transduction Mechanisms o f Genes Selected for RT-QPCR

The candidate genes for Real-time Reverse Quantitative PCR were selected
based on their association with health effects or involvement in disease
pathways. A summary of each of these genes are given below.

Glutathione-s-Transferase yc2 (Gst-yc2)

Gst-yc2 belong to a family of enzymes that play an important role in
detoxification

by catalyzing the conjugation of many hydrophobic and

electrophilic compounds with reduced glutathione (Klaassen, 1995).
increases

the

rate

of glutathione

conjugation

of xenobiotics

Gst

through

deprotonation of GSH to GS' by an active site tyrosinate (Tyr-O'), which
functions as a general base catalyst (Klaassen, 1995). Gst is a polymorphic
gene encoding active, functionally different proteins, thought to function in

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

xenobiotic metabolism and play a role in susceptibility to cancer and other
diseases.

It expression and activity is regulated by a wide range of

xenobiotics and drug compounds such as aflatoxin-b1, coumarin, oltipraz,
trans-stilbene oxide,

PAHs, and other compounds (Ingenuity Pathway

Analysis, Ingenuity Inc, CA). The enzyme is present in most tissues, with high
concentrations in the liver, intestine, kidney, testis, adrenal, and lung, where
they are localized in the cytoplasm and endoplasmic reticulum (Klaassen,
1995; Ingenuity Pathway Analysis, 2004). The Gst-yc2 subunit is a member of
the Gst apha (Gsta) family of proteins; rats express four Gsta subunits (ya1,
ya2, yc1, yc2). The rat Gsta is the major Gst family in the liver and kidney. In
rats, the individual members of the alpha and mu class of Gst are inducible by
3-methylcholanthrene,

anti-oxidants,

corticosteroids,

and

phenobarbital

(Klaassen, 1995; Bartosiewicz et al, 2001). Induction is usually associated
with increased levels of mRNA due to transcriptional activation of the gene
encoding a subunit of Gst. The enhancer regions of the genes encoding some
of the rat Gst families have been shown (Bartosiewicz et al, 2001) to contain
a xenobiotic (dioxin)-responsive element (XRE).
Electrophiles in cells/tissues are potentially toxic and can bind to critical
nucleophiles, such as proteins and nucleic acids, and cause cellular damage
and genetic mutations. Therefore, conjugation with glutathione represents an
important detoxication. Over-expression of Gst is associated with resistance
to some toxic compounds (Ingenuity Pathway Analysis, Ingenuity Inc, CA).
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Ingenuity Pathway knowledge (Ingenuity Pathway Analysis, Ingenuity Inc,
CA) base analysis shows that the Gst-yc2 gene regulates the ErK/MAP
kinase kinase signaling pathway. The microarray data revealed that this
pathway is regulated by BaP exposure. Induction of MAP kinase kinase
genes was observed in the microarray data. In addition, the expression of Gst
is also regulated by the large T antigen, TGM2, fos, EGF growth factors and
other proteins.

Cytochrome p450 (Cyp1a1 and Cyp1a2)

Cytochrome

p450

are

among

the

most

versatile

of

the

phase

1

biotransforming enzymes in terms of the sheer number of xenobiotics they
detoxify or activate to reactive intermediates (Klaassen, 1995). The highest
concentration

of

cytochrome

p450

enzymes

involved

in

xenobiotic

biotransformation is found in liver endoplasmic reticulum but they are also
present in virtually all tissues (Klaassen, 1995). The liver microsomal p450
enzymes play a very important role in determining the intensity and duration
of action of drugs, and they also play a key role in the detoxication of
xenobiotics (Barouki and Morel, 2001; Klaassen, 1995; Chen and Tukey,
1996). In addition, cytochrome p450 enzymes in liver and extrahepatic tissues
play important roles in the activation of xenobiotics to toxic and/ or
tumorigenic metabolites (Klaassen, 1995). Furthermore, microsomal and
mitochondrial p450 enzymes play key roles in the biosynthesis or catabolism
of steroid

hormones,

bile acids, fat-soluble vitamins, fatty acids and
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eicosanoids, which shows the catalytic versatility of cytochrome p450
(Klaassen,

1995). All cytochrome p450 enzymes are heme-containing

proteins and the basic reaction they catalyze is monoxygenation in which one
atom of oxygen is incorporated into a substrate, and the other is reduced to
water with reducing equivalents derived from NADPH (Klaassen, 1995, Hall
and Grover, 1990).
Cyp1a1 and Cyp1a2 are monooxygenases which catalyze many reactions
involved in drug metabolism and synthesis of cholesterol, steroids and other
lipids

(Ingenuity Pathway Analysis,

Ingenuity Inc, CA). The enzymes

endogenous substrate are unknown, however, they are able to metabolize
PAHs to carcinogenic intermediates. They are found in the sub-cellular
locations such as the cytoplasm, endoplasmic reticulum, microsome, and
mitochondrial membranes.
Species differences exist in the relative expression of Cyp1a1 and Cyp1a2 in
the livers (Ingenuity Pathway Analysis, Ingenuity Inc, CA). For instance, in
rats Cyp1a1 is preferentially used in catalyzing xenobiotics such as in the Odealkylation of 7-ethoxyresorufin, whereas Cyp1a2 preferentially catalyzes
the O-dealkylation of 7-methoxyresorufin (Klaasen, 1995).
Ingenuity Pathway knowledgebase analysis of the data indicates that their
expression is regulated by omeprazole, BaP, Genistein, LPS, and other
compounds. Their activity is regulated by several compounds such as
tetrachlorodibenzodioxin (TCDD), Ah receptor, 3-methylycholanthrene, 1aminobenzotriazole, and others. In addition, several of these compounds also
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regulate their transcription, quantity, accumulation, and are inhibited by
compounds such as tryptamine.

B-cell Lymphoma 2 (Bcl-2)

Bcl-2 is an integral inner mitochondrial membrane protein that blocks the
apoptotic death of some cells such as lymphocytes (Brown et al, 1990; Davila
et al, 1995). Constitutive expression of Bcl-2, such as its translocation to Ig
heavy chain locus, is thought to be a cause of follicular lymphoma (Ingenuity
Pathway Analysis, Ingenuity Inc, CA). Two transcripts variants, produced by
alternate splicing, differ in their C-terminal ends. Variant 1 is represented by a
5.5 kb mRNA and includes most of exon 1 and exon 2. A 3.5 kb mRNA
represents variant 2; it includes all of exon 1 and lacks exon 2 sequence
(Ingenuity Pathway Analysis, Ingenuity Inc, CA). It is involved in the regulation
of cell cycle (anti-apoptosis), humoral immune response, cell growth and/or
maintenance, and negative regulation of cell proliferation (Davila et al, 1995;
Salas and Burchiel, 1998). It is found in different sub-cellular locations such
as cell surface, cytoplasm, endoplasmic reticulum, intracellular membranes,
mitochondrial membrane, nuclear envelope, and other locations (Ingenuity
Pathway Analysis, Ingenuity Inc, CA). It expression is regulated by tumor
necrosis factor (TNF), glutamate, myc, growth hormone releasing peptide-6,
lnterleukin-1 beta (IL-1(S), and other factors (Ingenuity Pathway Analysis,
Ingenuity Inc, CA). For instance, the activity of Bcl-2 gene during programmed
cell death is believed to depend on collaboration (Alberts et al, 1994) between
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myc and the Bcl-2 gene. If myc alone is overexpressed, cells are driven round
the division cycle in appropriately, but no cancer results because the progeny
of such abnormally forced divisions are programmed to die (Alberts et al,
1994). If Bcl-2 is overexpressed at the same time, however, the excess
progeny cells survive and proliferate; Bcl-2 can act as oncogenes because
the Bcl-2 protein inhibits programmed cell death. Phosphorylation of Bcl-2 is
regulated

by MAPK and

NGF beta.

Other factors

also

regulate

its

transcription and quantity in cells (Alberts et al, 1994).

Tumor Suppressor Protein 53 (Tp53)

p53, a nuclear protein, plays an essential role in the regulation of cell cycle,
specifically in the transition from GO to G1 (Jeffy et al, 2000; Alberts et al,
1994, Binkova et al, 2000; Ingenuity Pathway Analysis, Ingenuity Inc, CA). It
is found in low levels in normal cell, however, in transformed cell lines it is
expressed in high amounts, and can contribute to transformations and
malignancies. Also, it is a DNA-binding protein containing DNA-binding,
oligomerization and transcription activation domains (Ingenuity Pathway
Analysis, Ingenuity Inc, CA). In addition, it is postulated to bind as a tetramer
to a p53-binding site and activate expression of downstream genes that inhibit
growth and/ or invasion, and thus function as a tumor suppressor. Mutants of
p53 frequently occur in a number of different human cancers; they fail to bind
the consensus DNA-binding site, and therefore cause the loss of tumor
suppressor activity (Ramet et al, 1995). It sub-cellular locations are in DNA
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replication foci, centrosome, chromatin, cytoplasm, nucleus, and others
(Ramet et al, 1995). It regulates the expression of Bax, Jun, NFkB1, Insulin
like growth factor binding protein {IGFBP3), Creb and other protein products
(Ingenuity Pathway Analysis, Ingenuity Inc, CA). In addition, it is regulated by
interleukin-3, NFkB, ATM, MAPkinase and other factors. As transcription
factor, p53 is involved in various biological processes such as cell cycle
checkpoint, DNA repair,

DNA recombination, apoptosis, DNA damage

response, and negative regulation of cell cycle. It is associated with
tumorigenesis,

immunological diseases,

metabolic diseases, and other

genetic disorders (Ingenuity Pathway Analysis, Ingenuity Inc, CA). Also,
Ramet et al (1995) has shown that p53 expression is correlated with BaPDNA adducts in carcinoma cells. Similarly, BaP has been shown to activate
the human p53 gene through induction of nuclear factor kappa B (NFkB)
activity.

Interleukin-1 beta (IL-1(S)

IL-1(3 is a cytokine produced by activated macrophages as a proprotein,
which is proteolytically processed to its active form by caspase 1 (Ingenuity
Pathway Analysis, Ingenuity Inc, CA). This cytokine is an important mediator
of the inflammatory response, and is involved in a variety of cellular activities,
including cell proliferation, differentiation, and apoptosis. IL-1p induces
cyclooxygenase-2 in the central nervous system and thereby contributes to
inflammatory pain hypersensitivity. Together with eight other interleukin 1
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family genes, they form a cytokine gene cluster on chromosome 2 (Ingenuity
Pathway Analysis, Ingenuity Inc, CA). The sub-cellular locations are in axons,
cell surface, and plasma membrane. In terms of molecular processes, the
expression of IL-1f.3 is regulated by a wide range of other genes such as IL-6,
FOS, NFKB1A, IL1RL1, malic enzyme, IGFBP4 and others. Also, it regulates
the binding, transcription, activation and degradation of several other genes.
Furthermore,

it expression

is also regulated

by compounds such as

glucocorticoids, prostaglandins, TNF, injury and others.

PAH have been

shown to cause an increase in intracellular calcium levels (Mounho et al,
1997) and cause immunosuppressive effects through a mechanism that
involves altered cytokine production/ or disruption of cell surface membrane
signaling (Davila et al, 1995).
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CHAPTER 111

MATERIALS AND METHODS

Chemicals

Benzo[a]pyrene (>99%pure) was purchased from Sigma Chemical (St Louis,
MO) and used to prepare diets.

All other chemicals and solvents used in

these experiments were reagent grade.

Reagents for mRNA extraction,

Affymetrix

expression

and

Real-Time

PCR

gene

analysis

were

as

recommended by the manufacturer and are listed in the methods sections for
those operations.

Chemical Exposures

Male Fischer-344 rats, 6- weeks post-weaning and weighing 140-180g, were
obtained from Charles River Laboratories (Mattawan, Ml). This study was
conducted under federal guidelines (Principles of Laboratory Animal Care;
NIH publication no 85-23, revised 1985 and Guiding Principles in the Use of
Animals in Toxicology) for the use and care of laboratory animals and the
protocols (99-09-01 and 03-04-02) were approved by the Institutional Animal
Care and Use Committee (IACUC) and the Environmental Safety Office of
Western Michigan University. The animals were individually housed in
hanging, stainless steel, wire mesh metabolic cages under controlled
conditions of temperature (20°C + 2°C) and light cycle 12 hr. light/12 hr. dark
with free access to water and a defined diet throughout the study. Animals
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were randomized by weight, assigned a unique identification number and
assigned into an experimental diet treatment group.

Preparation o f Food

A standard rat pellet food (Rodent Diet 5001, Lab Diet, St. Louis, MO) was
obtained from the Western Michigan University Animal Care Facility.

A

general procedure developed in the lab (Chiang, 2001) was used to prepare
BaP-spiked rat food pellets. BaP was dissolved in toluene to produce a stock
solution o f 200mg/ml. 2000g of pellet feed, 300ml of 95% ethanol and an
aliquot of stock solution (amount varied depending on final concentration
desired in the food) were mixed in 4000ml polypropylene bottle and incubated
at room temperature on a rotating shaker for 4hrs. The food was then dried in
a vacuum oven at 80°C for 48 hrs to evaporate the solvent. The same
process was used for preparing the control food, except that no BaP was
added to the mixture. Tests confirm that these conditions remove all of the
solvent carriers and further that the toxicant is uniformly distributed in the food
pellets using this method.

Dose Verification

The final concentration of BaP in the food pellets was determined using high
Performance Liquid Chromatography (HPLC). For the HPLC assay, a Hewlett
Packard 1090 HPLC system equipped with a DAD detector and a Zorbax SBC8 column (150 x 4.6 mm, 5//m) (Hewlett Packard, CA) was used. The
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detector was set to monitor the absorbance of BaP at 300 nm. The flow rate
was 1.0 ml/min and the injection volume was 10//L. Formic acid was used a
solvent A and 0.2% formic acid in acetonitrile was used as solvent B. A linear
gradient was run as follows: 0 min, 60% A, hold for 1min; 7min, 100 % A, hold
for 3 min; 10.1 min, 60 % A. BaP eluted at 7.1 minutes. Sample (five
replicates) preparation for HPLC was done using 2 to 5 grams of dose feed
soaked in a diluent containing 70/20/10 (%v/v/v) acetonitrile: methanol:
acetone with constant shaking for 24 hrs and then filtered through a 0.22 pm
glass fiber filter. A calibration curve spanning the range of expected
concentrations was obtained through analysis of four concentration levels of
BaP standards prepared from the same BaP stock in triplicates.

Dietary Exposures

Two independent studies were carried out (Acute and Sub-chronic); A 2-week
acute exposure and 12-weeks sub-chronic exposure. For both studies,
animals were randomly assigned into control or treatment groups (study 1, n
= 3 per group; study 2, n = 6 per group).
In the first study (Acute), animals were exposed to either control diet,
0.01mg/g-diet or 0.1 mg/g-diet for 2 weeks. In the second study (sub-chronic),
animals were exposed to either control diet, 0.01 mg/g-diet, 0.1 mg/g-diet or
1.0 mg/g-diet for 12 weeks.
Animal weights were recorded two-three times a week. The amount of the
diet consumed was estimated by measuring the amount of the food retained
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in the feeding jar at the end of each feeding period, the amount spilled, and
subtracting the values from the amount of food given at the beginning of the
feeding period. Over the entire exposure period, the total food intake for each
treatment group per week was calculated by summation of the measured food
intake from each feeding period in that week. These values were then
compared against the food intake data of control rats and represented as
percentage gain or loss in dietary intake relative to controls.

Animal Sacrifice and Tissue Isolation

At the end of each experimental time period, rats were euthanized using CO 2 .
liver, lungs, kidneys, thymus, and spleen were excised, weighed (fresh
weight) and flash frozen in liquid nitrogen for further analysis. Tissue weights
were normalized to the body weights of each animal to obtain actual
differences in tissue weight.
The liver tissue was excised and split into two pieces; one half for microarray
analysis and one half for Real-time PCR analysis. Tissue isolated for gene
expression was immediately frozen in liquid nitrogen and stored at -80° C until
RNA isolation.

Messenger RNA (mRNA) Isolation

Liver tissue was disrupted in liquid nitrogen using a mortar and pestle
followed by homogenization in extraction buffer (Ambion Inc, Austin, TX) with
a Dunce homogenizer. mRNA was isolated using a Poly A pure kit (Ambion
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Inc.,

Austin,

IX )

and

carried

out

according

to

the

manufacturer’s

specifications. The purity and concentration of mRNA was determined by gel
electrophoresis and UV spectrometry (Gene Quant Pro, Amersham)

Affymetrix GeneChip Analysis

Samples were prepared for microarray analysis according to Affymetrix
GeneChip ® protocols (Affymetrix, Inc., Santa Clara, CA). The Affymetrix rat
toxicology array (RG-U34A) used in these studies consist of 8,800 genes and
expressed

sequence

tags

(EST)

in

the

rat

UniGene

database

(http://www.ncbi.nlm.nih.qov/entrez/querv.fcqi?db=uniqene).
Experimental procedures including double-stranded complementary DNA
(cDNA) synthesis and biotinylated complementary RNA (cRNA) preparation
were conducted as recommended in the Affymetrix GeneChip Expression
Analysis Technical Manual (Affymetrix, Inc., 2003).

Double-Stranded cDNA Synthesis

For double strand complementary DNA

(cDNA) synthesis, an

aliquot

containing 10-15 pg mRNA was first hybridized with 100 pmol T7-(dT) 24
primer

[5’-(biotin)-GTCGTCAAAGATGCTACCGTTCAGCA-3]

(GENSET

Corp, La Jolla, CA). Primer hybridization was completed in a 20-pl reaction
containing a final concentration of 10mM dithiothreitol (DTT), 500mM each of
deoxyribonucleoside triphosphate (DNTP) mix, and 1x first strand cDNA
buffer. The reaction was incubated at 42°C for 2 min followed by addition of
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400-600 U superscript II reverse transcriptase (Gibco Life Technologies,
Rockville, MD) to synthesize first- strand cDNA.

After 1 hr, second-strand

cDNA synthesis was carried out by adding 200 pM each of dNTP, 10 U
Escherichia coli (E. coli) DNA ligase, 40 U E. coli DNA polymerase I, 20 U £.
coli RNase H, and 1x second-strand reaction buffer in a 1.5 mL volume and
incubated at 16° C for 2 hr. T4 DNA polymerase was added at the end of the
reaction for an additional 5 min and soaked in 10 pi 0.5 M EDTA (SigmaAldrich, MO). Phase-Lock Gel (Eppendorf Scientific, Inc., Westbury, NY)
extraction with phenol/chloroform followed by ethanol precipitation was
subsequently performed to clean up the double-stranded cDNA. The cDNA
pellet was resuspended in 12 //I Diethyl pyrocarbonate (DePC) treated
RNase-free water.

Biotin-Labeled cRNA Preparation and In Vitro Transcription

Biotin-labeled cDNAs were generated from the cDNA samples by in vitro
transcription with T7 RNA polymerase, Bioarray High Yield RNA Transcript
labeling kit (Affymetrix, Inc). Briefly, 3.3-5 p\ double-stranded cDNA was
mixed gently with 4 p\ each of 10x high-yield reaction buffer, 10x biotinlabeled ribonucleotides, 10x DTT, 10x RNase inhibitor mix, and 2 pi of 20x T7
RNA polymerase provided by the kit and incubated at 37° C for 4-5 hr, with
gentle mixing every 30 min. Labeled cRNA was then cleaned with RNeasy
Mini kit (Qiagen, Inc, Valencia, CA) to obtain an accurate quantification of the
labeled cRNA. 20 pg of labeled cRNA was then fragmented to 35-200 bp with
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8 jj\ 5x fragmentation buffer containing 200 mM Tris-acetate, pH 8.1; 500 mM
potassium acetate and 150 mM magnesium acetate in a total volume of 40 //I
for 35 min at 94° C. Before hybridization onto GeneChip Array, the quality of
labeling and fragmentation was verified on agarose gel.

Hybridization to GeneChip Array

After labeling and fragmentation, 15 pg fragmented biotinylated cRNA was
hybridized to the Affymetrix GeneChip Array in a 300 p\ cocktail containing 5
p\ of 3 nM control oligonucleotide B2, 15 p\ 20x eukaryotic hybridization
controls, and 150 p\ 2x hybridization buffer provided in the GeneChip
Eukaryotic Hybridization control kit (Affymetrix, Inc.) together with 3 p\ 10
pg!p\ herring sperm DNA and 3 p\ 50 pg!p\ acetylated bovine serum albumin
(BSA). The hybridization was carried out at 45° C and 60 rpm in GeneChip
hybridization oven 640 (Affymetrix, Inc.) for 16 hr. Prior to hybridization to
Affymetrix RG-U34A arrays, sample was hybridized to Affymetrix test3 Arrays
for quality control.

Washing, Staining, and Scanning the Array

After hybridization, the washing and staining procedures were carried out on
a GeneChip Fluidics station 400 in conjunction with Affymetrix Microarray
Suite 5.0 software (MAS 5.0; Affymetrix, Inc.). Briefly, the array was first
washed with 10 cycles of 2 filling and draining cycles in a non-stringent buffer
containing 6x SSPE (52.9 g sodium chloride, 8.28 g sodium phosphate,
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monobasic, 2.82 g EDTA, pH 7.9) and 0.01 % Tween 20 at 25°C, followed by
4 cycles o f 15 filling and draining cycles in a stringent buffer containing 100
mM MES [2-(N- morpholine) ethanesulfonic acid], 0.1 M Na+ and 0.01%
Tween 20 at 50° C. The probe array then was first stained with a 600

jj

\

streptavidin-phycoerythrin (SAPE) solution containing 1x MES stain buffer
(100 mM MES, 1 M N a \ and 0.05 % Tween 20), 2 jug/jul acetylated BSA, and
10 /jg//j\ SAPE (Molecular Probes, Inc., Eugene OR) for 10 min at 25° C. After
the first staining the array was washed with 10 cycles of 4 filling and draining
cycles in non-stringent buffer at 25° C.

The stained signals were then

amplified in a 600 //I antibody solution containing 1x MES stain buffer, 2 /vg/ywl
acetylated BSA, 0.1 jjg//j\ normal goat IgG, and 3 fjgl /j\ antistreptavidin
biotinylated antibody (Vector laboratories, Inc) for 10 min at 25° C, followed by
a second SAPE staining at the same temperature for another 10 min. Finally,
the probe array is washed for 15 cycles of 4 filling and draining cycles in a
non-stringent buffer and

scanned

by the Agilent GeneArray Scanner

(Affymetrix, Inc.) at an excitation wavelength of 570 nm. After scanning, each
image was inspected for major chip defects or abnormalities in hybridization
signal as a quality control and analyzed using MAS 5.0.
The scanner generates an image of the array by exciting each feature with its
laser, detecting the resulting photon emissions from the fluorescently labeled
RNA that has hybridized to the probes in the feature, and converting the
detected photon emissions into a 16-bit intensity value. The images
generated by the scanner are then ready for analysis.
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For the GeneChip analysis, two rats (n=2) were assayed individually from
each treatment group for both 2- and 12-weeks time points. The choice of two
animals per group for GeneChip Analysis is based on, 1) gene expression
validation studies that indicate one chip per treatment group may be sufficient
for expression analysis, 2) n of 2 is considered cost-effective in terms of data
analysis since p (number of genes) is large. Each sample (treatment or
control) for analysis was first run on an Affymetrix test3 array before
hybridization to Affymetrix RG-U34A array. Test chip contains probes
corresponding to commonly expressed genes from human, rat, mouse and
yeast genomes. Probes derived from 5’, middle and 3’-portions of genes and
can identify insufficient or degraded RNA target.
In order to assess the reproducibility of the GeneChip Microarray system, two
separate samples (control and 0.1mg/g-diet) from the same animal (12-weeks
exposed) were run on duplicate chips. This analysis revealed a 96% similarity
between the technical replicates from both samples. Therefore, subsequent
samples were analyzed using one chip per animal for each treatment group.

Data Analysis

The Affymetrix RG-U34A GeneChip contains 8800 genes and expressed
Sequence tags (ESTs) derived from the UniGene database. Each gene is
represented by 20 pairs of 20-25 mer sequence probes that contain a
perfectly matched probe (PM) and a mismatched (MM) sequence probe that
is altered by one base pair. The MM probes serve as controls for background
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and

cross

hybridization signals.

Gene Array Laser Scanner software

quantifies the expression of each gene by subtracting the signal intensity of
the MM from the PM probes.
The Affymetrix Microarray Suite 5.0 (MAS 5.0) software supplied

by

Affymetrix to process array images from the scanner performs all of the
fundamental operations necessary to analyze an array, including (I) image
segmentation, (2) background correction, (3) scaling/normalizing arrays for
array-to-array comparisons, (4) calculation of statistics to indicate whether a
gene transcript is present or absent and (5) calculation of statistics to indicate
whether a gene transcript is differentially expressed. The software uses a
variety of parameters to determine the expression level of each RNA
molecule. Absolute call determines whether RNA is present or absent, and
difference call determines the change between baseline and experimental
samples. The software also computes a signal log ratio that quantifies the
change in signal intensity between two samples (e.g. control versus treatment
or control versus control). These files are designated CHP files.
In this project, two GeneChips were processed for each dose and time point.
For analysis, comparative CHP files were produced that used the control
sample (at each time point) as a baseline and treatment groups as the
experimental sample.

Each experimental dose (n=2) was compared with

each time-appropriate control (n=2), resulting in a total of 4 pair wise
comparisons for each dose and exposure time interval. In order to minimize
false positives, only those transcripts that had an increase or decrease of >3-
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fold in at least 3 out of the 4 pair wise comparisons were selected for
interpretation. Additional data analysis to generate exploratory statistics,
scatter plots, filter genes based on various parameters (fold changes, signal,
signal-log ratios, count/percentage, Average Difference Intensity), clusters
(Hierarchical and Self-organizing maps), and to determine genes that were
unique or common between experiments was done using Affymetrix Data
Mining Tool (DMT 3.0) and Spotfire decision site for functional genomics
(Spotfire, Inc. CA). Smart Draw program (Smart Draw.com, CA) was used to
plot Venn diagrams that showed genes that are in common and unique
between treatment groups.

Cluster Analysis and Biological Processes Identification

Extracting biological process information from microarray data has been of
recent interest and some of the most recent analysis includes k-means
clustering, hierarchical clustering, self-organizing maps (SOM), and Principal
component analysis (PCA) (Eisen et al, 1998; Waring et al, 2001; Tamayo et
al, 1999; Yeung and Ruzzo, 2001). Because of the large number of genes
and complexity of biological networks, clustering is a useful exploratory
technique for analysis of gene expression data. Each of these techniques has
their limitations and therefore, a combination of two or more of these
techniques are suggested to represent a given data set. For hierarchical
clustering of the data, we used the Spotfire decision site program for
functional genomics to cluster the data set into genes that perform similar
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function or were induced by BaP in a similar pattern. The hierarchical
clustering measures similarity between genes based on expression profiles
across conditions. This measurement requires a definition of similarity that is
provided by a metric. The most common metrics are Euclidean distance,
which measures how different two profiles are taking into account the
magnitude of signals. Pearson correlation metric, on the other hand,
measures the shape or direction and association between two different
profiles. W e used the weighted average linkage method for hierarchical
clustering of the genes and Euclidean distance as the similarity metric. The
average signal intensity of each gene in each treatment group (8800) was
normalized to the control signal. The resulting normalized average signal
ratios were log transformed using log base 2. The log transformed signals
were used as the input values for hierarchical clustering of the data in Spotfire
decision site for Functional Genomics (Spotfire, Inc, CA). A threefold log ratio
was used to color the resulting hierarchical cluster. Genes with a positive shift
or increase equal or greater than threefold were shown with increasing
intensity of red. Genes showing a negative shift or decrease equal to or less
than negative log of threefold are colored green. The relationships among
genes are represented by a dendrogram whose branch length reflects the
degree of similarity between the genes. From the resulting dendrogram of the
hierarchical cluster, 10 small clusters were created to show the behavior of
genes within those clusters. In order to visualize the orientation of these
genes in N-dimensional space and get a clear picture of the behavior of the
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genes in each cluster, principal component analysis was done on the 10
clusters extracted from the hierarchical cluster.
Self-organizing maps (SOM) have recently been proposed as an alternate
unbiased method for extracting patterns; however, there are subtle issues
such as choosing the initial geometry of nodes and related parameters.
Therefore, a combination of both hierarchical clustering and SOM were
utilized to interpret the results. SOM clustering was performed using the
Affymetrix Data Mining Tool software 3.0. For SOM analysis, probe sets were
considered across experiments (n=2 for treatments) at each time-point.
Average signal intensity of each probe across experiments was used to
compare

relative

gene

expression

across

experiments.

The following

parameters were used; threshold signal was set at 20-20,000; row variation
filter: max/min = 3 and max - min = 100; grid geometry: rows (3) x columns
(2); initialization: random vectors; Neighborhood: bubble; neighborhood width:
5-0.02; learning rate (a): 0.1-0.05. The details and description of these
parameters can be found in Affymetrix data mining tool user’s guide, version
3.0. The row expression filter eliminated genes that did not change
significantly across the experiments and the genes that passed through the
filter were fed to the SOM algorithm.
For Principal component analysis (PGA), we utilized the Spotfire Decision site
for functional Genomics (Spotfire Inc, CA) to analyze the data. PGA is a
classical technique to

reduce the dimensionality of the data

set by

transforming to a new set of variables (Principal components) to summarize
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the features of the data. These summary variables can be used for
visualization or for more complex statistical modeling. The first aspect in PGA
(Yeung and Ruzzo, 2001) is creation of the components, which are weighted
averages of the original variables and they are constructed to be uncorrelated
with each other and to capture much of the original variability as possible. The
second aspect is the selection of the most representative (or principal)
components (PC) based on the fraction of variability that is retained using
them only. As in cluster analysis, PGA are also based on similarity (distance)
matrix between genes or objects. The Pearson correlation matrix commonly
used in gene expression analysis was similarity metric employed. Here the
first PC is the direction along which there is greatest variation in the data. For
example, we have 8800 genes in our array and therefore, the first PC is
described by a vector of “loadings” of length J, consisting of weights to be
applied to each gene’s expression. A loading close to 0 implies that a gene
does not vary much across arrays. Large negative and large positive loadings
imply that a gene shows considerable variation across arrays in the dataset.
The second principal component is created so that it is orthogonal to the first
PC. It represents the weighted average across genes that explain the largest
amount of variation in the data after controlling for the variation explained by
the first PC. As described for hierarchical clustering, Affymetrix data from both
time points and treatments was first transformed before importing data into
Spotfire. First, the average signal intensity of each gene from the various
treatment groups was normalized to the appropriate control signals to obtain
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average signal ratios as previously described. Average signals were log
normalized to obtain log signal ratios. The algorithms for PCA and many other
clustering

algorithms work best with

log

normalized values. The

log

normalized values for time point 1 (2-weeks) and Time-point 2 (12-weeks)
were combined into one table using time as an identifier to separate them.
These data was imported into Spotfire Decision site for Functional Genomics
and analyzed by PCA.

Biological Processes and Molecular Function Analysis

After clustering and PCA assessments, it is necessary to interpret microarray
data to some useful biological endpoints.

Biological process and molecular

function information for genes was obtained using Affymetrix NetAffix and
Gene Ontology program of National Center for Biotechnology Information
(NCBI). Other biological process information was obtained from various
databases such as KEGG, SWISSPROT, NCBI UniGene and GenBank
databases.

Ingenuity Pathways Analysis

(Ingenuity Systems, CA) and

GenMaPP software (University of California Gladstone Institute, CA) for
biological

pathways

identification

was

used

for

mapping

biochemical

pathways associated with various genes. Ingenuity pathways analysis allows
researchers to input into its pathways analysis application a set of genes or
proteins, the software’s knowledge base then dynamically computes a set of
relevant pathways. Similarly, GenMaPP is a free computer application
designed to visualize gene expression and other genomic data on maps
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representing biological pathways and groupings of genes. In addition, Paracel
pathworks (Paracel, Inc, GA) was used to easily draw the biological pathways
obtained from Ingenuity and GenMaPP.

Real-Time Quantitative PCR (RT-QPCR)

We use the ABI Prism 7700 SDS in combination with Taqman chemistry,
using specific sets of primers and an internal fiuorogenic probe for each target
of interest. In designing the primer sets, special care was taken to avoid co
amplification of contaminating genomic DNA.

Primer and Probe Design

mRNA sequences of 6 rat genes of interest (cytochrome p450 1a1, Cyp1a1;
cytochrome p450 1a2, CyP1a2; Glutathione-s-transferase yc2, Gst-yc2; B-cell
lymphoma, Bcl-2; Tumor suppressor protein 53, p53; lnterleukin-1 beta, IL-1(3)
and yeast actin control (internal standard) were downloaded from NCBI
GenBank. Real-time quantitative PCR (Taqman) primers and probes for the
yeast actin control and rat genes of interest were designed employing Primer
Express software (Applied Biosystems). The primary object of this program is
to design sets of primers and internal probes that can be run under universal
thermal cycling conditions (15 s at 94° C and 1 min at 60° C). The default
parameters of the software are therefore set to be very narrow. The required
parameters for well-designed primers and probe have been well documented
and are built into the program. These parameters include a Tm for the probe
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that is 10° C higher than the primers, primer Tms between 58° C and 60° C,
amplicon size between 50 and 150 bases, absence of 5’ Gs, and primer
length. More specifically for our experiment, we designed primers with no
more than 2 Cs or Gs in last five nucleotides of the 3’ end; probes with high
Cs in sequence and no Gs at 5’ of probe. The 5’- and 3’-end nucleotides of
each probe were labeled with a reporter flourochrome (6-carboxyfluorescin or
FAM) and a quencher dye (6-carboxy-tetramethyl-rhodamine or TAMRA),
respectively. Where possible, to avoid co-amplification of contaminating
genomic DNA, primers are designed on different exons or intron-exon
boundaries.

Taqman Chemistry and Principle

The principle of the Taqman real-time detection is based on the fluorogenic 5’
nuclease assay. The Taqman chemistry, which is the key to the detection
system based on two principles, 1) the intrinsic 5 -3 ’ exonuclease activity of
Taq polymerase, and 2) the presence of a dual-labeled Taqman probe. The
Taqman probe is designed to anneal to the target sequence between the
traditional forward and reverse primers. Also, the probe is created to emit a
fluorescent signal only upon cleavage, based on fluorescence resonance
energy transfer (FRET). The probe is labeled at the 5’ end with a reporter
flourochrome (6-FAM) and a quencher flourochrome (TAMRA) added at the
3’end. The probe is designed to have a higher Tm than the primers, and
during the extension phase, the probe must be 100 % hybridized for success
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of the assay. As long as both fiuorochromes are on probe, the quencher
molecule stops all fluorescence by the reporter. However, as Tag polymerase
extends the primer, the intrinsic 5' to 3’ nuclease activity of Tag degrades the
probe, releasing the reporter fluorochrome. The amount of fluorescence
released during the amplification cycle is proportional to the amount of
product generated in each cycle.
The ABI PRISM 7700 sequence detection system used in this experiment
consists of a 96-well thermal cycler connected to a laser and charge-coupled
device (CCD) optics system. An optical fiber inserted through a lens is
positioned over each well, and laser light is directed through the fiber to excite
the fluorochrome in the PCR solution. Emissions are sent through the fiber to
the CCD camera, where they are analyzed by the software’s algorithms. The
software package supplied with the instrument measures the increase in
fluorescence emissions in real-time, during the course of the reaction. The
increase in fluorescence
amplification.

The

is directly related to the increase in target

software

calculates

the

difference

between

the

fluorescence emissions of the product at each time point and fluorescence
emissions of the baseline. The cycle number at which the fluorescence
emissions of the product rise above the background or baseline is the
threshold cycle (Ct). The Ct is determined at the most exponential phase of
the reaction (usually 10 times the standard deviation of the baseline) and is
more reliable than end-point measurements of accumulated PCR products
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used by traditional PCR methods. The starting copy numbers of unknown
samples is determined through standard curve plots of Ct values.

Table 1
Sequence of Real-Time PCR Primers and Probe

Gene

Forward Primer

Reverse Primer

Probe

Cyp1a1

ccccggctttctgacaga

atgtcggaaggtctccagga

ctcagctgccctatctggaggccttc

Cyp1a2

tgatgagaagcagtggaagacc

ggccgtgttgtcattggtaag

tttgtgttccgcccagagcggtt

Gst-yc2

gccgatctggagttgatggt

atcttggcaagactcgcctc

ctctattacccctacatgccccctggg

P53

catgagcgttgctctgatg

cagatactcagcatacggatttcc

Bcl-2

aggattgtggccttctttgagtt

gccggttcaggtactcagtcat

ccctggtggacaacatcgctct

IL-1/3

cacctctcaagcagagcacag

gggttccatggtgaagtcaac

tgtcccgaccattgctgtttcctagg

Yeast

tggattccggtgatggtgtt

tcaaaatggcgtgaggtagaga

ctcacgtcgttccaatttacgctggttt

acggcctggctcctcccaac

RT-QPCR Reaction and Amplification

All reagents for one-step RT-PCR reactions were purchased from Applied
Biosystems, Inc. PCR amplifications are performed on the ABI PRISM 7700
SDS using 96-well microtiter plates. They are performed on a total volume of
25 p\ containing 4 ng of mRNA, 300 nM primers (forward and reverse), 200
nM Taqman probes,

AmpliTaq Gold DNA polymerase mix (2X) containing

AmpliTaq Gold DNA polymerase, dNTPs with dUTP, Passive Reference,
Taqman optimized buffer components, and 40X RT enzyme mix containing
MultiScribe™ Reverse Transcriptase and RNase inhibitor. All RT-PCR plates
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were covered with optical adhesive covers following complete loading of
reagents. For each gene of interest and yeast internal control, different
primer, probe and poly A RNA concentrations were tested to optimize the
PCR amplification. Also, no enzyme (reverse transcriptase) controls were run
for each reaction. RT and PCR amplifications were performed in duplicate
wells (except for the No enzyme controls), using the following temperature
cycles: 30 min at 48° C for the RT hold, 10 min at 95° C (AmpliTaq Gold DNA
polymerase activation), and then run for 40 cycles of PCR at 95° C for 15 s
(denature), and 60° C for 1 min for annealing and extension.

Normalization

In order to control for variations due to mRNA isolation or RT-PCR conditions,
50 ng of yeast mRNA was spiked into each sample during mRNA extraction.
Also, RT-PCR for each gene of interest was run in conjunction with yeast
actin for each sample to normalize the expression levels.

Quantification and Data Analysis

To quantify the results obtained by real-time RT-PCR we used the standard
curve method.

Standard curves for both the yeast internal control and the

target genes was generated from serial dilutions of untreated control samples,
and used to determine the amount of mRNA for each gene and yeast in all
experimental samples. The relative expression level of each gene was
computed with respect to yeast mRNA for each treatment group to account
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for variation in quality of mRNA or RT-PCR conditions. Gene Expression
levels for the treatment groups were compared with control groups using one
way AN OVA F- statistics followed by Bonferroni pairwise post-hoc test.
Levene statistic was used to test for homogeneity of variances.
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CHAPTER IV

RESULTS AND DISCUSSION

Affymetrix Microarray Analysis

To determine the effects of BaP on the expression patterns of genes in the rat
liver, RNA was extracted from rat livers and the results showed that all of the
RNA was intact. Representative gels are shown in Figure 5 below.

****»*■ fefejfum )-y

(a)

&***<$#

(b)

(c)

Figure 5. Representational Gels of mRNA, cRNA and Fragmented cRNA from
Rat Liver Tissue, (a) mRNA from rat liver tissue of 2-weeks exposed animals,
(b) cRNA produced from In Vitro Transcription of cDNA, and (c) fragmented
cRNA.

Gene expression profiles were determined using Rat toxicology RG-U34A
microarrays from Affymetrix. Expression changes were reflected in the
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differences in signal intensity from array hybridizations. Analysis of the
microarray differences in the hybridization signals was accomplished by the
use of Affymetrix Microarray Analysis Suite 5.0 software (MAS 5.0). A
threefold or greater change in signal intensity was considered a significant
change in expression (Figure 6-10). Analysis of the gene expression patterns
of rat livers in response to BaP demonstrated a threefold or greater change in
the expression of a large number of genes at both 2-and 12-weeks time and
exposure levels (Figures 6-10). Figure 6-10 shows scatter plots of differential
signal intensity between control and treatment groups (Pairwise comparison)
for 2- and 12-weeks exposure. Fold change of 2, 3, and 10 are represented
by black lines.

10000

% 1

1

10

100

1000

1000Q1

Average Contra! Signal Intensity

Figure 6. Scatter Plot of Differential Signal Intensity between Control and High
Dose (0.1 mg/g of diet) After 2-weeks of Exposure to BaP
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Figure 7. Scatter Plot of Differential Signal Intensity between Control and Low
Dose (0.01 mg/g of diet) After 2-weeks of Exposure to BaP
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Figure 8. Scatter Plot of Differential Signal Intensity between Control and High
Dose (1.0 mg/g of diet) After 12-weeks of Exposure to BaP
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Figure 9. Scatter Plot of Differential Signal Intensity between Control and
Medium Dose (0.1 mg/g of diet) After 12-weeks of Exposure to BaP
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Figure 10. Scatter Plot of Differential Signal Intensity between Control and
Low Dose (0.01 mg/g of diet) After 12-weeks of Exposure to BaP
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As shown in Figures 6 and 7, after 2-weeks of exposure to BaP, a large
number of genes were differentially expressed (up to 10 fold) at both low and
high dose exposure. This is in line with several studies characterizing the
temporal regulation of gene expression in cells or tissues exposed to various
toxicants (Huang et al, 2001; Yoneda et al, 2001). The induction of large
number of genes at early time points is explained by the genetic cellular
response to toxicant exposure by various cells. The study by Yoneda et al
(2001) show that cells first respond to an initial exposure by attempting to
counteract the chemical-induced effects on cellular metabolism, followed by
mechanistic counter-active responses that ensure continued cellular function
and survival during and after toxicant exposure. On the other hand, after 12weeks of exposure, differential expression of genes was greater for the high
and low dose groups compared to the medium dose groups. Some of the
variations may also arise from intrinsic sources of biological variability due to
inherent genetic variation among individuals within a population and the
environmental conditions.

Quality Control and Validation o f Affymetrix GeneChip Method

Initial samples were run on duplicate chips in order to determine the chip to
chip variability of the Affymetrix gene chips. For this analysis, we used one
control sample and one 0.1mg/g-diet BaP treated sample from the 12-weeks
exposed animals. For both samples, the chip replicates showed a 96.0%
similarity (Table 2) in gene expression. Therefore subsequent samples were
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run on single chips. Analysis was carried out to determine the variability
between animals from the same treatment groups. The results of this analysis
are shown in Table 3. This analysis showed that there was an 80-88%
similarity between animals (n=2) from the same treatment group. Table 3
shows that for each treatment group and time point, the animal to animal
variability was minimal (< 20%).

Table 2
Gene Expression Changes of Technical Replicates

0.1

12

2

96.0

Control

12

2

95.6

This is consistent with other reports (Bartosiewicz et al, 2001) on the
validation of the use of microarrays in an in vivo model. Bartosiewicz et al.
(2001) used various doses of a-napthoflavone, a known inducer of Cyp1a1
and Cyp1a2 genes in murine liver, to assess the issues of sensitivity and
dynamic range of microarray analysis (spotted arrays) in comparison to
Northern blots as well as to investigate sources of variability in the assay
(slide to slide, spot to spot, and animal to animal). The results from their work
shows that the dynamic range and sensitivity of DNA microarrays is
comparable to Northern blot analysis and that variability in the data is largely
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due to inter-animal differences rather than analysis-related variations in
hybridization or technique.

Table 3
Gene Expression Variability between Animals in Individual Treatment Groups

■
2

85.0

2

2

82.0

Control

2

2

82.0

0.01

12

2

88.0

0.1

12

2

80.0

1.0

12

2

85.0

Control

12

2

83.0

0.01

2

0.1

Exposure to BaP Altered Gene Expression in the Rat Liver

Table 4 summarizes the number of transcripts that were regulated in
response to BaP. Comparative CHP files produced in MAS 5.0 that used the
control sample (at each time point) as a baseline and treatment groups as the
experimental sample were generated. Each experimental dose (n=2) was
compared with each time-appropriate control (n=2), resulting in a total of 4
pair wise comparisons for each dose and exposure time interval. In order to
minimize false positives, only those transcripts that had an increase or
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decrease of >3-fold in at least 3 out of the 4 (75-100%) pair wise comparisons
were selected for interpretation. After two-weeks, exposure to 0.01mg/g-diet
increased expression of 266 genes and decreased expression of 67 genes
relative to controls, and two weeks of exposure to 0.1mg/g-diet increased
expression of 53 genes and decreased expression of 79 genes.

After 12-

weeks, a dose-dependent trend occurred in several genes that were up
regulated. For example, 28 genes were increased in rats exposed to
0.01mg/g-diet compared to controls, 64 genes increased in rats exposed to
0.1mg/g-diet and 102 genes increased in rats exposed to 1 .Omg/g-diet.
Furthermore, the expression of a large number of genes were decreased after
exposure to BaP for 12-weeks (185 genes decreased in rats exposed to
0.01mg/g-diet; 30 in rats exposed to 0.1mg/g-diet and 76 in rats exposed to
1. Omg/g-diet).
In a similar study with a limited set of genes on a custom array, Bartosiewicz
et al (2001) observed induction and repression of genes in liver and kidney in
response to intraperitoneal administration of 80 and 100 mg/kg of BaP. As
observed in this study, both time and dose were found to have significant
effects on the pattern of gene expression of the chemicals tested. Both time
and dose are important factors in determining not only which genes are
upregulated but also to what extent their expression increased. In this study,
induction of specific genes, on the one hand, followed the classic doseresponse relationship. On the other hand, the induction of a large number of
genes was found to be dose-independent. The dose-response relationships
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are not always monotonic (Neumann and Galvez, 2002). Exposures to low,
sub-lethal

concentrations

of

toxicants

may

actually

enhance

some

physiological responses, while exposure to a more elevated concentration of
the same toxicant may be inhibitory in a dose-dependent fashion.

Table 4
Total Number of Transcript Altered by Exposure to BaP
m

m

Weeks

Increased

Decreased

Increased

Decreased

0.01

2

266

67

1279

168

0.1

2

53

79

181

226

0.01

12

28

185

90

571

0.1

12

64

30

329

100

1

12

102

76

343

223

Mg/g

Dose Comparisons for Genes in Common/Unique for Individual Exposure
Time Intervals
Analysis of the genes whose expression was increased or decreased across
dose for individual exposure time intervals showed several genes in common
and others that were uniquely expressed. Affymetrix DMT 3.0 software tool
was used to create and combine probe lists of genes/transcripts that
increased or decreased across dose and time points. The Boolean algorithm
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‘and’ combines two different probe lists and produces a probe list of genes
that are in common for the two probe lists.
Figures 11 shows Venn diagram plots of genes that are in common or unique
across the different doses for the 2-weeks and 12-weeks time points. For the
genes whose expression was increased by 0.01mg/g-diet and 0.1mg/g-diet of
BaP after two weeks (Figure 11a), 16 genes were in common between these
two dose groups. The gene IDs, gene names and molecular function
description of these genes is shown in Table 5. These include immune
response genes (interleukin-1 beta, CD24 and CD74 antigen), anti-oxidants
(glutathione-s-transferase

yC2),

transcription

factors

(tumor suppressor

protein p53, pyruvate dehydrogenase, MIPP65), transporters, and other
genes. Similarly, for the genes whose expression was decreased by
0.01mg/g-diet and 0.1mg/g-diet of BaP after two weeks (Figure 11b), 15
genes were found to be in common. As shown in Table 6, these genes
include sodium ion transporters, transcription and DNA binding factors
(forkhead box, meprin 1 alpha, platelet derived growth factor receptor), and
other notable genes.
On the other hand, for genes whose expression was increased after twelve
weeks exposure to 0.01mg/g-diet, 0.1mg/g-diet and 1mg/g-diet of BaP
(Figure 11c), 8 genes were in common for all 3 doses. As shown in Table 7,
these genes include, the potassium voltage gated ion channels, cell cycle
regulators (B-cell lymphoma 2, pericentriolar material 1), lnterleukin-1 beta,
and glutathione-s-transferase yc2. In addition, between doses (Figure 11c), 5
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genes were in common between 0.01mg/g-diet and 0.1mg/g-diet, 4 in
common between 0.01mg/g-diet and 1mg/g-diet, and 11 genes in common
between 0.1mg/g-diet and 1 mg/g-diet.

Table 5
Genes That are in Common to All Doses and Showed Increased Expression
(> 3.0 fold) After 2-weeks of BaP Exposure
Probe Set ID

Gene Title

|

AB000098_at

MIPP65 protein

j

AF062741_at

pyruvate dehydrogenase
phosphatase isoenzyme 2

|

AF081366_s_at

j

Molecular Function Description

magnesium ion binding, catalytic activity
protein serine/threonine phosphatase activity

potassium inw ardly-rectifying j ion channel activity, voltage-gated ion channel
activity, ATP binding
channel, subfam ily J, member I
D N A binding, transcription factor activity

L01507_at

POU domain, class 1

j

L79910_s_at

Sarcosine dehydrogenase

j

M21842_at

apolipoprotein B

j

E01884_at

Interleukin-1 beta

| cytokine activity, interleukin-1 receptor binding

rc_AI05 8393_s_at

A rg/A bl-interacting protein

rc_ A I101743_s_at

hydroxysteroid (17-beta)
dehydrogenase 4

S82820_at

Glutathione-s-transferase yc2

U49062_at

CD24 antigen

j
j

X13058_at

tumor protein p53

j

X14254cds_g_at

CD74 antigen

X63253cds_s_at solute carrier fa m ily , member 4
Z35654_ai

MCF.2 cell line derived

j

cholesterol metabolism

intracellular signaling cascade

| estradiol 17-beta-dehydrogenase activity, sterol
carrier activity, oxidoreductase activity
j
glutathione transferase activity, transferase
defense response
D N A binding, transcription factor activity
chaperone activity, immune response

j
11

neurotransmitter:sodium symporter activity
Guanyl-nucleotide exchange factor activity
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Table 6
Genes That Are in Common to All Doses and Showed Decreased Expression
(> 3.0 fold) After 2-weeks of BaP Exposure
Gene Name

Molecular Function Description

M22253_at

sodium channel, voltagegated, type 1, alpha
polypeptide

ion channel activity, voltage-gated ion channel
activity, voltage-gated sodium channel activity
cation channel activity, calcium ion binding

M22254_at

sodium channel, voltagegated, type 2, alpha 1

Voltage-gated sodium channel activity

M87634_at

forkhead box 01

D N A binding, transcription factor activity

rc_AA8753 90_at

thioredoxin-like (32kD)

rc_AI639248_r_at

proline-rich protein

S43408 g at

meprin 1 alpha

endopeptidase activity, meprin A activity
metallopeptidase activity, zinc ion binding

acyl-CoA synthetase longchain fa m ily member 6

magnesium ion binding, catalytic activity
long-chain-fatty-acid-CoA ligase activity

Probe Set ID
D90102_s_at

S56508_s_at .
S73009_at

synuclein, alpha

S75275_at

Sim ilar to DEAD-box
protein 4 (V A S A homolog)

U10303_at

endothelial differentiation
sphingolipid G-proteincoupled receptor 1

rhodopsin-like receptor activity
lysosphingolipid and lysophosphatidic acid
receptor activity, G-protein coupled receptor a

Z14118cds_at

platelet derived growth
factor receptor, alpha
polypeptide

protein serine/threonine kinase activity,
transmembrane receptor protein tyrosine kinase
receptor activity, ATP binding, dim erization

For genes whose expression was decreased after 12-weeks, exposure to
0.01mg/g-diet, O.img/g-diet and 1mg/g-diet of BaP (Figure 11 d) showed 3
genes in common for all 3 doses. The three genes in common shown in Table
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8

are

DNA

binding

protein

N5,

glutamate

receptor,

and

the

EST

rc_AA859372.

Table 7
Genes That Are in Common to All Doses and Showed Increased Expression
(> 3.0 fold) After 12-weeks of BaP Exposure
Probe Set ID

Gene Name

Molecular Function Description

Sim ilar to EGF-containing
fib u lin -like extracellular m atrix
D89730_g_at protein 1 precursor (Fibulin-3)
(FD3L-3) (T16 protein)
(LOC305604), Mm a

J0473 l_a t

potassium voltage-gated
channel, shaker-related
subfamily, member 2

ion channel activity, voltage-gated
potassium channel, cation channel and
potassium channel activity, protein binding

M63991_at

serine (or cysteine) proteinase
inhibitor, clade A (alpha-1
antiproteinase, antitrypsin),
member 7

serine-type endopeptidase inh ib itor activity
thyroid hormone transporter activity

S82820_at

Glutathione-s-transferase yC2

Glutathione transferase activty

E01884_at

Interleukin -1 beta

cytokine activity, interleukin-1 receptor
binding, growth factor activity

L14680_at

B -cell lymphoma 2

protein binding

pericentriolar material 1

regulation o f cell cycle

rc_AI639037_
U95920_at

Between doses (Figure 11d), 23 genes were in common for 0.01mg/g-diet
and 1mg/g-diet, 5 were in common between 0.01mg/g-diet and 0.1mg/g-diet,
and 5 genes in common between 0.1mg/g-diet and 1mg/g-diet.
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Table 8
Genes That Are in Common to All Doses and Showed Decreased Expression
(£ 3.0 fold) After 12-weeks of BaP Exposure
Probe Set ID

Gene Name

Molecular Function Description

L31882_at

D N A binding protein
(N5)

double-stranded D N A binding
transcription factor activity

glutamate receptor,
ionotropic, 2

receptor activity, ionotropic glutamate receptor
activity, alpha-amino-3 -hydroxy- 5-methyl-4isoxazole propionate selective glutamate receptor
activity, transporter activity, ion channel activity
glutamate-gated ion channel activity
potassium channel activity

M36419_s_at

rc_AA859372

Exposure Time interval Comparisons for Genes in Common and Unique to all
Doses
Analysis of the genes whose expression was increased or decreased across
time points for the same or different dose level showed only a small number
of genes in common. A large number of the genes expressed were unique for
given exposure time interval and dose level.
For instance, for genes whose expression increased

(Figure 12a) at

0.01mg/g-diet (2-and 12-weeks), 3 genes were in common, and in case of
0.01mg/g-diet (2-weeks) and 0.1mg/g-diet (12-weeks), 8 genes were found to
be common. Similarly, 0.01mg/g-diet at 2-weeks compared to 1mg/g-diet after
12-weeks (Figure 12b) showed 7 genes in common.
Furthermore, comparison of gene expression changes for genes whose
expression increased (Figure 12c) between 0.1mg/g-diet (2-and 12-weeks), 4
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genes were found to be in common. No genes were found to be (Figure 12c)
in common when gene expression changes for Q.1mg/g-diet (2-weeks)
increasers were compared to 1mg/g-diet (12-weeks) increasers.
On the other hand, comparison of gene expression changes for genes whose
expression decreased (Figure 13a) between 0.01 mg/g-diet (2-and 12-weeks)
showed 4 genes in common, and only 2 genes in common between
0.01 mg/g-diet (2-weeks) and 0.1 mg/g-diet (12-weeks).
Also, comparison of 0.01 mg/g-diet (2-weeks) and 1mg/g-diet (12-weeks)
decreased genes (Figure 13b) showed 3 genes were in common, while only 1
gene was in common to all the doses in the time points compared.
In addition, comparison of gene expression changes for genes whose
expression decreased (Figure 13c) between 0.1 mg/g-diet (2-and 12-weeks)
showed 1 gene in common, and comparing 0.1 mg/g-diet (2-weeks) and
1mg/g-diet (12-weeks) showed 3 genes in common.
Other studies have also found uniquely expressed genes among classes of
compounds and dose (Bartosiewicz et al, 2001; Waring et al, 2001). Doseresponse studies of three chemicals (BaP, Dimethylnitrosamine, and CCI4)
showed variation in gene expression patterns with dose (Bartosiewicz et al,
2001 ).
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(a)

(c)

(b)

(d)

Figure 11. Venn Diagrams of Transcripts Unique or in Common to All
Treatment Groups After 2 and 12-week Exposure to BaP. (a) Transcripts that
Increased After 2-weeks, (b) Transcripts that Decreased After 2-weeks, (c)
Transcripts that Increased After 12-weeks, and (d) Transcripts Decreased
After 12-weeks of Exposure to BaP. Numbers in the intersection indicates
genes in common between the two doses.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

87

(a)

(b)

(c)
Figure 12. Venn Diagrams of Unique and Common Transcripts That Showed
Increase Expression Across 2 and 12-week Dose Comparisons, (a) Dose
Comparison for 0.01 mg/g (2 and 12-weeks) and 0.1 mg/g (12-weeks), (b)
Dose Comparisons for 0.01 mg/g (2 and 12-weeks) and 1.0 mg/g (12-weeks),
(c) Dose Comparisons for 0.1 mg/g (2 and 12-weeks) and 1 mg/g (12-weeks).
Numbers in the Intersection indicates genes in common for two or more dose
and time points.
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(a)

(b)

(c)

Figure 13. Venn Diagrams of Unique and Common Transcripts that Showed
Decrease Expression Across 2 and 12-week Dose Comparisons, (a) Dose
Comparison for 0.01 mg/g (2 and 12-weeks) and 0.1 mg/g (12-weeks), (b)
Dose Comparisons for 0.01 mg/g (2 and 12-weeks) and 1.0 mg/g (12-weeks),
(c) Dose Comparisons for 0.1 mg/g (2 and 12-weeks) and 1 mg/g (12-weeks).
Numbers in the Intersection indicates genes in common for two or more dose
and time points.
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Cluster and Principal Component Analysis o f Genes

Affymetrix absolute files containing 8800 genes for the individual experiments
were used to generate various clusters of genes. Because, it is possible to
obtain different results depending on the clustering algorithm or method used,
three separate clustering operations were performed; 1) Hierarchical Cluster,
2) Self Organizing Maps (SOM), and 3) Principal Component Analysis (RCA).
Hierarchical cluster analysis as previously described in the methods section
and by Eisen et al (1998) and Waring et al (2001) was applied across the
various treatment groups

using MAS

5.0 absolute files of individual

experiments. In this analysis individual genes or transcripts are represented in
rows, while time points are in columns. The average signal intensity of genes
across similar treatments was first determined. This was normalized to the
control signal of each treatment time point. The control normalized signal
intensities ratios of each gene for all treatment were transformed to a log 2
signal log ratio. These weighted signal log ratio were used to cluster each
gene based on threefold change in signal log ratio (increase or decrease)
from control gene expression. The hierarchical cluster showing similarities in
the expression profile of genes is shown in Figure 14. The weighted average
method (Eisen et al, 1998) was used to generate the hierarchical cluster
using Euclidean distance as the similarity metric or measure. Euclidean
distance measures how different two different profiles are taking into account
the magnitude of the signals. Genes showing similarities in expression are
joined together by the dendrogram on the left (Figure 14). The dendrogram
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arrange the clustered genes in terms of their similarity to one another. The
genes that are most similar are joined at low heights and those that are
dissimilar are joined at larger heights. Individual cells are colored based on
the log of fluorescent ratios; increasing ratios (>=3.0) indicative of increased
expression over control are represented by decreasing gray intensity, while
decreasing ratios (<=-3.0) are represented by increasing intensities of gray
and reveal decreased gene expression. Gene annotations on the right (Figure
14) allow easy visualizations of groups of genes joined by a node on the
dendrogram for biological relevant processes. Further resolution of the
dendrograms is shown in Figure 15.

Initial examination (Figure 14) of the

data revealed apparent patterns of gene expression across experimental
treatments; for example, a good number of genes are upregulated at the low
dose as against the high dose after two-weeks of exposure to BaP. However,
after 12-weeks of exposure, a significant number of genes were induced by
the medium and high dose, with only few genes showing increase in the low
dose treatment.

These

results

(Figure

14) demonstrate the temporal

separation of the gene expression response and most importantly, it confirms
the idea of an adaptive versus the toxic response to toxicity over a given
range of time. For instance, after two-weeks of exposure to the low dose, the
expression of a large number of genes increased over the controls (Figure
14), however, after 12-weeks of exposure to the same dose, only few genes
showed increased expression over the control level. This may be explained
by the adaptive or tolerance response to sub-lethal concentrations of a toxic
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compound (Neumann and Galvez, 2002; McDonald and Wood, 1993;
Schmidt and Bradfield, 1996). McDonald and Wood (1993) demonstrated
these adaptive responses in fish as occurring in three distinct physiological
responses upon exposure to sub-lethal concentrations of waterborne metals.
Initially, a shock phase that last for a few days is elicited, during which time
the metal causes much of its morphological damage to fish gills. This shock
phase is followed by a more gradual recovery phase when physiological
conditions return back to normalcy or achieve a new steady state. These
cellular turnover and repair process may cause increase tolerance to
subsequent lethal exposures of the toxicant. On the other hand, as the dose
(toxicity) increases as shown in Figure 14, the toxic response sets in and
therefore an increase expression of genes was observed in both the medium
and high dose groups. At the same time also, a good number of genes in
medium and high dose groups after 12-weeks showed decreased expression,
which may have been cause by the increase toxicity at the high dose or
temporal regulation of these genes. The dendrogram on the left of the
hierarchical cluster can be used to generate clusters of genes; 10 such
clusters were generated as shown in Figure 16a. Principal component
analysis of the 10 clusters (Figure 16b) was done to visualize the distribution
of the genes in space and also determine to which clusters carry genes with
the most variability. A 3-dimensional principal component analysis plot is
shown in Figure 16b. Genes in cluster 8 and 10 showed strong downward
shift and in addition some genes in cluster 4 and 9 and also show a negative
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shift in their variability. On the other hand, genes in cluster 3, 6 and 7 show a
positive shift in their variability. The use of this analysis after hierarchical
clustering allows transformation of the data to a smaller dimension that shows
genes with the most variability in the data.
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Figure 14. Hierarchical Cluster of Genes Across Treatment Groups. The
dendrogram on left connects genes with similar expression pattern. Partial
annotation of the genes is shown on the right. A three-fold increase or
decrease in expression indicated by decreasing or increasing intensities of
grayness, respectively.
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Figure 15. Zoom Version of a Hierarchical Cluster Node.
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Figure 16. Principal Component Analysis of Hierarchical Clusters, (a) Ten
Clusters extracted from the Hierarchical Cluster, (b) Principal Component
Analysis of the ten clusters.
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The results from the SOM analysis are presented in Figure 17. The SOM
program in the Affymetrix data mining tool analysis function was used for
clustering the dataset. SOM is well suited for exploratory data analysis, to
expose the fundamental patterns in the data. The underlying structure can be
readily explored by varying the geometry of the node. The nodal geometry
was set to identify six clusters as described in materials and methods section.
Each of the clusters represent a group of genes that peak at a particular dose
and time and have a similar pattern, therefore each SOM cluster represents
the average pattern of genes within the cluster. The y-axis represents relative
expression levels (average signal intensity) and the x-axis represents the
treatments groups and control.
For the 2-weeks SOM cluster of genes (Figure 17a) showed 19 genes
clustered in cluster 1, 72 genes in cluster 2, 0 genes in cluster 3, 120 genes in
cluster 4, 10 genes in cluster 5, and 56 genes in cluster 6. After 12-weeks of
exposure, the SOM cluster of genes (Figure 17b) showed 48 genes in cluster
1, 31 genes in cluster 2, 31 genes in cluster 3, 12 genes in cluster 4, 52
genes in cluster 5, and 75 genes in cluster 6. Table 10 and 11 shows
summaries of the genes present in SOM clusters of the 2-and 12-weeks
exposure period. As with hierarchical clustering, the clusters represent distinct
patterns of detectable gene expression. Affymetrix Accession numbers and
associated GenBank ID’s are given.
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Figure 17. Self Organizing Maps (SOM) Clusters of Genes Across Treatment
Groups, (a) Six SOM clusters of 2-week BaP differentially expressed genes,
(b) Six SOM clusters of 12-week BaP differentially expressed genes.

After 2-weeks of exposure, the results of the clusters (Figure 17a) show some
distinct patterns of gene expression. For example, cluster 1, consisted of
genes in their exponential phase of induction, where as cluster 5 showed
genes that were initially induced and showing decrease in expression over
time. In addition, clusters 2, 3, 4, 6 grouped together genes that showed late
induction from an initial lag. The gene names and Gene Ontology molecular
function description of the annotated genes from each of the SOM clusters
after 2-weeks exposure to BaP are shown in Appendix A1 to A5. The list of
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annotated genes from the SOM cluster 1 (Appendix A1) are involved in
molecular functions such as metabolism (aldehyde dehydogenase, alcohol
dehydrogenase, steroid 5 alpha-reductase 1, cytochrome p450 II C6),
peroxisome

organization

(peroxisomal

membrane

protein),

and

other

functions. In cluster 2 (Appendix A2), the annotated genes show a more
diverse

molecular function;

enzymatic

catalysis

(acyl-coA

synthetase,

argininosuccinate lyase, ATP citrate lyase, glycine-N-methyltransferase),
immune and inflammatory response (interleukin-1 beta, intercellular adhesion
molecule 1, fibrinogen), chaperone activity (DnaJ homolog), RAS oncogenes
(RAB11a), and so on. The genes with diverse molecular function are also
clustered together in cluster 4 (Appendix A3). These include genes involved
in enzymatic catalysis (palmitoyl-protein thioesterase 2, hepatic lipase, 3hydroxy-3-methylglutaryl coA lyase), transcription regulators and kinases
(pyruvate kinase, NF-E2 related factor 2, adenylate kinase), stress and
defense response (clusterin, TGFB inducible early growth response, CD81
antigen, leukotriene B 4, 12-hydroxydehydrogenase), hormone activity, signal
transduction, transporters. A much smaller subset of genes consisting mostly
of protein kinases (platelet derived growth factor receptor, SH3-domain
kinase), phosphatases, and calcium ion binding proteins (S100 calciumbinding protein, matrix Gla protein), GTP binding protein such as tubulin are
represented in the cluster 5 (Appendix A4).

Also, cluster 6 (Appendix 5)

consist of various transcription factors (forkhead box A2, one cut domain
family member 1, dual specificity phosphatases), apoptosis (programmed cell
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death 8), ATpases, cell adhesion, enzymatic metabolism, and other molecular
functions. On the other hand, after 12-weeks of exposure (Figure 17b), the
expression patterns of these genes differ from the 2-weeks genes. For
instance, cluster 6 showed genes that were initially induced, followed by a
peak and then gradual decrease in expression to a more stable level. Similar
patterns are shown by genes in cluster 3 and 5. In the case of duster 1, 2,
and 4, the expression of genes initially decreased, followed by a gradual
increase to peak levels and subsequently decreased in their expression. The
names and Gene Ontology molecular function description of the annotated
genes from each of the SOM clusters after 12-weeks of exposure to BaP are
shown in Appendix B1 through B6.
As shown in

Appendix B1, cluster 1 consists of various growth factors

(insulin-like growth factor, activin beta E), apoptosis and cell cycle regulators
(similar to cytochrome c, B-cell lymphoma 2), DNA binding, metal ion binding
and transcription factor such as ATpase Calcium transporter, carbonic
anhydrase 3, nuclear factor I/A, one cut domain, and cold shock domain
protein A. Genes in cluster 2 (Appendix B2) consist mostly of electron and
cation transporters (solute carrier family 26, ATpase Hydrogen transporter,
ceruloplasmin, cytochrome b, solute carrier family 28), transcription regulators
(mitogen activated protein kinase, integrin alpha 1, cofilin 1), metabolism
(apolipoprotein B, steroid 5 alpha reductase 1), and others.
In cluster 3 (Appendix B3) of the 12-weeks SOM, the genes represented
include the DNA repair and DNA binding (DnaJ Hsp40 homolog, zinc finger
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protein 354A, hairy and enhancer of split 1, nuclear receptor subfamily,
CD151 antigen, and CCAAT/enhancer binding protein), and transferases
such as glutathione-s-transferase a2, catechol-o-methyltransferase, and
dopa/tyrosine sulfotransferases. Also, cluster 4 (Appendix B4) consists of
nuclear receptor subfamily, cytochrome oxidase subunit Vic, pyruvate kinase,
and UDP glycosyltransferase 1 polypeptides family of genes. In addition,
cluster 5 (Appendix B5) of various detoxification and metabolism genes
(NADPH cytochrome p450 reductase, Cytochrome p450 1a2, ATP citrate
lyase, UDP glucuronosyltransferase 1 polypeptide family, aldo-keto reductase
family, steroI-C4-methyl oxidase, pyruvate dehydrogenase kinase), CD74
antigen, and

rat senescence marker.

Similarly, cluster 6 consists of

detoxification and xenobiotic metabolism genes (aldehyde dehydrogenase,
squalene

expoxidase,

cytochrome

p450

1a1,

NADPH

dehydrogenase

quinone 1, cytochrome p450 1a2, glutathione-s-transferases), oncogenes and
GTpases (RAP1B and RAB7 ras ooncogene families), and other genes.
The data from the SOM clusters is comparable to some of the panels from
hierarchical clusters. Recent studies (Tamayo et al, 1999; Burton et al, 2002;
Toronen et al, 1999; Waring et al, 2001; Amin et al, 2004; Eisen et al, 1998)
have also employed hierarchical and SOM clustering to identify gene
expression patterns and determine mechanisms of toxicity. For example,
Waring et al. (2001) used hierarchical clustering to classify 15 hepatotoxins
based on mechanisms of toxicity. Recently, Amin et al (2004) has used
hierarchical clustering and PCA to identify putative gene based markers of

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

renal toxicity in male Sprague-Dawley rats.

Similarly, Tamayo et al. (1999)

and Burton et al. (2002) has also applied SOM clustering to interpret patterns
of gene expression. Principal Component Analysis (PCA) was also applied to
data as previously discussed in the methods section. The results (Figure 18a)
of the PCA is shown as a 3D scatter plot with three PC; PCA1, PCA 2, and
PCA3. A large percentage (>50 %) of the variability in the expression of the
genes was associated with PCA 1, while PCA2 and PCA3 accounts for the
remaining variability. Time 1 (2-weeks) and Time 2 (12-weeks) are indicated
by blue and red dots (Figure 18a), respectively.
As in hierarchical clustering described above, the control normalized signal
log ratios for treatment group at each time point from the Affymetrix MAS 5.0
software were loaded into Spotfire Decision site for functional genomics, and
PCA was conducted. The PCA scatter plot of the genes (Figure 18a) had a
similar pattern when compared to the PCA plot generated from the
hierarchical cluster (Figure 16b). The PCA1 and PCA2 cluster of genes were
considered the most relevant in terms of providing useful gene expression
information and similarities in terms of their variation with dose. The PCA plot
of the 2-weeks and 12-weeks showed similarities in the distribution of the
genes in 3-D space. The distribution of the genes in the two time points is
comparable to two parallel planes with only difference being a vector; with a
negative direction. If one were looking at the data from a 2D point of view, the
only difference rests on PCA1, which carries most of the variability. The use
of PCA for multidimensional visualization of gene expression in order to
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observe the spatial distribution of the treatment groups is extensively
discussed in the literature (Yeung and Russo, 2001; Parmigiani et al, 2003).
In a related study, Amin et al (2004) used PCA to profile the dose-response
and temporal regulation of genes by two classes of toxicants. This approach
offers opportunity to visualize expression patterns that can reflect similarities
in biological responses. The visualization of high dimensional data in two-orthree dimensional components reveals unsupervised clusters within the data.
The result of the PCA as shown in Figure 19 and Table 9 can be scored, and
based on those PCA scores, unknown samples can be determine and placed
into one of the previously identified clusters where gene expression is clearly
linked to biological processes.
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Figure 18. Principal Component Analysis of Gene Expression Across Time,
(a) 3-Dimensional PCA Scatter Plot showing variation in Gene Expression for
the 2 and 12-week time point, (b) Percent variability plot of the PC1, PC2, and
PCS variables
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Table 9
Eigenvalue Loadings for PCA1, PCA2, PCA3 Variables

Principal
Component

Time

Low Dose

Medium
Dose

High Dose

PC(1)

0.153

0.873

0.403

0.226

PC (2)

0.539

0.318

-0.691

-0.362

PC (3)

-3.5e-2

2.8e-2

0.452

-0.891

0.8

CA1
0.6

0.4

0.2

PCA3

0
-

0.2

-0.4

PCA2

-0 .6

-

0.8

Time

log2 (L D...

lo g2(M D .. . lo g2(HD .. .

Figure 19. Scree Plot of PCA1, PCA2, and PCA3 Variables. Scree plots show
variability in the gene expression profiles with time and dose.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

102

Table 10
Affymetrix Accession Numbers of Representative Genes or Transcripts
Present in the Six SOM Clusters of the 12-weeks Exposure Period
Cluster 2
AA801441_at

AB017544_g_at

AF014503_at

AB002558_at

AF030091 UTR#1_g_at
AF037072_at

AB009890_at

AFFX-BioB-M_at

AF045464_s_at

AF001898_at

AF034582_g_at

AFFX-BioC-3_at

AJ011656cds_s_at

AF003835_at

AF063102_at

AFFX-BioB-3_at

AFFX-BioC-5_at

D28339_s_at

AF036761_g_at

AF077000_at

D12769_at

AFFX-BioDn-3_at

D83796_s_at

AF061971_at

AF079864_at
AF089825_at

J05035_g_at

AFFX-BioDn-5_at

E01184cds_s_at

AF062389_at

L23413_at

AFFX-CreX-3_at

E01524cds_s_at

AF072411_at

AFFX-BioB-5_at

M13100cds#2_s_at

AFFX-CreX-5_at

E12625cds_at

AF072411_g_at

D00698_s_at

M13100cds#3_f_at

D13417_g_at

D10655_at

D28557_s_at

M13100cds#6_f_at

D86580_at

J03179_at
J03179_g_at

Cluster 3

J00738_s_at

M27440_at

D86745cds_s_at

J03865mRNA_f_at

M57718mRNA_s_at

D88890_at

L38482_at
M91235_f_at

M58758_g_at

D89375_s_at

M91599mRNA_g_at

J03190_at

rc_AA799538_g_at

rc_AA817854_s_at

J03190_g_at

rc_AA800029_at

rc_AA852046_s_at

M58587_at

rc_AA800787_at

rc_AA859612_f_at

M93257_s_at

Cluster 5

Cluster 6

Cluster 1
AA799276_at

D10655_g_at

J05210_at

D30040_at

J05210_g_at
K01934mRNA#2_at

D37920_at
E00717UTR#1 _s_at

K02815_s_at

E00778cds_s_at

L00320cds_f_at

E03358cds_at

L38615_jg_at

J02679_s_at
J05460_s_at

rc_AA859848_at

rc_AA859966_i_at

M96548_at

M10068mRNA_s_at
M21476_s_at

rc_AA859897_at

rc_AA894207_g_at

rc_AA800005_at

M25157mRNA_i_at

L12380_at

rc_AA859994_at

rc_A1105348_i_at

M26127_s_at

L13619_at

rc_AA860014_i_at

rc_AI171355_s_at

rc_AA892775_at
rc_AA893239_at

M74067_at

L22294_at

rc_AA874926_at

rc_A1171630_s_at

rc_AA875097_at

rc_AI180108_at

rc_AA943892_at

M89945mRNA_at

rc_AA892522_at

rc_AI639043_at

rc_AA946040_at

M89945mRNA_g_at

M36151cds_s_at

rc_AA893664_at

rc_AI639108_at

rc_AI010632_s_at

rc_AA799778_at

M37584_at

rc_AI008815_s_at

rc_AI639120_at

rc_AI011998_at

rc_AA852004_s_at

M63983_s_at

rc_AI071866_s_at

U58858_at

rc_AI171085_at

rc_AA892828_at

rc_AA799279_g_at

rc_AI176460_s_at

U66723_s_at

rc_AI175935_at

rc_AA945050_f_at

rc_AA799326_s_at

rc_AA893384_g_at M76767_s_at

Cluster 4
J02612mRNA_s_at
L21711_s_at
M25804_at
M25804_g_at
M27467_at
M33025_s_at
rc_AA859372_s_at
rc_AA945573_f_at
X05684_at
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K03241cds_s_at

M26594_at
M33329_f_at
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Table 11
Affymetrix Accession Numbers of Representative Genes or Transcripts
Present in the Six SOM Clusters of the 2-weeks Exposure Period
Cluster 1
AB002558_at
AF025308_f_at
D13667cds_s_at
D14989_f_at
E03358cds_at
E12286cds_at
M14776_f_at
M21476_s_at
rc_AA893242_g_at
rc_AA925473_g_at
rc_AA996484_g_at
rc_AI102838_s_at
rc_A1171734_s_at
S35751_f_at
S81448_s_at
X13527cds_s_at
X53054_g_at
X70223_at
X72792cds_s_at

Cluster2
AA685903 at
AB012933_at
AB012933_g_at
AF023302_s_at
AFFX_rat_GAPDH
AJ223355_at
D00913 g at
D13921_s_at
D13978_s_at
D37934_g_at
D85435_at
D85435_g_at
D87839_g_at
D87991_at
D90401_at
D90401_g_at
E01050cds_g_at
E03859cds_s_at
E13557cds_s_at
J00735_at
J05210_at
K00750exon#2-3_at
K02817cds_s_at
M15481 g at
M17412_at
M26247_at
M57718mRNA_s_at
M62832_at
M64755_at

Cluster 4
AB000491_at
AB005547_at
AF012714_at
AF029240_at
AF061971_at
AF089825_at
AJ000347_g_at
D00569_at
D00698_s_at
D00729_g_at
D00753__at
D10874_at
D10874_g_at
D13623_g_at
D13907_g_at
D21215cds_s_at
D30647_at
D30649mRNA_s_at
D45254_g_at
D88250_at
D90211_s_at
D90265_s_at
D90404_at
D90404_g_at
E01184cds_s_at
J00728cds_f_at
J04171_at
J05035_at
J05035_g_at

Cluster 5
AF023087_s_at
rc_AA799448_g_at
rc_AA818593_g_at
rc_AA892498_at
rc_AI012030_at
rc_AI232379_at
rc_AI639058_s_at
U90261 UTR#1_g_at
V01227_s_at
X06916_at

Cluster 6
D12769_at
D12769_g_at
D32249_s_at
D89655_at
J03190_g_at
J03863_at
L00191cds#1_s_at
L09647_at
L28135_at
L36532_s_at
M77479_at
M91235_f_at
S81478_s_at
U02553cds_s_at
U06230_s_at
U18762_at
U19614_g_at
U32314_g_at
X13119cds_s_at
X55298_at
X78997_at
X95096_at
Y14933mRNA_s_at

Influence o f BaP on Gene Expression Profiles and Biological Processes

Table in Appendix C shows a summary of the annotated genes that were
regulated and found to be relevant in the BaP-Ah receptor mediated as well
as other signaling pathways leading to cancer and other health effects. The
effects of BaP on the Ah receptor mediated pathway as deduced from the
microarray data is shown in Figure 22. A large number of genes were
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differentially expressed in response to varying doses of BaP. In addition, the
results show temporal regulation of gene expression of a good number of
genes. The gene expression profile of our microarray data (Figure 20) show
variations in gene transcription patterns, under the influence of temporal and
dose-response relationship. A good number of the genes show greater than
three-fold changes in their expression from the control and vary between
treatments groups.

A\

Low D o s e _ T 2

M e d .D o s e _ T 2

H ig h D o s e _ T 2

Low D ose_T1

H ig h D o s e _ T 1

Figure 20. Gene Expression Profiles of Genes Across Treatment Groups and
Time.
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Both dose and exposure time interval was found to be important factors in
determining not only the number of genes that are regulated, but also the time
period for which these genes are increased or decreased (Appendix C). For
instance, several genes in our analysis were up-regulated after 2-weeks but
their expression decreased after 12-weeks of exposure (Appendix C) to
control levels or below. Similarly, within exposure time intervals, variation in
expression of some genes with dose (Appendix C) was observed. Some
genes tend to be induced or repressed at high, medium or low doses in a
dose-dependent pattern, while others tend to be induced or repressed only at
specific dose level at each exposure time interval. This apparent non-linear
dose-response relationship has been noted for BaP and other compounds in
previous studies (Bartosiewicz et al, 2001).
Some of the genes identified in the microarray data and differentially
expressed (threefold or greater) in at least one of our arrays (sample) were
classified into biologically relevant pathways, based on information from
Affymetrix NetAffix, NCBI databases, GenMAPP, Gene Ontology (GO) or
Ingenuity Pathway knowledgebase. Several recent validation studies (Amin et
al, 2004; Ezendam et al, 2004) consider one present call in at least one of
their samples to determine which genes were differentially expressed. Also,
Affymetrix absolute calls (Absent to absent, Absent to Marginal, Absent to
present, present to absent, present to present, present to marginal) were
utilized to select other genes as differentially expressed. After two weeks of
exposure to 0.01 and 0.1 mg/g of BaP in the diet, a good number of the
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genes induced were transcription regulators, anti-apoptotic genes, apoptotic
genes, and genes involved in metabolic pathways, oxidative stress, cell cycle
regulators and calcium metabolism (Appendix C). Subsequently, the induction
of a large number of these genes was repressed or decreased over time. For
instance, some of the genes upregulated at this time point are p53, p21, Bax
(apoptotic genes), Bcl-2, Bcl-2 like, (anti-apoptotic), c-Ha-ras, ras-related p23
(Oncogenes),

antioxidants

GST-yc2,

GST-ya,

reductases, aldehyde dehydrogenase-3A1

peroxidases,

NADPH

(Acute phase proteins), and

others. A representing pathway map showing the induction and repression of
apoptotic and anti-apoptotic genes is shown in Figure 21.

Apoptosis

Ubiquitin
pathway

m(Sm2

m<im2
P roteasom e’

Figure 21. Apoptosis Pathway Genes Regulated by BaP. Transcripts induced
by BaP are shaded gray.
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After 12-weeks of exposure, the gene expression profile consisted of
detoxification enzymes (Cytochrome p450), some heat shock proteins and
DNA repair enzymes (Appendix C). This apparent temporal phase distinction
in gene expression has been observed in other studies of other compounds
(Yoneda et al, 2001; Huang et al, 2001). Using DNA microarrays, Yoneda et
al. (2001) observed that gene expression in human epithelial cells undergo
distinct temporal phases when exposed to oxidants such as hydrogen
peroxide and smoke.
Previous studies (Parish et al, 1998; Binkova et al, 2000; Ramet et al, 1995;
Mounho et al, 1997) on the effects of BaP on expression of some of these
genes confirms this finding. For example, Ramet et al. (1995) show that p53
protein expression is correlated with BaP-DNA adducts in carcinoma cell
lines. Similarly, Salas and Burchiel (1998) have demonstrated an association
between BaP, increase in intracellular calcium and induction of Apoptosis in
Daudi cells.
In addition, the microarray data also reveals that BaP may be capable of
disrupting key rate limiting transcripts or enzymes in various metabolic
pathways as shown in Figure 23 and cause health effects. For instance, the
results show disruption of the steroid hormone signaling via up regulation of
the rate limiting enzyme of cholesterol (HMG-CoA reductase), suppression of
Cyp450C17 hydroxylase, and by suppression of Androgen receptor (AR) may
affect estrogen/androgen metabolism, which leads to endocrine disruption.
Studies by Vinggaard et al. (2000) support the microarray finding that BaP
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affect androgen receptor activation. Using Chinese Hamster Ovary cells
(CHO), Vinggaard et al (2000) show that BaP act as antagonists of the AR.
Additionally,

differential

expression

of cytochrome

p4501

gene family

(Cyp1a1, Cyp1a2), Gst, and other genes involved in detoxification was
observed in at least one of the doses in this study. BaP is known to induce
these genes through binding to and activation of the Ah receptor (Barouki and
Morel, 2001; Tian et al, 1999; Denison and Heath-Pagliuso, 1998; Schmidt
and Bradfield, 1996). This is considered to be one of the major biochemical
pathways through which BaP is metabolically activated to cause cancer and
other health effects. The exact mechanism by which BaP causes cancer and
other toxic health effects is not fully understood. As shown in Figure 22,
binding to the aryl hydrocarbon Ah receptor and the subsequent metabolic
activation and transport of the receptor from the cytosol to the nucleus is
linked to the increase transcription of Cyp1a1, Gst, and several other genes
containing

the

dioxin

response

elements

(DRE)

promoter.

Increase

transcription of Cyp1a1 genes leads to increase in Cyp1a1 enzyme activity
and oxidative conversion of BaP to reactive intermediates capable of binding
to cellular macromolecules such as DMA; this induces mutations and/or
oxidative DMA damage.

The resulting DNA adducts (Canova et al, 1998;

Chakravarti et al, 1995; Cheh et al, 1993; Miller and Miller, 1976) formed are
considered to be the first step in the initiation of cancers and other health
effects in mammals. Also, the induction of Gst-mu in mice administered BaP
intraperitoneally has been observed by Bartosiewicz et al (2001) using a
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limited set of cDNA arrays.

Gst are involved in detoxification mechanisms

and their up-regulation may due to oxidative stress caused by BaP
metabolism in the cell. These results are also consistent with other studies on
the oxidative alteration of DNA and protein, and antioxidant enzymes in
several organs (liver, kidney, lungs) of rats treated with BaP (Bartosiewicz et
al, 2001; Kim et al, 1997)

A h r Receptor and other Pathways involved in BaP Toxicity Response

BaP

DRE

Other Pathways Affected:
□Lipid Peroxidation
[Immunosuppression
□Cardiopulmonary/ Respiratory
□Thyroid Hormone Receptor
□Altered ER Signalling
.□Deregulated Lipid Metabolism
Gras Oncogene Activation
□Vitamin ADepletion
CProinflamrratory Cytokines
xtivation

mRNA

DRE

Translation

BaP
I Proiniiainrnafcttv Cytokines

Oxidative Stress (H ,0 2, Superoxide)'

Vitarrin ADepletion

Hydrophilic Products

Less Harmful Products (H ,0 )

Cancer

Figure 22. Ah Receptor Mediated Pathways of BaP Activation
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Figure 23. Metabolic and Steroid Hormone Pathways Regulated by BaP.
Increase or Decrease Expression of Transcripts is indicated by light gray or
dark gray, respectively.

Ingenuity Pathway Analysis o f the Microarray Data

As previously described in the materials section, Ingenuity Pathway Analysis
was used to construct biological pathways based on the genes that were
differentially expressed threefold or greater by BaP. Affymetrix microarray
data was uploaded into the Ingenuity knowledgebase system and program
was run to include as many nodes. The results of the pathway analysis
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suggest that BaP may have a wide ranging effect on a host of pathways
(Appendix D1). For instance, BaP may regulate IL-1 beta activity via the p38
MAPK pathways and NFkB pathway shown in Appendix D2. Also, observed
are the signal transduction involved in the regulation of Bcl-2 (Appendix D3)
and the tumor suppressor gene p53 (Appendix D4), which plays a central role
in cell cycle regulation, apoptosis, and cell death.

Real-Time Quantitative PCR (RT-QPCR) Analysis

Based on the results of the microarray data, we selected six genes for further
analysis and for validation of our GeneChip data.

The candidate genes

selected were based on their association with health effects and involvement
in pathways relevant to the understanding of the mechanisms BaP toxicity. As
previously discussed, we used real-time quantitative one-step Taqman PCR
to analyze our target genes of interest. The results with minimal variations
confirm our findings from the microarray experiments. Some of the variations
are explained by the differences in sensitivity and resolution between the
GeneChip and RT-QPCR; higher fold changes are usually observed with RTQPCR than by microarray. In order to control for variations due to mRNA
isolation or RT-QPCR conditions, 50 ng of yeast mRNA was spiked into each
sample during mRNA extraction. Also, RT-QPCR for each gene of interest
was run in conjunction with yeast actin for each sample to normalize the
expression levels.
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The mRNA levels of each gene were quantified using Taqman ABI PRISM
7700 Sequence Detection System (Applied Biosystems). Standard curves for
both the yeast internal control and the target genes was generated from serial
dilutions of untreated control samples, and used to determine the amount of
mRNA for each gene and yeast in all experimental samples. A representative
standard curve measurement for Cyp1a2 and yeast actin internal control
gene is shown Figure 24 below. The relative expression level of each gene
was computed with respect to yeast mRNA for each treatment group to
account for variation in quality of mRNA or RT-PCR conditions. To control for
genomic DNA amplification, primers were constructed to include one intron,
and in addition, no amplification control curves were ran alongside each
gene’s standard curve.

12-weeks yeast controls

12-weeks Cyp1a2 control samples
-3.2389X + 24.369
24.5 ,
~

24

I
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y = -2.8045X + 25.005
R2 = 0.9989
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Figure 24. Standard Curves from Serial Dilutions of Untreated Control
Samples, (a) serial dilutions (log standard) for Cyp1a2 gene standard curve,
(b) serial dilutions (log standard) for yeast actin internal control standard.
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Effects o f BaP on Gst-yc2 Expression

Significant changes (p < 0.05) in gene expression of Gst-yc2 in rat livers after
12-weeks (Figure 25b) of exposure to control, 0.01, 0.1, 1.0 mg/g of BaP in
the diet. The increase in expression of Gst-yc2 observed after 12-weeks of
exposure was dose dependent. Highest expression was observed for 1.0
mg/g of BaP in diet (Figure 25b). The low, medium and high dose showed
approximately two, three and four old increases in expression over the control
average.
On the other hand

after two weeks of exposure, only a slight increase in

expression of Gst-yc2 over the control was observed; 37 % and 78 %
increase for the low and high dose, respectively.
The observed increased was not significant at p < 0.05. No significant
difference in Gst-yc2 expression was observed after 2-weeks (Figure 25a) of
exposure to control, 0.01, and 0.1 mg/g of BaP in the diet. A high variation in
expression of Gst-yc2 was observed within treatment and control groups in 2and 12-weeks weeks exposed rats as indicated by the box plot.
The results clearly show differences in the temporal expression of Gst-yc2
between the 2- and 12-weeks time period. Higher expression of Gst-yc2 at
the 12-weeks time period is consistent with the induction of such genes,
whose protein products are responsible for detoxification and metabolism of
oxidants.
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Figure 25. Relative Change in Gene Expression of Gst-yc2. (a) Percent
change in Gst-yc2 after 2-weeks Exposure to 0.01 and 0.1 mg of BaP/g of
Diet, (b) Percent Change in Gst-yc2 after 12-weeks Exposure to 0.01, 0.1 and
1.0 mg of BaP/g of Diet
Effect o f BaP on Cyp1a1 and Cyp1a2 Expression

We observed significant differences over control animals (p < 0.05) in
expression of Cyp1a1 and Cyp1a2 in rat livers after 12-weeks (Figure 26b &
27b) of exposure to 0.1 and 1.0 mg/g of BaP in the diet. Bonferroni post-hoc
analysis also reveals significant differences (p < 0.05) between controls of
Cyp1a1 and Cyp1a2 expression compared to the high dose (1.0 mg/g-diet).
For Cyp1a1 expression, the low, medium, and high dose showed 2, 10, and
74 fold increases over the control expression, while Cyp1a2 showed 2, 3, and
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9 fold increases in expression over the control values, respectively. No
significant difference (p < 0.05) in expression of Cyp1a1 and Cyp1a2 was
observed between treatment groups after 2-weeks (Figure 26a and 27a) of
exposure to BaP. Only slight increases in the expression of Cyp1a1 (79 %
and 88% for low and high dose) was observed. For Cyp1a2, the expression
after 2-weeks of exposure was less than 2-fold in both low and high dose.
Furthermore, the expression of Cyp1a1 and Cyp1a2 was consistently higher
than controls in all animals exposed to the medium dose (0.1 mg/g) and high
dose (1mg /g) after 12-weeks of exposure to BaP. This shows that in addition
to temporal regulation, the amount and nature of the dose as discussed
earlier may be important for the expression of detoxification enzymes such as
Cyp450 1a1 and 1a2.

Effect o f BaP on p53 and Bcl-2 Expression

Significant (p < 0.05) changes in p53 expression were observed in rat livers
after 12-weeks (Figure 28b) of exposure to control, 0.01, 0.1, and 1.0 mg/g of
BaP in the diet. After 12-weeks, the highest increase (3-fold) in expression
over controls was observed in the low dose (0.01 mg/g), followed by a 2-fold
increase in both the medium (0.1

mg/g) and high (1.0 mg/g) dose,

respectively. Similarly, after 2-weeks, significant differences in p53 expression
were observed in rat livers exposed to 0.1 mg/g of BaP in their diet (Figure
28a).
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Figure 26. Relative Change in Gene Expression of Cyp1a1. (a) Percent
Change in Cyp1a1 after 2-weeks Exposure to 0.01 and 0.1 mg of BaP/g of
Diet, (b) Percent Change in Cyp1a1 after 12-weeks Exposure to 0.01, 0.1 and
1.0 mg of BaP/g of Diet

A threefold increase in p53 expression was observed after exposure to the
BaP dose of 0.1 mg/g of diet food after 2-weeks. Only a slight mean increase
in p53 expression was observed in the 0.01 mg/g of BaP treatment group.
Similar changes in expression were observed for Bcl-2, which showed
significant changes (p < 0.05) in gene expression in all 4 doses (control, 0.01,
0.1, and 1.0 mg/g-diet) after 12-weeks (Figure 29b) of exposure to BaP.
Bonferroni post-hoc analysis reveals significant differences (p<0.05) from
control for the medium and high dose after 12-weeks of exposure.
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Figure 27. Relative Change in Gene Expression of Cyp1a2.. (a) Percent
Change in Cyp1a2 after 2-weeks Exposure to 0.01 and 0.1 mg of BaP/g of
Diet, (b) Percent Change in Cyp1a2 after 12-weeks Exposure to 0.01, 0.1 and
1.0 mg of BaP/g of Diet

On the other hand, Bcl-2 expression increased by 2, 9.5, and 4.5 fold for the
low, medium and high dose, respectively after 12-weeks of exposure. A slight
increase in mean expression of Bcl-2 was observed during the 2-weeks
exposure period to BaP, however, this differences was not significant (p
<0.05) (Figure 29b).

These results are in agreement with previous studies

that show BaP induces apoptotic genes such as p53. A study by Pei et al.
(1999) demonstrated that BaP activates the human p53 gene through
induction of the nuclear factor kB activity. Exposure of A549 and NIH 3T3
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cells to BaP resulted in an increase in p53 mRNA levels. A related study by
Salas and Burchiel (1998) also found that BaP induces apoptosis in Daudi
cells via a mechanism that involves Bcl-2 family proteins, potentially
secondary to the formation of p450-derived metabolites and alterations.
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Figure 28. Relative Change in Gene Expression of p53. (a) Percent Change
in p53 after 2-weeks Exposure to 0.01 and 0.1 mg of BaP/g of Diet, (b)
Percent Change in p53 after 12-weeks Exposure to 0.01, 0.1 and 1.0 mg of
BaP/g of Diet
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Figure 29. Relative Change in Gene Expression of Bcl-2. (a) Percent Change
in Bcl-2 after 2-weeks Exposure to 0.01 and 0.1 mg of BaP/g of Diet, (b)
Percent Change in Bcl-2 after 12-weeks Exposure to 0.01, 0.1 and 1.0 mg of
BaP/g of Diet

Effect o f BaP on IL-1/3 Expression

Significant differences (p < 0.05) in expression of IL-1(3 were observed in rat
liver mRNAs after 12-weeks (Figure 30b) of exposure to BaP. The increase in
expression after 12-weeks was also found to be dose-dependent. For
example,

the

low,

medium

and

high

dose

after

12-weeks

showed

approximately 2.5, 4, and 5.5 fold increases in expression over the control
value. In addition, significant differences were also observed in the 2-weeks
exposed (Figure 30a) animals; both the low and high dose levels of BaP
caused 4 and 2-fold induction of IL-1b over the controls. For the 2-weeks
treatment groups, a wide range of variations in the mean values was
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observed, with one or two outliers as shown by the red dots in Figure 30a.
These results are in line with the role of IL-1b as ubiquitous molecule that
plays a role in the inflammatory response and the immune system.
Expression of lL-1b is linked to increases in Intracellular calcium levels
(Davila et al, 1995), and since BaP and other PAHs can cause increase in
intracellular calcium levels, they may also cause increase in the IL-1b gene
expression.
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Figure 30. Relative Change in Gene Expression of IL-1/3. (a) Percent Change
in IL-1(3 after 2-weeks Exposure to 0.01 and 0.1 mg of BaP/g of Diet, (b)
Percent Change in IL-1(5 after 12-weeks Exposure to 0.01, 0.1 and 1.0 mg of
BaP/g of Diet.

In Vivo Rat Feeding Experiments

In vivo rat feeding study was conducted as discussed in the materials and
methods section. BaP was administered to rats through the diet for 2-and 12-
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weeks tim e period. A HPLC assay was run on each feed sample prior to
administration to ensure the homogeneity and potency of BaP in feed before
it was used.

A standard plot was constructed based on the peak area to

achieve the more accurate result. The linear equation of y = 23953x and R2 =
0.9996 were obtained with accuracy from 99% to 104%. The standard
deviation o f three injections for all levels of standards was less than 0.5 %
and the highest percent relative standard deviation (%RSD) for all levels of
standard injections was less than 0.5 %. This data indicates the method of
determining BaP concentrations in the diets is accurate, precise and suitable
for the analysis. Representative chromatograms of feed samples are shown
in Figure 31.

QAB1 A, S**300,4 J W = 4 W ,« » (B M W -400040}

Control

OWOI A $ 0 * 3 0 0 .4 Rs>f=4Sffl„fiO (BMMaCPOQCSX}

Medium dose

Figure 31. LC Chromatograms of Feed Samples.
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During the in vivo rat feeding study period, the body weight of the rats and
amount of food consumed was monitored constantly. No significant change in
the body weight of the rats was observed after two weeks of exposure to 0.01
and 0.1 mg/g o f BaP. However, after 12-weeks of exposure to BaP, the
average weight gain of the high dose (1.0 mg/g) group was significantly lower
than other groups throughout the 12-weeks study period. The Animals in high
dose group appeared slower and abnormal fur loss was observed. They were
less active than the other groups and internal organs showed some
morphological differences from the control animals.
The in vivo rat experiment average weight gain results are presented in Table
12. The average weight gain results normalized to feed consumption are
presented in Figures 32 and 33. Similar changes in body weight with dose
has been observed in other studies (Chiang, 2001, Ramesh et al, 1999)
At the end of each in vivo rat feeding study period (2-and 12-weeks), animals
were sacrificed, blood collected through heart puncture and various organs
(liver, lungs, kidneys, spleen, thymus, and heart) were collected. The organs
were weighed immediately after extraction to obtain the fresh weight of each
organ. Significant differences in weight of the organs between control and
treated animals were observed for each time point.
The average weights of the various organs compared to the control animals
are in Figures 34 through 39.
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Table 12
In Vivo Dosage and Average Weight Gain Results
2 -week Exposure
Dosing
Period
(Weeks)
High Dose
(1.0mg)
Medium
Dose
(0.1 mg)
Low Dose
(0.01 mg)
Control

12-week Exposure

Average
Weight
Gain
(gm)

1

2

3

4

5

6

7

8

9

10

11

12

Average
Weight
Gain
(gm)

NA

NA

10.1

12.5

3.8

2.0

3.6

3.5

8.0

9.5

10.0

9.5

8.6

8.5

7.5±3.3

23.2

20.1

21.7±2.2

20.1

13.7

12.8

11.8

9.0

9.5

9.1

8.5

7.8

10.5

9.6

10.5

11.1+3.3

24.6

21.7

23.2±2.3

22.5

21.3

9.5

15.1

11.3

10.1

9.5

8.1

6.3

7.5

8.1

9.4

11.6±5.3

19.9

19.3

19.6±0.4

20.9

20.1

15.2

14.7

10.5

11.3

9.9

10.1

8.8

8.3

8.9

9.5

12.4±4.4

1

2

NA
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Figure 32. In Vivo Dosage and Average W eight Gain Normalized for Feed
Consumption
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Figure 33. In Vivo Dosage and Average Feed Consumption Normalized for
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Figure 34. Percent Change in Liver Weight, (a) 2-weeks of Exposure to BaP
Control, 0.01, 0.1, and 1.0 BaP mg/g of diet, (b) 12-weeks of Exposure to
Control, 0.01, 0.1, and 1.0 BaP mg/g of diet.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

As shown in Figure 34, changes in liver size were observed for both the 2-and
12-weeks treatment period. A mean increase of 3-5 % in liver weight was
observed in liver weight after 2-weeks of exposure (Figure 34a) to low (0.01
mg/g) and high dose (0.1 mg/g) of BaP. On the other hand, after 12-weeks
(Figure 34b) of exposure, a 5-8 % decrease in the size of the liver was
observed in the low (0.01 mg/g) and Medium (0.1 mg/g) dose of BaP,
whereas a 6% increase in the size of the liver was observed in high dose
treatment groups (1mg/g). The liver is an important organ in protection from
oxidative damage. It plays a major role in the breakdown of potentially toxic
lipophilic toxins through the action of oxidation and reduction enzymes such
as cytochrome p-450 enzymes.
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Figure 35. Percent Change in Lung Weight, (a) 2-weeks of Exposure to BaP
Control, 0.01, 0.1, and 1.0 BaP mg/g of diet, (b) 12-weeks of Exposure to
Control, 0.01, 0.1, and 1.0 BaP mg/g of diet.
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For the lungs data, as shown in Figure 35a, a dose-dependent increase in
size of the lungs was observed; 4 % in the low dose (0.01 mg/g) and 11.0 %
in the high dose (0.1 mg/g). For the 12-weeks exposure (Figure 35b), lung
size also showed no change from the control animals in the low dose
(0.01 mg/g) treated groups, whereas, in the medium (0.1 mg/g) and high (1.0
mg/g) dose, the increase in lung size was dose-dependent; 9% and 37%
increase in lung size in the medium and high dose after 12-weeks of
exposure. The induction of Cyp1a1 and Cyp1a2 in human lungs by BaP is
associated with lung cancer (Wei et al, 2001).
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Figure 36. Percent Change in Kidney Weight, (a) 2-weeks of Exposure to
BaP Control, 0.01, 0.1, and 1.0 BaP mg/g of Diet, (b) 12-weeks of Exposure
to Control, 0.01, 0.1, and 1.0 BaP mg/g of Diet.
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As an excretory organ, the kidney plays an important role in detoxification and
metabolism of xenobiotic compounds and drugs. An increase of about 4 % in
the kidney weight was observed for the low and high dose after 2-weeks
(Figure 36a). On the other hand, after 12-weeks, the kidney size decreased in
the high (1.0 mg/g) and low (0.01 mg/g) dose of animals by 3-8%, and only
increased by 4% in the medium (0.1 mg/g) of BaP treatment (Figure 36b). In
addition, no significant increase in the size of the heart was observed after 2weeks of exposure to low and high dose of BaP (Figure 37a). For the 12weeks exposure period, the mean size of the heart for the low dose and the
control remain the same, whereas a 4% increase in heart size was observed
for the medium (0.1 mg/g) and high (1.0 mg/g) dose of BaP after 12-weeks of
exposure (Figure 37b).
BaP has been implicated in cardiovascular diseases such as atherosclerosis
(Yan et al, 2000) in animals ranging from chickens to rats (Ou and Ramos,
1992).

Also, Yan et al. (1998) has detected BaP-related adducts in

atherosclerotic arteries. COX-2 gene is expressed in atherosclerotic lesions
and BaP has been shown to induce the COX-2 gene, which in epithelial cells
inhibits apoptosis, and increases the invasiness of malignant cells, favoring
tumor formation. Prolong period of dosing may be needed to observe these
effects in the heart.
A change in mean spleen weight was observed after 2-weeks of exposure to
BaP (Figure 38a). A moderate mean increase in weight of 2-3% was
observed for the low dose group, while there was a 12% increase in the mean
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weight of the spleens in high dose group after 2-weeks of exposure to BaP.
However, after 12-weeks of exposure (Figure 38b), a 6 - 8 % decrease in mean
weight was observed for the low (0 . 0 1 mg/g) and medium (0 . 1 mg/g) dose of
BaP. High dose (1 mg/g) of BaP, on the other hand, showed a

6

% mean

increase in spleen weight after 12-weeks of exposure (Figure 38b).
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(a)

Figure 37. Percent Change in Heart Weight, (a) 2-weeks of Exposure to BaP
Control, 0.01, 0.1, and 1.0 BaP mg/g of Diet, (b) 12-weeks of Exposure to
Control, 0.01, 0.1, and 1.0 BaP mg/g of Diet.

In the case of the thymus, only the high dose (0.1 mg/g) of BaP showed a
mean increase of

6

% over the control animals after

2

-weeks of exposure

(Figure 39a).
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Figure 38. Percent Change in Spleen Weight, (a) 2-weeks of Exposure to
BaP Control, 0.01, 0.1, and 1.0 BaP mg/g of Diet, (b) 12-weeks of Exposure
to Control, 0.01, 0.1, and 1.0 BaP mg/g of Diet.
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Figure 39. Percent Change in Thymus Weight, (a) 2-weeks of Exposure to
BaP Control, 0.01, 0.1, and 1.0 BaP mg/g of Diet, (b) 12-weeks of Exposure
to Control, 0.01, 0.1, and 1.0 BaP mg/g of Diet.
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After 12-weeks of exposure, there was no difference between the mean
weights of the control thymus and the thymus from the low (0 . 0 1 mg/g) and
medium (0.1 mg/g) dose groups. Conversely, there was 36% increase in the
thymus weight of rats exposed to the high dose of 1 mg/g of BaP for 12weeks (Figure 39b)
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CHAPTER V

C O N C LU S IO N

Gene expression profiling using DNA microarrays and validation by Real-time
Quantitative PCR as shown in this study may be instrumental in defining
molecular and biochemical mechanisms of the action of toxicants. This study
was focused on the analysis of BaP induced gene expression changes in
Fisher 344 rat livers utilizing these expression profiling techniques. The
ultimate goal of our research project was to identify and characterize
biomarkers or signature genes associated with BaP toxicity. This may also be
useful in understanding the relationship between environmental exposures
and human disease susceptibility. The result of the BaP microarray analysis
experiment has provided answers to the following questions:

1

) reliability of

microarray GeneChips as a tool for risk assessment and gene expression
profiling,

2

) the nature of the dose-response and temporal regulation of gene

expression by BaP, 3) the gene expression profile of markers associated with
BaP exposure, and 4) functional understanding of the biological complexity
associated with mechanism of toxicity of BaP and other related compounds.
We show in our experimental data that microarrays can act as a reliable tool
for toxicogenomics studies. Chip to chip comparisons of technical replicates
showed 96 % similarity in the genes expressed. The only variation that was
observed in the data comes from normal biological variation between
individual animals. Furthermore, the microarray experiments also showed that
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BaP causes differential expression of a large family of genes in the rat livers
under acute as well as sub-chronic conditions. Differential expression was
observed for all doses and time points used. In addition, the results show that
both dose and exposure time intervals are important factors in determining
not only the number of genes that are regulated, but also the extent to which
these genes are increased or decreased. A strong variation in the expression
profile of genes belonging to different functional categories was observed
from the data. A good number of the genes were induced early, while others
showed late induction. A temporal separation in the expression of several
genes was observed from the data. Furthermore, at the low dose exposure
level, an adaptive response was observed for a good number of genes,
indicating some form of tolerance or a return to normal or sub-normal
expression levels.
Additionally, the microarray data revealed changes in gene expression for
several interesting physiological pathways including the p450 detoxification,
redox,

cell

signaling,

metabolism,

oncogenes,

apoptosis

and

steroid

biosynthesis pathways. A wide range of genes and express sequence tags
(ESTs) previously unknown to be induced by BaP were uncovered. Other
genes that are known to be regulated by BaP were confirmed by the data.
The data also reveals other genes or ESTs that may be involved in the
regulation of these genes. Through construction of pathway maps, the
relationships between the exposure to BaP and the molecular mechanisms
for disease susceptibility were elucidated. Disruption of a good number of
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genes in these pathways is implicated in biochemical processes leading to
cancer and other health effects in humans. Also, we have used a real-time
quantitative Taqman PCR to validate and quantify the changes in expression
of

6

target genes of interest, that were previously identified from Affymetrix

microarray rat RG-U34A gene chips containing 8,800 genes. A significant
change in gene expression over control groups (p < 0.05) was observed after
2-and

12

-weeks of exposure to BaP for the genes of interest.

Gene expression profiling using DNA microarrays represent a snapshot of the
gene transcription occurring at a particular time and within a particular tissue.
Toxicity, on the other hand, represents a continuum of possible effects
governed by both temporal and spatial factors that depend on the exposure
conditions.

The

environmental

conditions

that

define

exposure

to

a

contaminant may also cause significant variability in gene expression data.
Therefore, future studies that take into account a wide range of time points,
tissue or cell types, dosage routes and doses are required. Dose-response
relationships need to be characterized in order to make sense of gene
expression patterns derived from microarrays. The use of different dosing
route would help determine better routes of bioavailability. The use of different
tissues or cells would allow comparison of the spatial differences in gene
expression patterns, and therefore give a clearer picture of the transcription
profile of specific genes in different tissues. Also, an increase number of time
points allow capture of the temporal phase distinction and regulation of genes
or gene families in response to specific toxicants or classes of toxicants. The
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use of better or improved mathematical and statistical techniques specifically
designed for gene expression analysis would enhance interpretation of the
data. One such promising technique involves analysis of gene expression
data using functional principal components (Barra, 2003). This method
considers gene profiles as continuous curves, and applies a mathematical
function

analysis to gather genes with similar variations and extract

characteristic parameters of gene profiles. Finally, proteomic techniques such
as western blot, mass spectrometry, proteomic arrays, as well as RNA
interference should be utilized in future studies to determine protein profiles
and mechanisms of action of potential genes.
Integration of these tools will help in elucidating the various cellular networks
in biological systems, and help in predicting the toxicological outcome of
contaminant exposure in model and non-model organisms. This may
eventually create a good knowledge base for protecting human health.
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APPENDIX

A1
List of Gene Ontology Annotated Transcripts from 2-week SOM Cluster 1
Probe Set ID

Gene Name

Molecular Function Description

AB002558_at

glycerol-3-phosphate dehydrogenase 1
(soluble)

glycerol-3-phosphate dehydrogenase
(N A D + ) a c tiv ity

A F 025308_

RT1 class I, A 3 , RT1 class lb , locus

D13667cds_s_

alanine-glyoxylate aminotransferase

D 14989_f_at

M R N A fo r hydroxysteroid
sulfotransferase subunit, complete cds

E03358cds at

proteasome (prosome, macropain)
subunit, alpha type 2

E12286cds at

G M 2 ganglioside activator protein

M 14776_f_at

C ytochrom e P450, su b fa m ily IIC 6

monooxygenase a c tiv ity , oxidoreductase

M 21476_s_at

p ro ly l 4-hydroxylase, beta polypeptide

protein d isu lfid e isomerase a c tiv ity
procollagen-proline 4-dioxygenase a c tiv ity
electron transporter a c tiv ity

rc__AA92547

ce ll d iv is io n cycle 42 hom olog (S.
cerevisiae)

GTPase a c tiv ity

rc_A A 99648

aldehyde dehydrogenase fa m ily 3,
s u b fa m ily A 2

aldehyde dehydrogenase a c tiv ity
aldehyde dehydrogenase (N A D ) a c tiv ity
oxidoreductase a c tiv ity

rc_A I171734_
s_at

fum arate hydratase 1

catalytic a c tiv ity , fumarate hydratase
a ctiv ity , lyase a c tiv ity

S35751_f_at

3-alpha-hydroxysteroid dehydrogenase

S81448 s at

steroid 5 alpha-reductase 1

X 53054 a at

RT1 class II, locus B b
RT1 class II, locus D b l

X70223__at

peroxisom al membrane p ro te in 2

peroxisom e organization and biogenesis

X72792cds

a lcohol dehydrogenase 1

alcohol dehydrogenase a ctivity, zincdependent,zinc io n bin d in g , oxidoreductase

serine-pyruvate transaminase a c tiv ity
alanine-glyoxylate transaminase a ctivity

endopeptidase a c tiv ity , peptidase a c tiv ity
hydrolase a c tiv ity

3 -oxo-5 -alpha-steroid 4-dehydrogenase
a ctiv ity , oxidoreductase a c tiv ity
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A2
List of Gene Ontology Annotated Transcripts from 2-week SOM Cluster 2
Probe Set ID

Gene Name

Molecular Function Description

AA685903 at Sim ilar to Endoplasmin precursor
(Endoplasmic reticulum protein 99) (94
kDa glucose-regulated protein)
(GRP94) (ERP99) (Polymorphic tumor
rejection antigen 1) (Tumor rejection
antigen gp96) (LOC362862), mRNA
ABO 12933 g
at

acyl-CoA synthetase long-chain fam ily magnesium ion binding,catalytic activity
long-chain-fatty-acid-CoA ligase activity
member 5

AF023302_s_ flo tillin 2
at
A FFX Rat G glyceraldehyde-3-phosphate
dehydrogenase
APDH_5_at

AJ223355_at

glyceraldehyde-3-phosphate
dehydrogenase (phosphorylating) activity
oxidoreductase activity

solute carrier fa m ily 25 (mitochondrial
carrier; dicarboxylate transporter),
member 10

D00913 g at intercellular adhesion molecule 1

defense response, cell adhesion, cell-cell
adhesion

D13921_s_at

acetyl-coenzyme A acetyltransferase 1

acetyl-CoA C-acetyltransferase activity
acyltransferase,transferase activity

D13978_s_at

argininosuccinate lyase

catalytic activity, argininosuccinate lyase
activity, lyase activity, urea cycle
arginine biosynthesis

D37934 g at Sim ilar to proteasome 26S non-ATPase
subunit 2 (LOC287984), m RNA
D85435 g at protein kinase C, delta binding protein

protein kinase C binding, regulation o f
cell growth

D87839 g at 4-aminobutyrate aminotransferase

4-aminobutyrate transaminase activity
transaminase activity, transferase activity

D87991_at

galactose transporter

D90401 g at afadin
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List of Gene Ontology Annotated Transcripts from 2-week SOM Cluster 2 Continued
E01050cds % alanine-glyoxylate aminotransferase
at

serine-pyruvate transaminase activity
alanine-glyoxylate transaminase activity
transaminase activity, transferase activity

E03859cds_s_ RAB1 la , member RAS oncogene
fam ily
at

GTP binding, protein transporter activity
GTPase mediated signal transduction

E13557cds_s__ cysteine-sulfinate decarboxylase
at

sulfmoalanine decarboxylase activity
lyase activity, carboxy-lyase activity,
amino acid metabolism, taurine
biosynthesis

J00735_at

fibrinogen, gamma polypeptide

inflammatory response, blood coagulation

J05210_at

ATP citrate lyase

magnesium ion binding, catalytic activity
ATP citrate synthase activity, citrate (Si)synthase activity, ATP binding,
transferase activity, lyase activity, ligase

K00750exon# Sim ilar to Cytochrome c, somatic
(LOC365738), m R NA
2-3_at
M l 5481

r

at insulin-like growth factor 1

hormone activity, growth factor activity

M17412_at

growth and transformation-dependent
protein

M26247_at

coagulation factor 9

M62832_at

plasminogen

M64755_at

cysteine-sulfinate decarboxylase

M64795_f_at

RT1 class lb, locus A w 2

X13058_at

Tum or suppressor protein p53

D N A binding, transcription factor

M86870_at

protein disulfide isomerase related
arotein (calcium -binding protein,
intestinal-related)

protein disulfide isomerase activity

M95768_at

chitobiase, di-N-acetyl-

catalytic activity, hydrolase activity,

coagulation factor IX a activity
serine-type endopeptidase activity
chymotrypsin activity, trypsin activity
calcium ion binding, hydrolase activity

sulfmoalanine decarboxylase activity
lyase activity, carboxy-lyase activity
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List of Gene Ontology Annotated Transcripts from 2-week SOM Cluster 2 Continued
rc_AA799279 Sim ilar to mitochondrial carrier
homolog 2 (LOC295922), mRNA
rc_AA7994

Hypothetical LOC293114
(LO C293114), m RNA

rc_AA799571 Sim ilar to R IK E N cD N A 1110001M20
(LOC298308), m RNA
rc _ A A 8 17854 ceruloplasmin
sat

ferroxidase activity, copper ion binding
oxidoreductase activity

rc_AA858573 spp-24 precursor
rc_AA858640 heat shock protein 60 (liver)
rc_AA892799 Sim ilar to glyoxylate
reductase/hydroxypyruvate reductase
(LOC298085), m RNA
rc_AA892861 Sim ilar to R IK E N cD N A 2610528J11
at
(LOC362576), m RNA
rc_AA893905 tripartite m o tif protein 39
K at
rc_ A I0 1 1998_ DnaJ (Hsp40) homolog, subfam ily B,
member 9
at
rc_AI013194

chaperone activity

eukaryotic translation initiation factor 5 translation initiation factor activity
GTP binding

rc_AI044341_ valosin-containing protein

nucleotide binding, A TP binding
hydrolase a ctivity

rc_AI169735

monooxygenase activity, oxidoreductase

cytochrome P450IIB3

rc_AI170568_ dodecenoyl-coenzyme A delta
s_at
isomerase

catalytic activity, dodecenoyl-CoA deltaisomerase a ctivity

rc_AI235890_ M H C class I b R T l. S3
rc_AI237007

electron-transferring-flavoprotein
dehydrogenase

S45663_at

glycoprotein, synaptic 2
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List of Gene Ontology Annotated Transcripts from 2-week SOM Cluster 2 Continued
S75019 at

Sim ilar to aldehyde dehydrogenase
fam ily 7, member A 1; aldehyde
dehydrogenase 7 fam ily, member A l;
D N A segment, Chr 18,

S78217_s_at

protein phosphatase 1, catalytic subunit, protein phosphatase type 2A activity
gamma isoform
protein phosphatase type 1 activity
phosphoprotein phosphatase activity
protein seriiie/threonine phosphatase
activity, calcium-dependent protein
magnesium-dependent protein

U36482 g at

endoplasmic retuclum protein 29

U56839_at

purinergic receptor P2Y, G-protein
coupled 2

rhodopsin-like receptor activity
G-protein coupled receptor activity
ATP binding, purinergic nucleotide
receptor activity, G-protein coupled

E01884_at

Interleukin-1 beta

cytokine activity, interleukin-1 receptor
binding, growth factor activity

U75917 g at

clathrin-associated protein 17

X06150cds_at glycine N-methyltransferase

catalytic activity, fo lic acid binding
methyltransferase activity, Sadenosylmethionine-dependent
methyltransferase activity, glycine N methyltransferase activity

X06357cds_s_ alanine-gl yoxyl ate amin otransferase
at

serine-pyruvate transaminase activity
alanine-glyoxylate transaminase activity

X13044_at

CD74 antigen (invariant polpypeptide
o f major histocom patibility class II
antigen-associated)

chaperone activity

X53363cds_s_ calreticulin
at

chaperone activity, calcium ion binding
calcium ion storage activity

X62295cds_s_ angiotensin II receptor, type 1 (A T I A )
at

rhodopsin-like receptor activity
receptor activity, G-protein coupled
receptor activity, angiotensin type II
receptor a ctivity
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List of Gene Ontology Annotated Transcripts from 2-week SOM Cluster 2 Continued
X69834_at

serine protease inhibitor 2.4

X81448cds_at Similar to cytokeratin (LOC294853)
X84047cds_at GNAS complex locus, XLas protein
X86178

alpha-2-glycoprotein 1, zinc

Z50052_at

complement component 4 binding
protein, pseudogene 1

Z50144_at

aminoadipate aminotransferase

signal transducer activity,GTP binding
zinc ion binding

transaminase activity
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A3
List of Gene Ontology Annotated Transcripts from 2-week SOM Cluster 4
Probe Set ID
AB000491_at

Gene Name

Molecular Function Description

proteasomal ATPase (SUG1)

AB005547_at aquaporin 8

transporter activity, water channel activity

AF012714_at multiple inositol polyphosphate inositol-1,3,4,5,6-pentakisphosphate 3-phosphatase
histidine phosphatase 1
activity, inositol-1,4,5,6-tetrakisphosphate 6phosphatase activity
AF029240_at M H C class Ib R T l.S3
AF061971 at palmitoyl-protein thioesterase 2 catalytic activity, palm itoyl-(protein) hydrolase activity
AF089825_at activin beta E

hormone activity, growth factor activity

AJ000347_g_ 3(2),5-bisphosphate
nucleotidase
at

inositol or phosphatidylinositol phosphatase activity
3'(2'),5'-bisphosphate nucleotidase activity

D00569_at

2,4-dienoyl CoA reductase 1,
mitochondrial

2,4-dienoyl-CoA reductase (N A D P H ) activity
oxidoreductase activity

D00698_s_at

insulin-like growth factor 1

hormone activity, growth factor activity

DQ0729 g at dodecenoyl-coenzyme A delta
isomerase
D00753_at

Serine protease inhibitor

D10874_at

ATPase, H + transporting,
lysosomal (vacuolar proton
pump) 16 kDa

catalytic activity, dodecenoyl-CoA delta-isomerase

ATPase activity, coupled to transmembrane movement
o f ions

D13623 g at Sim ilar to ribosome-binding
protein p34 - rat (LOC287633),
D 13907 g at mitochondrial processing
peptidase beta

metalloendopeptidase activity
mitochondrial processing peptidase, hydrolase activity

D21215cds_s_ coagulation factor X

serine-type endopeptidase activity, chymotrypsin
activity, trypsin activity, peptidase activity, hydrolase

D30647_at

acyl-Coenzyme A

D30649mRN

ectonucleotide

acyl-CoA dehydrogenase activity
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List of Gene Ontology Annotated Transcripts from 2-week SOM Cluster 4 Continued
D21215cds_s_ coagulation factor X

serine-type endopeptidase activity, chymotrypsin
activity, trypsin activity, peptidase activity, hydrolase

D30647_at

acyl-Coetizyme A

acyl-CoA dehydrogenase activity

D30649mRN
A_s_at

ectonucleotide
pyrophosphatase/phosphodiester
ase 3

D45254 g at cellular nucleic acid binding
protein

single-stranded D N A binding, single-stranded R N A
binding

D88250_at

complement component 1, s
subcomponent

D90211_s_at

lysosomal membrane
glycoprotein 2

tRNA ligase activity, A TP binding

D90265_s_at

proteasome (prosome,
macropain) subunit, alpha type
1

endopeptidase activity
transporter activity
peptidase activity
hydrolase activity

D90404_at

cathepsin C

cysteine-type endopeptidase activity
dipeptidyl-peptidase I activity, hydrolase activity

E01184cds_s_ cytochrome P450, fa m ily 1,
subfamily a, polypeptide 2
at

monooxygenase activity
oxidoreductase activity

J00728cds_f_a cytochrome P450, 2b 19
t

monooxygenase activity

J04171__at

glutamate oxaloacetate
transaminase 1

aspartate transaminase activity, transaminase a ctivity

J05035_at

steroid 5 alpha-reductase 1

3-oxo-5-alpha-steroid 4-dehydrogenase activity
oxidoreductase activity

J05470_at

carnitine palmitoyltransferase 2 carnitine O-palmitoyltransferase activity
acyltransferase activity, transferase activity

L07736_at

carnitine palmitoyltransferase 1, carnitine O-palmitoyltransferase activity
acyltransferase activity, transferase activity
iver
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List of Gene Ontology Annotated Transcripts from 2-week SOM Cluster 4 Continued
|L13619_at

insulin induced gene 1

jM16235 at

lipase, hepatic

catalytic activity, triacylglycerol lipase activity
lipid transporter activity, heparin binding, hydrolase

Jm 22359

alpha(l)-inhibitor 3, variant I

protease inhibitor activity, inflam m atory response

M32016_at

lysosomal membrane
glycoprotein 2

tRNA ligase activity, A T P binding

M33648_at

3-hydroxy-3-methylglutarylCoenzyme A synthase 2

hydroxym ethylglutaryl-CoA synthase activity
transferase activity

M35270

alanine-glyoxylate
aminotransferase

serine-pyruvate transaminase activity
alanine-glyoxylate transaminase activity

M55015cds

nucleolin

nucleic acid binding, D N A binding, R N A binding

M64733mRN
A s at

clusterin

response to stress, spermatogenesis

M67465_at

hydroxy-delta-5-steroi d
dehydrogenase, 3 beta- and
steroid delta-isomerase

steroid dehydrogenase a ctivity

M74067_at

claudin 3

structural molecule activity

M 8 1183Exon_ Rat insulin-like growth factor I
mRNA, 3 'end o f m RNA
UTR_g_at
M81687_at

syndecan 2

cytoskeletal protein binding

M83143 g at sialyltransferase 1

beta-galactoside alpha-2,6-sialyltransferase activity
sialyltransferase activity, transferring glycosyl groups

M86912exon_ angiotensin I I receptor, type 1
(A T I A )

rhodopsin-like receptor activity, G-protein coupled
receptor activity, angiotensin type I I receptor activity

rc_AA799452 transaldolase 1

transaldolase activity, transferase activity

rc_AA79952

Sim ilar to E25B protein

rc AA799762 Sim ilar to R IK E N cD N A
270003 8C09 (LOC296470),
g at
rc_AA800250 succinate dehydrogenase
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List of Gene Ontology Annotated Transcripts from 2-week SOM Cluster 4
Continued
rc_AA800268 Sim ilar to Ormdl2 protein
rc_AA800272 Sim ilar to mitochondrial
ribosomal protein L3 (L3m t)
rc_AA800296 Sim ilar to po ly(A ) polymerase
rc_A A 800318 serine (o r cysteine) proteinase
inhibitor, clade G (C l inhibitor)
rc_AA859700 Sim ilar to Protoporphyrinogen
oxidase (LOC289219), mRNA
g at
rc_AA891800 Sim ilar to R IK E N cD N A
1110013G13(LOC310856),
_at
rc_AA891914 aminoacylase 1
_at

aminoacylase activity, metallopeptidase activity
hydrolase activity

rc_AA891916 membrane interacting protein o f glycerophosphodiester phosphodiesterase activity
RGS16
g at
rc_AA892128 peroxisomal biogenesis factor
11A
_at
rc_AA892470 Sim ilar to histone H 2A.F/Z
variant isoform 1; purine-rich
_at
binding element protein B
(LOC314176), m R NA
aldehyde reductase activity
rc_AA892821 aldo-keto reductase fam ily 7,
member A 2 (aflatoxin aldehyde aldo-keto reductase a ctivity
_£_at
reductase)
rc_AA892828 Sim ilar to pyruvate
dehydrogenase (lipoamide) beta
_at
(LOC289950), m R NA
rc_AA892888 Sim ilar to R IK E N cD N A
0610006F02 (LOC366792)
g at
rc_AA892916 Ab2-305 m R N A , complete cds
rc_AA893235 Sim ilar to G0S2-like protein
rc_AA893353 Sim ilar to Aspartyl
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List of Gene Ontology Annotated Transcripts from 2-week SOM Cluster 4 Continued
rc_AA893515 Sim ilar to Ab2-292
(LOC294912), mRNA
_at
rc_AA893552 serine (or cysteine) proteinase)
rc_AA893658 Sim ilar to alcohol
dehydrogenase PAN ! B-like
protein (LOC305150), m RNA
rc_AA893690 Sim ilar to neuronal protein 15.6
(LOC299310), m RNA
rc_AA894101 Sim ilar to N-terminal
asparagine amidohydrolase
rc_AA894130 Unknown (protein for
MGC:72638)
rc_AA894277 Sim ilar to R IK E N cD N A
2010107G23 (LOC294499)
at
rc_AA944007 Nucleobindin

structural constituent o f bone

rc_AI103957_ CD 81 antigen

protein binding, response to wounding
regulation o f growth / cell proliferation

rc_AI171090_ 3-hydroxy-3-methylglutaryl
CoA lyase
g_at

catalytic activity, hydroxym ethylglutaryl-CoA lyase
activity

rc_AI172476_ TGFB inducible early growth
response
rc_AI176052_ adenylate kinase 3
at

adenylate kinase activity

rc_AI177161_ NF-E2-related factor 2

D N A binding

rc_AI178135_ complement component 1, q
subcomponent binding protein
at
rc_AI639418_ deiodinase, iodothyronine, type thyroxine 5'-deiodinase activity, selenium binding
oxidoreductase activity, hydrolase activity
I
at
rc_H31813_at Sim ilar to cD N A sequence
BC021917 (LOC361730)
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List of Gene Ontology Annotated Transcripts from 2-week SOM Cluster 4 Continued
S45663 g at

glycoprotein, synaptic 2

S61865 s at

syndecan 1

S61960_s_at

Sim ilar to kynurenine
aminotransferase/glutamine

S63521_i_at

heat shock 70kD protein 5

heat shock protein activity, A TP binding

S69874_s_at

fatty acid binding protein 5,
epidermal

transporter activity, binding, fatty acid binding
lip id binding

S74351_s__at

dual specificity phosphatase 1

M AP kinase phosphatase activity

U05675__at

fibrinogen, B beta polypeptide

blood coagulation, wound healing

U08976_at

enoyl coenzyme A hydratase 1, catalytic activity, isomerase activity
peroxisomal

U28504_g_at

solute carrier fa m ily 17 (sodium transporter activity, sodium:phosphate symporter
phosphate), member 1
activity, phosphate transporter activity, symporter

U61729_at

proline rich 2

U66322_at

leukotriene B4 12hydroxydehydrogenase

U89280_at

hydroxysteroid (17-beta)
dehydrogenase 9

X04070_at

gap junction membrane channel gap-junction form ing channel activity
protein beta 1
connexon channel a ctivity

X05684_at

pyruvate kinase, liver and RBC magnesium ion binding, pyruvate kinase activity
kinase activity, transferase activity

X06107_r_at

insulin-like growth factor 1

cytoskeletal protein binding

response to toxin

hormone activity, growth factor activity

X51615_g_at Hypothetical LOC290275
X54096_at

ecithin cholesterol
acyltransferase

X62660mRN
A__g_at

Sim ilar to G LU T A T H IO N E STRANSFERASE 8 (GST 8-8)
(C H A IN 8) (GST CLASS-

catalytic activity, phosphatidylcholine-sterol 0 acyltransferase activity, transferase activity
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List of Gene Ontology Annotated Transcripts from 2-week SOM Cluster 4 Continued
X79807_at

jcoagulation factor X

serine-type endopeptidase activity, chymotrypsin
activity, trypsin activity, peptidase activity, hydrolase

X86561cds#2 {fibrinogen, alpha polypeptide

jblood coagulation tissue regeneration

X91234_at

estradiol 17-beta-dehydrogenase activity
pxidoreductase activity

Jhydroxysteroid (17-beta)
jdehydrogenase 2

X97443_s_at jintegral membrane protein
jTm p21-I (p23)

jprotein carrier activity, protein transporter activity

Z50144_g_at Jaminoadipate aminotransferase jtransaminase activity
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A4
List of Gene Ontology Annotated Transcripts from 2-week SOM Cluster 5

Probe Set ID

Gene Name

Molecular Function Description

AF023087

early growth response 1

nucleic acid binding, D N A binding
transcription factor activity, transcriptional

rc_A A 818593

phosphatidate phosphohydrolase
type 2a

phosphatidate phosphatase activity

rc_AA892498_at

Similar to tetraspanin T M 4 -A
homolog (LOC300733), m RNA

rc_AI012030_at

matrix Gla protein

calcium ion binding

rc_AI232379_at

platelet derived growth factor
receptor, alpha polypeptide

protein kinase activity, protein serine/threonine
kinase activity, protein-tyrosine kinase activity
transmembrane receptor protein tyrosine kinase

rc_AI639058_s_at Similar to Nedd4 W W binding
protein 4 (LO C 311676), mRNA
U90261UTR#1_

SH3-domain kinase binding

protein binding, regulation o f apoptosis

V01227_s_at

tubulin, alpha 1

structural molecule activity, GTP binding
protein domain specific binding, protein
heterodimerization activity, microtubule-based

X06916_at

S100 calcium-binding protein A 4 calcium ion binding
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A5
List of Gene Ontology Annotated Transcripts from 2-week SOM Cluster 6
1 Probe Set ID

Gene Name

M olecular F unction Description

DI2769_at

basic transcription element binding
protein 1

D32249_s_at

praja 2, RING-H2 m o tif containing neurogenesis

D89655_at

scavenger receptor class B, member

J03I90 g at

aminolevulinic acid synthase 1

L00191cds#l_s fibronectin 1
_at

5-aminolevulinate synthase activity, acyltransferase
transaminase activity, heme biosynthesis
heparin binding, oxidoreductase activity
mercury ion binding, acute-phase response
cell adhesion, metabolism, wound healing

L09647_at

forkhead box A2

D N A binding, transcription factor activity

L28135_at

solute carrier fam ily 2 (facilitated
glucose transporter), member 2

transporter activity, sugar porter activity
glucose transporter activity, carrier activity

L36532_s_at

complement receptor related protein

M77479_at

solute carrier fam ily 10
(sodium/bile acid cotransporter
fam ily), member 1

rc_AA799729_g phosphodiesterase 4B

carrier activity, bile acid:sodium symporter activity
symporter activity

cAMP-specific phosphodiesterase activity

rc_AA799803_a Similar to complement component
t
1, r subcomponent (LO C 312705)
rc_AA859869_s proteasome (prosome, macropain)
26S subunit, non-ATPase, 1
_at
rc_AA859954_a vacuole Membrane Protein 1
rc_AA874784_s lipase A, lysosomal acid

catalytic activity, sterol esterase activity, hydrolase
activity

rc_AA875097_a fibrinogen, alpha polypeptide

blood coagulation, tissue regeneration

rc_AA891194_s Arg/Abl-interacting protein ArgBP2 intracellular signaling cascade
rc_AA891591_a programmed cell death 8

DNA fragmentation during apoptosis
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List of Gene Ontology Annotated Transcripts from 2-week SOM Cluster 6 Continued
rc_AA892545_ajsim ilar to IT M (LOC309131)
rc_AA892547_a Similar to RIKEN cD NA
t
2010311DQ3 (LOC362134), m R NA
rc_AA893239_a 2-hydroxyphytanoyl-CoA lyase
rc_AA957510_s ATPase, Ca++ transporting, cardiac magnesium ion binding, calcium-transporting
at
muscle, slow twitch 2
ATPase activity, calcium ion binding
ATP binding, ATPase activity, coupled to
transmembrane movement o f ions, phosphorylative
mechanism, hydrolase activity
S81478_s_at

dual specificity phosphatase 1

M AP kinase phosphatase activity

U02553cds_s_at dual specificity phosphatase 1

M AP kinase phosphatase activity

U06230_s_at

protein S (alpha)

U18762_at

retinol dehydrogenase type III

retinol dehydrogenase activity

U19614 a at

lamina-associated polypeptide 1C

lamin binding

U32314 g at

Pyruvate carboxylase

catalytic activity, pyruvate carboxylase activity
ATP binding, biotin binding
ligase activity, manganese ion binding

X55298_at

ribophorin II

dolichyl-diphosphooligosacchari de-protein
glycotransferase activity, transferase activity

X78997_at

cadherin 17

calcium ion binding, cell adhesion

X95096_at

Macrophage stimulating 1
(hepatocyte growth factor-like)

thrombin activity, serine-type endopeptidase
activity, chymotrypsin activity, trypsin activity
calcium ion binding, peptidase activity, hydrolase

Y14933mRNA_ one cut domain, fam ily member 1
s_at

D N A binding transcription factor activity, glucose
metabolism, regulation o f transcription
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B1
List of Gene Ontology Annotated Transcripts from 12-week SOM Cluster 1
Gene Name

Probe Set ID

Molecular Function Description

AA799276_at

ATPase, Ca++ transporting,
cardiac muscle, slow tw itch 2

AF030091UTR

cyclin L I

AF037072_at

carbonic anhydrase 3

carbonate dehydratase activity, zinc ion binding
lyase activity

A F063102_at

latrophilin 2

G-protein coupled receptor activity

AF077000_at

protein tyrosine phosphatase,
non-receptor type 23

AF079864_at

olfactory receptor gene 01r59

olfactory receptor activity

AF089825_at

activin beta E

hormone activity, growth factor activity

D00698_s_at

insulin-like growth factor 1

hormone activity growth factor activity

D28557_s_at

cold shock domain protein A

D N A binding

J00738_s_at

alpha-2u globulin PGCL4
Terpenoid biosynthesis

J03865mRNA_f_a
L38482_at

Sim ilar to cell division cycle 34;
ubiquitin-conjugating enzyme

rc_AA800029_at

Sim ilar to highwire; P A M ; rpm

rc_AA875097_at

fibrinogen, alpha polypeptide

rc_AI008815_s_at Sim ilar to Cytochrome c,
somatic (LOC365738), m R NA
X13058__at

magnesium ion binding, calcium-transporting
ATPase activity, calcium ion binding

tumor suppressor protein p53

Blood clotting cascade
Apoptosis, Electron-transport chain

Apoptosis, D N A binding, transcription factor

rc_A I0 7 1866_s_at N clonelO m R N A
Cell-Cycle

rc_AI236721_r_at
L14680_at

B-cell lymphoma 2

U33500 g at

retinol dehydrogenase type II

Protein binding, cell survival
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List of Gene Ontology Annotated Transcripts from 12-week SOM Cluster 1 Continued
(J37138_at

steroid sulfatase

steryl-sulfatase activity, sulfuric ester hydrolase

X06107_r_at

insulin-like growth factor 1

hormone activity, growth factor activity
Terpenoid Biosynthesis

X13119cds_s_at
X14552_at

alpha-2u globulin PGCL4

X53588_at

glucokinase

glucokinase activity, hexokinase activity, ATP

X84210complete

nuclear factor I/A

DNA binding transcription factor activity

X86561cds#2_at

fibrinogen, alpha polypeptide

Y14933mRNA

one cut domain, family

DNA binding, transcription factor activity
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List of Gene Ontology Annotated Transcripts from 12-week SOM Cluster 2
Probe Set ID

Gene Name

Molecular Function Description

AA801441_at

platelet-activating factor
acetylhydrolase, isoform lb

1-alkyl-2-acetylglycerophosphocholine esterase
activity, hydrolase activity

AB009890_at

trophoblast specific protein

AF034582 g at

SEC31-like 1 (S. cerevisiae)

D12769_at

basic transcription element
binding protein 1

J05035 g at

steroid 5 alpha-reductase 1

L23413_at

sulfate porter activity, sulfate transporter activity,
solute carrier fam ily 26
(sulfate transporter),member 1 antiporter activity

M27440_at

apolipoprotein B

M58758 g at

ATPase, H+ transporting

3-oxo-5-alpha-steroid 4-dehydrogenase activity
oxidoreductase activity

hydrogen ion transporter activity

rc_AA817854_s_a ceruloplasmin

Ferroxidase activity, copper ion binding

rc_AI 105348_i_at cofilin 1

actin binding

rc_AI171355_s_at cytochrome b, mitochondrial

electron transporter activity

rc_AI171630_s_at mitogen activated protein
kinase 14

protein serine/threonine kinase activity
protein kinase CK2 activity, M AP Kinase activity
cAMP-dependent protein kinase activity

rc_A1180108_at

Similar to Wbscrl

U58858_at

junction plakoglobin

U66723_s_at

solute carrier fam ily 28

nucleoside:sodium symporter activity

X52140_at

integrin alpha 1

magnesium ion binding receptor activity

X55660_at

aroprotein convertase
subtilisin/kexin type3
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List of Gene Ontology Annotated Transcripts from 12-week SOM Cluster 3
Gene Name

Probe Set ID

Molecular Function Description

ABO17544

peroxisomal biogenesis factor
14

peroxisome organization and biogenesis

D13417 g at

hairy and enhancer o f split 1

DNA binding, transcriptional repressor activity

D86745cds_s_at nuclear receptor subfamily 0,
group B, member 2

ligand-dependent nuclear receptor activity

D89375_s_at

dopa/tyrosine sulfotransferase

J03190_at

aminolevulinic acid synthase 1

5-aminolevulinate synthase activity, acyltransferase
activity, transaminase activity, transferase activity

M93257_s_at

catechol-O-methyltransferase

magnesium ion binding, methyltransferase activity
O-methyltransferase activity, Sadenosylmethionine-dependent methyltransferase

M96548_at

zinc finger protein 354A

nucleic acid binding, D N A binding, transcription
factor activity

rc_AA800005_a CD151 antigen
rc_AA892775

iysozyme

rc_AA893239_a 2-hydroxyphytanoyl-CoA lyase
rc_AA893384_ Similar to interferon regulatory
factor 3 (LOC292892), mRNA
rc AA946040_a Similar to Uroplakin la (UPIa)
(UPKa) (LOC365227), mRNA
t
rc_AI011998_at DnaJ (Hsp40) homolog,
subfamily B, member 9

chaperone activity

rc_AI171085_at ribosomal protein L39

RNA binding, structural constituent o f ribosome

rc_AI175935_at myosin IE

motor activity, ATP binding

rc_AI180442_at 'arensyl diphosphate synthase

Dimethylallyl transtransferase,
famesyltranstransferase activity
geranyltranstransferase activity

rc AJ230260_s_ casein kinase II beta subunit

rrotein serine/threonine kinase activity
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rc_AI235747_at Glutathione-S-transferase, a2

glutathione transferase activity, transferase activity

rc_AI639418_at deiodinase, iodothyronine, typel thyroxine 5'-deiodinase activity, selenium binding
oxidoreductase activity, hydrolase activity
X15580

6-phosphofructo-2kinase/fructose-2,6
biphosphatase 1

X55660 g at

proprotein convertase
subtilisin/kexin type3

X60769mRNA_ CCAAT/enhancer binding
protein (C/EBP), beta

catalytic activity, 6-phosphoffucto-2-kinase activity
fructose-2,6-bisphosphate 2-phosphatase activity
ATP binding, kinase activity, transferase activity
hydrolase activity

DNA binding, protein binding
transcriptional activator activity
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List of Gene Ontology Annotated Transcripts from 12-week SOM Cluster 4
Probe Set ID

Gene Name

Molecular Function Description

J02612mRNA

UDP glycosyltransferase 1
family polypeptide, A1-A8

glucuronosyltransferase activity
transferring glycosyl groups, hexosyl

L21711_s„at

lectin, galactose binding

Sugar binding

M25804 g at

nuclear receptor subfamily 1,
group D, member 1

DNA binding, transcription factor activity
steroid hormone receptor activity receptor

M27467_at

cytochrome oxidase subunit V ic

M33025__s_at

parathymosin

X05684_at

pyruvate kinase, liver and RBC magnesium ion binding, pyruvate kinase

enzyme inhibitor activity, zinc ion binding
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List of Gene Ontology Annotated Transcripts from 12-week SOM Cluster 5
Probe Set ID
AF014503_at

Gene Name
nuclear protein 1

Molecular Function Description
transcription factor activity

AF045464_s_at aldo-keto reductase fam ily
7, member A3 (aflatoxin
aldehyde reductase)

aldehyde reductase activity, aflatoxin
metabolism

AJ011656cds_s claudin 3
_at

structural molecule activity

D28339„s_at

3-hydroxyanthranilate 3,4dioxygenase

3-hydroxyanthranilate 3,4-dioxygenase
activity oxidoreductase activity

D83796_s_at

UDP glycosyltransferase 1
family polypeptide, A l,
A2, A4, A6, A7, A8

glucuronosyltransferase activity
transferring glycosyl group, transferring
hexosyl groups, bilirubin conjugation
metabolism

E01184cds_s_at cytochrome P450, fam ily 1, monooxygenase activity, oxidoreductase
subfamily a, polypeptide 2 activity
E01524cds__s_at P450 (cytochrome),
oxidoreductase

NADPH-hemoprotein reductase activity
electron transporter activity, oxidoreductase

E12625cds_at

sterol-C4-methyl oxidase

catalytic activity, oxidoreductase activity

J03179 g at

D site albumin promoter

DNA binding, transcriptional activator

J05210 g at

ATP citrate lyase

magnesium ion binding, catalytic activity
ATP citrate synthase activity, lyase activity
ligase activity

K01934mRNA

thyroid hormone responsive

K02815_s_at

RT1 class II, locus Ba

L00320cds_f

cytochrome P450, 2b 19

monooxygenase activity

L38615 g at

glutathione synthetase

glutathione synthase activity, ATP binding
ligase activity

M10068mRNA P450 (cytochrome)
oxidoreductase

NADPH-hemoprotein reductase activity
electron transporter activity
oxidoreductase activity
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protein disulfide isomerase activity
procollagen-proline 4-dioxygenase activity
electron transporter activity

M21476_s_at

prolyl 4-hydroxylase, beta
polypeptide

M26127_s_at

cytochrome P450, fam ily 1, monooxygenase activity oxidoreductase
subfamily a, polypeptide 2 activity

M74067_at

claudin 3

M89945mRNA_ farensyl diphosphate
g_at
synthase

structural molecule activity
dimethylallyltranstransferase activity
famesyltranstransferase activity
geranyltranstransferase activity
transferase activity

hydrogen ion transporter activity
rc_AA799778_a ATP synthase, H+
transporting, mitochondrial
t
FO complex, subunit b,
isoform 1
rc_AA852004

glutamine synthetase 1

rc_AA892828

Similar to pyruvate
dehydrogenase (lipoamide)
beta (LOC289950), mRNA

rc_AA945050

rat senescence marker
protein 2A gene, exons 1
and 2

glutamate-ammonia ligase activity

rc_AI008131_s_ S-adenosylmethionine
decarboxylase 1
at

adenosylmethionine decarboxylase activity
lyase activity, carboxy-lyase activity

rc_AI030175_s_ sorbitol dehydrogenase
at

L-iditol 2-dehydrogenase activity
alcohol dehydrogenase activity, zincdependent, zinc ion binding
oxidoreductase activity

rc_AI137856_s__ P450 (cytochrome)
at
oxidoreductase

NADPH-hemoprotein reductase activity
electron transporter activity, oxidoreductase

rc_AI 169695_f_ M RNA for hydroxysteroid
sulfotransferase subunit,
at
rc_AI171734_s__ fumarate hydratase 1

catalytic activity, fumarate hydratase
lyase activity
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rc_AI175764_s_ stearoyl-Coenzyme A
desaturase 1
rc_AI176052_at adenylate kinase 3

adenylate kinase activity

rc_AI230712_at Subtilisin - like
endoprotease

serine-type endopeptidase activity
subtilase activity, transmembrane receptor
protein tyrosine kinase activity, electron
transporter activity, ATP binding peptidase
activity, serine-type peptidase activity
hydrolase activity

rc_A!23269 l a t lectin, galactose binding,
soluble 8

sugar binding

rc_AI235585__s_ cathepsin D
at

aspartic-type endopeptidase activity
cathepsin D activity, pepsin A activity
hydrolase activity

rcH31813_ at

Similar to cDNA sequence
BC021917 (LOC361730),

S56937_s_at

UDP glycosyltransferase 1 glucuronosyltransferase activity,
family polypeptide A 1 , A2, transferring glycosyl groups, transferring
hexosyl groups
A4, A6, A7, A8

U10357_at

pyruvate dehydrogenase
kinase, isoenzyme 2

U17971_at

protein tyrosine phosphatase protein tyrosine phosphatase activity
2E

U67915_at

mast cell protease 1

serine-type endopeptidase activity chymase
activity

X13044_at

CD74 antigen (invariant
polpypeptide o f major
histocompatibility class II
antigen-associated)

chaperone activity

X59859_i_at

decorin

collagen binding, protein N-terminus
binding

X70871_at

cyclin G1

cyclin-dependent protein kinase regulator

[pyruvate dehydrogenase (lipoamide)]
kinase activity, ATP binding kinase activity
transferase activity

X72792cds_s_at alcohol dehydrogenase 1

alcohol dehydrogenase activity, zinc ion
ainding, oxidoreductase activity

lydroxysteroid (17-beta)
dehydrogenase 2

estradiol 17-beta-dehydrogenase activity
oxidoreductase activity

X91234_at

Z15123exon#5_ S-adenosylmethionine
s_at
decarboxylase 1

adenosylmethionine decarboxylase activity
yase activity, carboxy-lyase activity
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List of Gene Ontology Annotated Transcripts from 12-week SOM Cluster 6
Probe Set ID

|

Gene Name

Molecular Function Description

AB002558_at

jgl ycero I-3-ph osph ate
dehydrogenase 1 (soluble)

glycerol-3-phosphate dehydrogenase (NAD+)
activity

AF001898_at

aldehyde dehydrogenase
family 1, member A1

aldehyde dehydrogenase, oxidoreductase activity

AF003835_at

isopentenyl-diphosphate delta magnesium ion binding, isopentenyl-diphosphate
isomerase
delta-isomerase activity

AF036761 g at

stearoyl-Coenzyme A
desaturase 1, stearoylCoenzyme A desaturase 2

AF061971__at

palmitoyl-protein thioesterase catalytic activity, palmitoyl-(protein) hydrolase
activity, hydrolase activity
2

AF062389_at

kidney-specific protein (KS)

AF07241 l_at

cd36 antigen

receptor activity, fatty acid binding

D10655_at

dihydrolipoamide
acetyltransferase

nucleotide binding, dihydrolipoyllysine-residue
acetyltransferase activity, protein binding
dihydrolipoamide S-acyltransferase activity

D37920_at-

squalene epoxidase

monooxygenase activity, oxidoreductase activity

E00717UTR#l_s_ cytochrome P450, fam ily 1,
subfamily a, polypeptide 1
at

monooxygenase activity, oxidoreductase activity

E00778cds_s_at

cytochrome P450, fam ily 1,
subfamily a, polypeptide 1

monooxygenase activity, oxidoreductase activity

E03358cds_at

proteasome (prosome,
macropain) subunit, alpha
type 2

endopeptidase activity, peptidase activity
hydrolase activity

J02679_s_at

NAD(P)H dehydrogenase,
quinone 1

N AD (P)H dehydrogenase (quinone) activity
oxidoreductase activity

J05460_s_at

cytochrome P450, fam ily 7,
subfamily a, polypeptide 1

monooxygenase activity, cholesterol 7-alphamonooxygenase activity, oxidoreductase activity

K03241cds_s_at

cytochrome P450, fam ily 1,
subfamily a, polypeptide 2

monooxygenase activity, oxidoreductase activity
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L12380_at

ADP-ribosylation factor 1

L13619_at

insulin induced gene 1

L22294_at

pyruvate dehydrogenase
kinase 1

[pyruvate dehydrogenase (lipoamide)] kinase
ATP binding, kinase activity, transferase activity

M26594_at

malic enzyme I

malic enzyme activity, malate dehydrogenase
(decarboxylating) activity, malate dehydrogenase
(oxaloacetate-decarboxylating) (NADP+) activity
oxidoreductase activity

M33329_f_at

rat senescence marker protein
2A gene, exons 1 and 2

M36151cds_s_at

RT1 class II, locus Bb

M37584_at

CDNA clone MGC:72814
IMAGE:6922321, complete
cds

M63983_s_at

hypoxanthine guanine
phosphoribosyl transferase

rc_AA799279

Similar to mitochondrial
carrier homolog 2

rc_AA799326

cd36 antigen

rc_AA799442_at

Hypothetical L0C 293114
(LOC293114), mRNA

GTPase activity, receptor signaling protein, GTP
binding, protein transporter activity

magnesium ion binding
hypoxanthine phosphoribosyltransferase activity
transferase activity, transferring glycosyl groups

receptor activity, fatty acid binding

rc_AA799442_g_ Hypothetical LOC293114
(LOC293114), mRNA
at
rc_AA800053_at

Similar to androgen receptor
N-terminal-interacting protein
(LOC289508), mRNA

rc_AA800243__at

Similar to cell death activator
CIDE-A (LOC291541),
mRNA

rc_AA801174_at

Rat ig delta heavy chain
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rc_AA859980

Similar to acetyl CoA
transferase-like
(LOC308100), mRNA

re AA875126 g.
at

Similar to Myosin Id (Myosin
heavy chain myr 4)
(LOC289785), mRNA

rc_AA891226

proteasome (prosome,
endopeptidase activity, peptidase activity
macropain) subunit, beta type hydrolase activity
5

rc_AA891950_at

Similar to RIKEN cDNA
1810021J13 (LOC300516),
mRNA

rc_AA89256l_at

Similar to RIKEN cDNA
4931406C07 (LOC363016),
mRNA

rc_AA892801_at

eukaryotic translation
elongation factor 2

rc_AA892835_at

Similar to RIKEN cDNA
5730434103 gene

rc_AA892842_at

Similar to capping protein
alpha 2 subunit (LOC368086),

rc_AA892950_at

Similar to mitochondrial DNA
polymerase accessory subunit

rc_AA893173_at

Similar to vacuolar protein
sorting 29 isoform 2

rc_AA925752_at

cd36 antigen

receptor activity, fatty acid binding

rc_AA944856_at

RAP IB , member o f RAS
oncogene fam ily

GTPase activity, GTP binding

rc_AA945082_at

glutathione-S-transferase a2

glutathione transferase activity

rc_AA946368_at

cd36 antigen

receptor activity, fatty acid binding

rc AA996484 g

aldehyde dehydrogenase

aldehyde dehydrogenase activity, oxidoreductase

translation elongation factor activity, ATP
binding, GTP binding
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rc_A A997614_s_a cytochrome P450, subfamily
51
t

trypsin activity, monooxygenase activity
methyltransferase activity, sterol 14-demethylase
activity, oxidoreductase activity

rc_AI171506_g_at malic enzyme 1

malic enzyme activity, malate dehydrogenase
(decarboxylating) activity, malate dehydrogenase
(oxaloacetate-decarboxylating) (NADP+) activity
oxidoreductase activity

rc_AI175486_at

ribosomal protein S7

RNA binding, structural constituent o f ribosome

S35751_f_at

3-alpha-hydroxysteroid
dehydrogenase

S69874_s_at

fatty acid binding protein 5,
epidermal

transporter activity binding, fatty acid binding
lipid binding

S72506_s_at

glutathione-S-transferase,
alpha type2

glutathione transferase activity
transferase activity

S82820mRNA_s_ glutathione-S-transferase,
alpha type2

glutathione transferase activity
transferase activity

U23056 at

CEA-related cell adhesion
molecule 10

U64705cds_i_at

Similar to translation
initiation factor eIF-4A II -

X12535cds_at

RAB7, member RAS
oncogene family

X53054 g at

RT1 class II, locus Bb

X 6 1654_at

CD63 antigen

X63410cds_f_at

rat senescence marker protein
2A gene, exons 1 and 2

X68782cds_at

Rat ig delta heavy chain
constant region and 3' ut,
mma

X77235_at

ADP-ribosylation-like 4

GTP binding

X92097_at

coated vesicle membrane

protein carrier activity, protein transporter

D NA binding, GTPase activity, ATP binding
GTP binding, protein transporter activity
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Gene Ontology Molecular Function Classification of Transcripts.
12-weeks

2-weeks
Rat Transcripts
Gene Family

Genbank
Accession #

Dose (mg/g)
0.01

Dose (mg/g)

0.1

Cytochrome P450 Enzymes
CYPC17 Hydroxylase

M21208

CYPXIB2

D11354

CYP2D18

U48220

cYP11B2 gene(aldosterone synthase)

D14097

CYP1A1

E01184

Cytochrome P450 15-beta

J03786

CYP1A2

E00778

CYP450 1 B "
CYP450

rc_AI176856
E00717

Transcription Regulators
Mitogen-Activated Protein Kinase Kinase Kinase

M94454

Protein Phosphatase 3, Catalytic subunit, beta
isoform
Protein Phosphatase 3, (regulating subunit B,
alpha
Casein Kinasel, alpha 1

M31809

rc_A!235291

Casein kinase II, alpha 1 polypeptide

rc_AA875506

D10393

Tsx

X99797

Protein Kinase C

D85435

Protein Tyrosine Phosphatase

U69673

Heat shock protein

S75280

Tyrosine Kinase receptor

L26525

ras-related protein p23

X12535

Jun-D

D26307

bcl-2

L14680

c-myc

Y00396

Aldehyde dehydrogenase

AF001898

Interferon Gamma Receptor

U68272

NF1-like DNA binding protein

AB012230

Phosphoryl kinase

M98826

Prostatic Acid Phosphatase

M32397

HNF-3/Forkhead homolog

L13201

Stat 5

U24175

Enigma homolog
Cyt. B5
PACAP

U48247
rc_AA817685
D14909

G-Protein Coupled Receptor 6

AF064706

Bradykinin receptor B1

AJ132230

Protein Kinase , AMP-activated, alpha 1 catalytic
myc box dependent interacting protein

U40819
rc„A!102031
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Peptidygiycine alpha amidating monoxygenase

M82845

Myogenic Regulatory fact. (MYOD)

M84176

LIM-motif containing protein kinase 1

D31873

Meprin 1 alpha

S43408

Janus Kinase 2 (Protein Tyrosine kinase)

U13396

Protein Tyrosine Phosphatase, non-receptor type
1
protein Tyrosine Phosphatase, receptor type 2

M33962

M

|

U09357

Transcription elongation factor A2

D129

BHF-1

D82074

Olf-1

L24051

T16m R NA

D89730

pericentriolar material

U95920

Phosphoribosylpurophosphate synthetase II

X16555

Cox-2

M

I

|

I

S67722

High sulfur Protein B2E

AB003753

MIPP65

AB000098

Ras p21 Small GTP binding

M75153

APOB

M21842

Enzyme Regulators
Tissue inhibitor of metalloproteinase I

rc_AI169327

Biosynthesis & Metabolism
L-3-Hydroxyacyl-CoA dehydrogenase, short chain
HMG-COA reductase
Phosphofructokinase

rc_AA891362
X55286
J04197

Phosphoiipase A2

U03763utr

Pyruvate Dehydrogenase phosphatase

AF062740

Acetyl CoA Carboxylase

J0380S

Glycerol-3-phosphate dehydrogenase 2

U83880

Glycerol-3-phosphate dehydrate dehydrogenase

AB002558

phosphoiipase C beta

L15556

3-Phosphogiycerate Dehydrogenase

X97772

Mast Cell Protease 9

U72143

Prostaglandin 12 Synthase
Glutaminase

U53855
rc_AI176504

Pancreatic Lipase

088534 BSPS!!

Glutamate receptor-B

M36419

Stearyl CoA desaturase
Stearyl CoA

f

rc_AA875269
AF036761

Glycogen synthase

J05446

Acyl-CoA dehydrogenase

U64451

Cyt. Oxidase V 111

U40836

Anti-Oxidants
Glutathione-S-Transferase alpha type 2
gluthatione-S-Transferase yc2

rc_AA945082
S82820
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Glutathione peroxidase

D00680

CU*Zn SOD

M21060

NADPH Cytochrome P450 Reductase

E01524

NADH Cytochrome b5 reductase

J03867

NADPH Quinone Reductase

M58495

Immune System
Interleukin -6B
IL-1 beta
Fos-like antigen

M26744
E01884
rc_AI230842

Interleukin -1 alpha

D00403

IgM kappa chain

S81289

T-cell receptor alpha chain

L37966

T-cell receptor beta chain
Vascular Ceil Adhesion

M84488

Piateiet Derived Growth factor receptor alpha

Z14118

Prostaglandin F2 receptor negative regulator

rc_AI145502

MHC class II

I

X14254

Cell Growth & Maintenace
Fibroblast Growth Factor 16

AB002561

3-Hydroxy-3-methylglutaryl Coenzyme Areductase
Transforming growth factor

X55286

Hepatocyte Growth factor

D90102

X-ray repair cross complementation
Insulin like growth factor
A Disintegirn and Metalloproteinase Domain 17
(Adam)
Basic fibroblast growth factor

L26110

rc_AA893188
M81183
AJ012603
X07285

Structural
Crystallin, gamma D
Fast Myosin Alkali Light Chain
Actin, beta
H36-alpha 7 integrin

X57169
L00088
rc_AA874855
X65036

Angiotensin/Converting Enzyme

U03734

Proteolipid Protein

M25888

Unconventional Myosin from rat3
beta tubulin T beta

X7769
X03369

Oncogenes
Tumor protein P53

X13058

Rat heart derived c-ros 1 protooncogene

M35104

Ost oncogene

Z35654

Fyn-Protooncogene

rc_A!009191

[
31111

Electron Transport & Conjugation
UDP-glucuronsyitransferase

D38061

Sulfotransferase family, cytosolic 2A, DHEA

J02643

■

' I ------
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Arylamine N-acetyl transferase

U01348

Peroxisomal
. Peroxisome forming factor

E03344

Binding
DNA Binding Protein
Oncomoduiin
CCAAT/enhancer binding protein
Killer cell lectin-like receptor subfamily C
Guanylate binding protein 2, Interferon inducible
Calnexin
Ubiquitin-Conjugating Enzyme E2D2
Isopentenyl Diphosphate delta isomearse
Forkhead box 01
Synaptophysin

12752
JO2705
X12752
AF021349
M80367
rc_A1235707
U56407
rcjAH 76778
M87634
X06655

Myristoyiated alanine rich protein kinase c

rc_AA859896

Oxidized Low Density Lipoprotein Receptor

ABQ05900

Hypocretin Receptor

AF041244

Opiod Receptor

D16349

Neurogenic Differentiation

D82868

D site albumin promoter binding protein

J03179

Dynamin 2

L25605

Retinol binding protein

M13947

Neuronal 64 domain family member

X66022

Gamma Aminobutyric Acid A receptor, rho 1

X95579

A disintegirn and Metalloproteinase Domain 3
(Adam3)
Calcium Independent aipha-latrotoxin receptor
homolog
Calpain 3

Y07903

Sialytransferase 8 (alpha-2,8-sialytransferase)B

----------

...

AF063103
AF061726
L13445

Metaliothionein 3

rc„AA924772

Nuclear Receptor Subfamily.2, group F, Member
2
Nuclear Receptor Subfamily 4, group A , Member
3
Nuclear Receptor binding factor 1

rc_AI012183
rc_AI176710
AB015724

Carbonic anhydrase 4

S68245

Carbonic anhydrase 3

AF037072

Sry-related HMG box prot. Sox II

AJ004858

DNA Binding (N5)mRNA

L31882

Zinc Finger Protein 35A

M96548

Neurai Zinc Finger Factor 3

U67080

liver mrNA

U96490

Bioenergetics & Transport
Calcium Channel voltage dependent alpha 1A
subunit
GABA receptor rho-3 subunit

AF051526
D50671
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Gene Ontology Molecular Function Classification of Transcripts - Continued

Solute carrier family 21 , member 7
Sodium Channel, voltage gated type 2, alpha

AF041105
M22254

Solute Carrier family 1

X637-' •

Solute carrier family 8, member 1

X68191

Potassium inwardly rectifying channel

X83585

Glycine Receptor,alpha 1 subunit

DO0833

Vacuolar Protein Sorting homolog (r-vps33b)
Probasin
Potassium voltage-gated channel
A TP -R egulated P otassium channel

j

]

-

rc_A!072341
M27156
J04731
AF081366

Cell Signalling/Communication
3-phosphoinositide dependent protein kinase -1
Thymopoietin (lamina associated polypeptide)

Y15748
rc_AA818982

Cyclic AMP regulatory phosphoprotein

S65091

Drosophila discs-large tumor suppressor,
homologue
Secreted Frizzled Related Protein 4

U14950

Prostaglandin E receptor 3
Synapsin 2
Ephrin A1

AFO12891
D16443
rc_Al 145494
D38056

Muscarinic Receptor

J03025

Endothelial Differentiation Sphingolipid G-protein
Rece
Ca/Calmodulin dependent protein kinase 2 delta
subun
Chorionic Somatommatropin hormone 1 variant

U10303
rc_AA925495

Histone 2B

rc_AA964055

High Mobility group box 2

rc_AA996401

Myelin Oligodendrocyte Glycoprotein

rc_A1179075.

M99485

CD5 antigen

D10728

Prostaglandin F2 receptor negative regulator

D28581

5-Hydroxytryptamine (Serotonin) receptor alpha
Toll-like Receptor 4

II

L22558
—

rc_AIQ3Q997

Adenylate Cyclase Activating Polypeptide

rc_A!228407

CD36 antigen

rc_AA946368

Fibrobiast growth factor

X56551

Inositol Triosphosphate

M64698

Phosphatidy inositol-4-kinase

D83538

5-Hydroxytryptamine(serotonin) receptor 7

L22558

Adenosine A1 receptor

M64299

Glial cell line derived neutrophic factor

U97143

Transmembrane protein tMDC 1

Y07903

calcium/calmodulin protein Kinase

L13407

CAMP Kinase

M12492

Serotonin transporter

X63253

ifiiiitii

Hormone Related

Thyroid Hormone Receptor, beta

J03819

Corticotropin Releasing Hormone

M54987

Luteinizing Hormone subunit beta

U25802

Thyroxine bindingglobulin

MS3991

Androgen Repressive Liver prot

J02643

Parathyroid Horrrone Receptors

M77184

Proiactin-fike protein
Estrogen receptor

rc_AI013523
S5212S
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Gene Ontology Molecular Function Classification of Transcripts - Continued
Other
AF009329

wm mmmd

Defensin

U50353

■ S I

Sperm Adhesion Molecule

X89999

Tuberous Sclerosis

U24150

Basic helix-loop helix domain

Amelogenin

U01245

Tonin

M11564

RVLG(vasa-like gene protein)

S75275

Transcripts that increase or decrease are indicated by light and dark gray,
respectively.
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D1

Molecular Signal Transduction Pathways Regulated by BaP
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D2
BaP Regulation of IL-1j3 Through the p38 MAPK and NF-kappa B Signaling
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D3
BaP Regulation of p53 and Other Oncogene Families
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D4
BaP Regulation of Bcl-2 and Other Anti-apoptosis Genes
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05
Ah Receptor Involvement in the Regulation of p53 and Other Genes
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